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Abstract 
Evaluation of glycaemic control and diabetes treatment strategies 
during the religious fasting period of Ramadan 
 
Ramadan is one of the longest periods of religious fasting. Muslims abstain from 
food and drink from sunrise to sunset for the month of Ramadan. In patients with 
diabetes, dietary changes during Ramadan can influence the glycaemic control. 
Since Ramadan is a key part of the Islamic faith, many Muslims with diabetes are 
willing to endure the hardship and choose to fast.  
The thesis included discussions on the physiology and the practice of fasting in 
different religious groups. The current evidence for the optimum diabetes 
management during Ramadan was reviewed and recommendations were made 
based on randomised, comparison and observational studies and expert consensus.  
The practice of fasting among pregnant women with diabetes was assessed in North 
West London in a questionnaire-based survey. Only 10% of women fasted. Having 
diabetes and hypoglycaemia were the likely deterrent factors. Imams (religious 
advisors) were as important as healthcare professionals in advising about fasting. 
The glycaemic variability in patients with diabetes who followed the 
recommendations for optimal diabetes management was studied using continuous 
glucose monitoring. The glycaemic variability during fasting and non-fasting periods 
of Ramadan was similar, suggesting that pre-Ramadan assessment was useful in 
negating glycaemic excursions during Ramadan. 
Changing to Humalog Mix 50 insulin at Iftar (sunset meal) in type 2 diabetes patients 
that were on twice daily Human Mixtard 30 insulin minimised their risk of 
hypoglycaemia without compromising their glycaemic control during Ramadan. The 
incretin-based therapies were more suitable than gliclazide when considering an 
add-on to metformin for type 2 diabetes patients who planned to fast for Ramadan.   
In summary, the main aim of pre-Ramadan assessment and therapeutic adjustments 
is to allow patients with type 2 diabetes to fast safely during Ramadan. 
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Chapter 1: introduction 
1.1 Overview of Diabetes  
Diabetes Mellitus is a group of metabolic disorders resulting in hyperglycaemia due 
to defects in insulin secretion and/or insulin action. The long-term effects of 
hyperglycaemia include damage to multiple organs, in particular, the heart, kidneys, 
eyes, nerves, and blood vessels.  
The earliest descriptions that resembled the features of diabetes were found in the 
Ebers papyrus (1550 BC), the ancient Egyptian document relating to the practice of 
medicine. During the 9th – 11th centuries AD, Arabian physician, Shaikh-Ul-Rais Bu 
Ali Ibne Sina (960 – 1037 AD) described the clinical features of diabetes and noted 
two complications of the disease, namely gangrene and sexual dysfunction. Another 
Arabian physician, Musa Bin Maimoon (1135 – 1209 AD), proposed that diabetes 
was caused by the sweet water of river Nile. The term ‘diabetes’ was first coined by 
Aretaeus (81 -138 AD), meaning to ‘Siphon’ – a melting down of the flesh and limbs 
into urine. Thomas Willis (1621 – 1675 AD) added the term ‘mellitus’, observing the 
presence of sugar in the urine and blood of diabetes patients1.  
In modern times, the diagnostic criteria of diabetes mellitus is based on glucose 
criteria, either the fasting plasma glucose (FPG), or the 75-g oral glucose tolerance 
test when blood is taken for glucose determination at baseline and 2 hours after a 75 
grams of oral glucose challenge. Its diagnosis was previously made according to the 
World Health Organisation (WHO) criteria using a FPG and subsequent 75-g OGTT 
as updated in 20062, or the American Diabetes Association (ADA) criteria as 
updated in 20053.   The WHO criteria classified diabetes mellitus as a FPG > 7.0 
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mmol/l (126 mg/dl) or a 2-hour venous plasma glucose > 11.1 mmol/l (200 mg/dl). 
More recently, the International Expert Committee of the ADA issued a statement 
proposing an HbA1c level of 6.5% (48 mmol/mol) as a diagnostic level for the 
diagnosis of diabetes mellitus. The cut-point of 6.5% was chosen as levels above 
6.5% were associated with an increased incidence of diabetes retinopathy4, as are 
the diagnostic threshold for FPG and 2-hr PG4. Subsequently, the ADA has updated 
its diagnostic criteria of diabetes to include: FPG 7.0 mmol/l (126 mg/dl), or a 2-hour 
plasma glucose > 11.1 mmol/l (200 mg/dl), HbA1c > 6.5% , or having symptoms of 
hyperglycaemia with a random plasma glucose of > 11.1 mmol/l (200 mg/dl)5. The 
test should be performed in a laboratory using a method that is National 
Glycohaemoglobin Standardization Program (NGSP) certified and standardized to 
the Diabetes Control and Complications Trial (DCCT) assay. The use of HbA1c as a 
diagnostic test has the advantages of not relying on a fasting sample and smaller 
intra-individual measurement variability.  However, HbA1c measurements can be 
misleading in conditions that alter red cell survival, such as haemoglobinopathies, 
anaemia (both iron deficient and haemolytic anaemias), and renal failure. Another 
disadvantage is the discrepancies in HbA1c between individuals from different races 
and also individuals of different ages.  
Type 1 diabetes is caused by the autoimmune destruction of the β-cells of the 
pancreas, leading to absolute insulin deficiency. The autoimmune destruction of the 
β-cells is characterised by the presence of islet cell auto-antibodies, glutamic acid 
decarboxylase (GAD 65) antibodies, autoantibodies to insulin and tyrosine 
phosphatase IA-2, IAA. These autoantibodies are present in 85-90% of individuals at 
the onset of fasting hyperglycaemia. Zinc T8 autoantibodies were found in 26% of 
type 1 diabetes subjects previously classified as autoantibody-negative on the basis 
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of other markers (GAD, IA-2, IAA, ICA)6. Absolute insulin deficiency manifests 
clinically as hyperglycaemia and ketoacidosis. Individuals usually present in 
childhood or adolescence, but can present at any age. The rate of β-cell destruction 
is also variable among individuals, with some patients dependent on insulin for 
survival at the outset, and others may retain sufficient β-cells function to prevent 
ketoacidosis for years.  
Type 2 diabetes results from a combination of insulin resistance and relative insulin 
deficiency of varying degrees. It accounts for 90 – 95% of adults with diabetes. 
Autoimmune destruction of β-cells does not occur, but specific causes for this type of 
diabetes are unknown. It is often associated with obesity which leads to insulin 
resistance. Adequate glycaemic control can be achieved with weight loss, physical 
exercise, with or without oral anti-diabetic medication. Insulin is not required for 
survival, at least in the early stage of the disease, but is sometimes needed later on 
in patients with poor glycaemic control. Ketoacidosis does not usually occur in 
patients with type 2 diabetes, but some patients, such as those from African origin, 
can present in a subtype of diabetes known as ketosis-prone atypical diabetes. It is 
characterised by ketosis or ketoacidosis at presentation in individuals with an 
otherwise type 2 phenotype. Insulin-free near-normoglycaemia is achieved by oral 
hypoglycaemic agents after initial insulin treatment within days or weeks. Islet cell 
auto-antibodies are absent but the cause of the acute onset and remission is not fully 
elucidated. Viral infections, such as human herpes virus 8, may contribute to the 
acute presentation of ketosis-prone diabetes7. On the other hand, patients who were 
initially diagnosed as type 2 diabetes but presented with ketoacidosis may actually 
be unrecognised latent autoimmune diabetes in adults (LADA). It is characterised by 
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adult onset, presence of islet cell auto-antibodies, and rapid decline in β-cell function, 
requiring long-term insulin treatment shortly after diagnosis (Table 1.1).   
Gestational diabetes (GDM) arises during pregnancy, usually in the second or third 
trimester and resolves after delivery. If untreated, GDM is associated with adverse 
maternal and foetal outcomes such as foetal malformation, macrosomia and pre-
eclampsia. The number of undiagnosed patients with type 2 diabetes presenting in 
early pregnancy is also on the rise, as the ongoing epidemic of obesity and diabetes 
has led to more type 2 diabetes in women of childbearing age.       
Other types of diabetes include: 1) maturity-onset diabetes of the young (MODY), 
characterised by monogenic defects in β-cell leading to impaired insulin secretion 
and the absence of islet cell auto-antibodies. Patients present at an early age, 
usually before 25 years of age, and are treated with sulphonylurea, which facilitates 
insulin secretion in MODY cases involving mutations in the genes encoding 
hepatocyte nuclear factor 1 homeobox A (HNF1A) and 4 (HNF4); 2) diseases that 
structurally damage the pancreas can also lead to diabetes, such as pancreatitis, 
cystic fibrosis, and haemochromatosis; 3) Endocrinopathies that are diabetogenic 
such as Acromegaly, Cushing’s syndrome and glucagonoma. These diseases 
resulted from an excess in hormones that antagonise insulin action, namely growth 
hormone, cortisol and glucagon respectively. Patients with any types of diabetes 
may require insulin at some stage of their disease. Table 1.1 summarises the 
classification of diabetes mellitus according to the aetiology of the glycaemic 
impairment.  
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Types of Diabetes Mellitus Aetiology Insulin requirement 
Type 1 β cell destruction Absolute insulin deficiency 
Type 2 Insulin resistance and insulin 
secretory defect of variable 
degrees 
May require insulin for 
glycaemic control at a later 
stage 
Other specific types: 
- Genetic defects of β 
cell function (Mature 
onset diabetes of the 
young, MODY) 
 
Monogenic defects in genes, such 
as: 
hepatic nuclear factor-4 (MODY 1), 
glucokinase (GCK) (MODY2), 
hepatic nuclear factor-1A (MODY 
3),  insulin promoter factor 
(MODY4), mitochondrial DNA 
 
Generally not requiring 
insulin:  
- Sensitive to sulphonylurea 
in HNF1A and HNF4  
- Mild hyperglycaemia not 
requiring treatment in GCK 
- Require insulin at later 
stage and avoid metformin 
due to lactic acidosis in 
mitochondrial dysfunction 
- Latent autoimmune 
diabetes in adults 
(LADA) 
Autoimmune β cell destruction with 
variable progression of β cell failure 
from months to years 
Require insulin for glycaemic 
control after initial insulin-free 
period  
- Diseases of exocrine 
pancreas 
Chronic pancreatitis, 
pancreatectomy, cystic fibrosis, 
haemochromatosis 
Likely requiring insulin for 
glycaemic control 
- Endocrinopathies Excess hormones antagonising 
insulin action: 
Acromegaly (growth hormone) 
Cushing’s syndrome (cortisol) 
Glucagonoma (glucagon) 
Phaeochromocytoma 
(catecholamines)  
Likely requiring insulin for 
glycaemic control 
Gestational Diabetes Any degree of impaired glucose 
tolerance during pregnancy 
May require insulin for 
control 
 
Table 1.1 Classifications of the different types of diabetes mellitus depending on the causes of 
impaired glycaemia. (adapted from American Diabetes Association position statement, 2010
5
).  
 
1.2 Complications of diabetes 
Acute complications of uncontrolled diabetes include hyperglycaemia with 
ketoacidosis and (HHS) hyperosmolar non-ketotic state. Chronic hyperglycaemia 
leads to microvascular complications, namely retinopathy with threatening loss of 
vision; nephropathy leading to renal failure; peripheral neuropathy resulting in foot 
ulcers, amputations, and Charcot joints. Diabetes-related autonomic neuropathy can 
affect gastrointestinal delay, bladder instability and cardiovascular symptoms and 
sexual dysfunction. Macrovascular complications, including atherosclerotic 
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cardiovascular, peripheral arterial and cerebrovascular disease, account for 
morbidity and mortality in patients with uncontrolled diabetes. 
The UK Prospective Diabetes Study (UKPDS) is a landmark multicentre randomised 
trial to study the glycaemic treatments of newly diagnosed type 2 diabetes patients. 
Over the course of 20 years, it has shown that intensive blood-glucose control with 
sulphonylurea or insulin, as compared to conventional treatment, reduced the risk of 
‘any diabetes-related endpoint’ by 12% and microvascular disease by 25%8. The 
mean haemoglobin A1c (HbA1c) was 7.0% (53 mmol/mol) in the intensive-control 
group and 7.9% (63 mmol/mol) in the conventional-control group at the end of the 
follow-up period. Furthermore, intensive glucose control with metformin had risk 
reduction of 32% (95% CI 13-47, p=0.02) for any diabetes-related endpoints, 
including macrovascular complications and is associated with less weight gain and 
lower incidence of hypoglycaemia than insulin and sulphonylureas9.  
However, recent studies on the effect of intensive blood glucose control on 
cardiovascular outcomes have opened the debate on the optimal glycaemic target. 
In the ACCORD study10, type 2 diabetes patients with either established 
cardiovascular disease or additional cardiovascular risk factors, targeting the blood 
glucose control to an HbA1c of less than 6% led to higher all-cause mortality, 
compared to targeting an HbA1c value of 7.0% - 7.9%. One of the reasons for the 
excess mortality is the higher risk of death from cardiovascular causes in the 
intensive-therapy group compared to the standard-therapy group in the treatment 
period of 3.7 years and in the follow-up period where both groups were treated in the 
standard approach targeting HbA1c of 7.0% - 7.9%11.  
19 
 
Several other randomised control trials, such as ADVANCE12 and VADT13, did not 
find significant difference between the intensive and conventional glucose control 
groups in the incidence of cardiovascular events or all-cause mortality. However, 
non-glycaemic cardiovascular risk factors, such as lipid control, were not optimally 
controlled in the ACCORD study and VADT’s study population was predominantly 
men.  
It has become clear that an intensive treatment strategy should be initiated at an 
early stage of diabetes. In patients with long duration of diabetes or with established 
complications, it may be more reasonable to continue conventional control due to the 
increased cardiovascular risk associated with intensive treatment approach and 
weight gain associated with intensive augmentation with insulin therapy. Individual 
circumstances and the side effects of hypoglycaemic agents should be taken into 
account in the diabetes management on an individual basis.  
 
1.3 Religions and fasting  
One of the individual circumstances that can influence the management of diabetes 
includes fasting for religious reasons. 
1.3.1 Islam 
Islam is the second largest religion in the world with over 1 billion followers. 
1,591,000 Muslims were recorded in the 2001 UK census, around 2.7% of the 
population. The Islamic month of Ramadan is one of the longest periods of fasting. 
The holy month of Ramadan is one of five main pillars of Islam.  
20 
 
The Five Pillars consist of: 
 Shahadah: reciting the Muslim profession of faith 
 Salat: performing ritual prayers five times each day 
 Zakat: paying an alms (charity) tax to benefit the poor and the needy 
 Sawm: fasting during the month of Ramadan 
 Hajj: pilgrimage to Mecca 
1.3.1.1 The month of Ramadan  
Fasting during Ramadan involves abstaining from food and drink from dawn to 
sunset for approximately 30 days as it is based on a lunar calendar. Most people 
take two meals a day during Ramadan - Suhur (the meal before dawn) and Iftar (the 
meal after sunset). Although the Koran exempts sick people from the duty of 
fasting14, many Muslims with diabetes may not perceive themselves as sick and are 
keen to fast. The majority of Muslim people with diabetes are passionate about 
fasting. A large epidemiological study of Muslims with diabetes in 13 Muslim 
countries (n=12,243), the EPIDIAR study, showed that 43% of patients with type 1 
and 79% of those with type 2 diabetes fasted during Ramadan15. 
1.3.1.2 The impact of Ramadan fasting in the Northern Hemisphere 
As the month of Ramadan follows the lunar calendar, the fasting month is brought 
forward by about 10 days each year, which means that the season in which 
Ramadan falls into, changes over time. For the next decade Ramadan will fall in the 
summer in the northern hemisphere (Table 1.3). As daylight hours vary considerably 
between summer and winter months in non-equatorial countries, the length of the 
fast (which lasts from dawn to sunset) increases in the summer to about 16-20 
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hours. People with diabetes who fast are at risk of adverse events and the risks may 
increase with longer fasting periods.  
Year  Start date of 
Ramadan 
Time fasting starts Time fasting ends Number of fasting hours 
2000 28
th
 November 05:40 15:58 10:18 
2001 17
th
 November 05:26 16:09 10:43 
2002 6
th
 November 05:10 16:25 11:16 
2003 26
th
 October 04:53 16:45 11:52 
2004 15
th
 October 05:35 18:08 12:33 
2005 4
th
 October 05:17 18:32 13:15 
2006 23
rd
 September 04:57 18:57 14:00 
2007 13
th
 September 04:37 19:20 14:43 
2008 1
st
 September 04:11 19:47 15:36 
2009 22
nd
 August 03:45 20:09 16:24 
2010 11
th
 August 03:10 20:33 17:23 
2011 31
st
 July 02:45 20:50 18:05 
2012 20
th
 July 02:38 21:07 18:29 
2013 9
th
 July 02:33 21:17 18:44 
 
Table 1.2 The number of fasting hours during the month of Ramadan in consecutive years in the 
United Kingdom based on Greenwich Mean Time (Adapted from www.Ramadantimetable.co.uk). 
 
1.3.1.3 Metabolic changes during fasting 
Fasting involves partial or total abstinence from all oral intakes, or select abstinence 
from prohibited food. The response of fasting will depend on the size and the 
composition of the meal that is last ingested before fasting begins.  
The initial stage of fasting is the post-absorptive period, which starts when all the 
ingested nutrients at the last meal have been absorbed from the small intestine. This 
can occur as soon as 3 – 4 hours or as long as 7 – 8 hours depending on the 
amount and type of food in the meal. It lasts for about 24 hours as the body adjusts 
to the absence of nutrients. Blood glucose is maintained in normal individuals as the 
liver glycogen store is hydrolysed and released as glucose into the circulation16. As 
the liver glycogen store is depleted, blood glucose begins to fall. This results in 
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hormonal changes, including a reduction in plasma insulin concentration and 
stimulation of glucagon, catecholamines, growth hormone, thyroid-stimulating 
hormone and corticosteroids. The net result is gluconeogenesis, a process to 
generate glucose from non-carbohydrate substrates. Substrates for gluconeogenesis 
include the carbon skeletons of some amino acids, lactate released by glycolysis in 
red blood cells and the glycerol released from adipose tissue. 
The rate of carbohydrate utilisation is decreased in the fasted state and the rate of 
fat oxidation increases to meet energy demand. The limited carbohydrate store is 
reserved for the central nervous system and the erythrocytes, which rely solely on 
carbohydrate metabolism. Triglycerides reserve within the adipose tissue is 
mobilised in the process of lipolysis, leading to an increase in the circulating free 
fatty acids in the plasma that is available to the body as a source of fuel.  
After a few days of fasting, ketone bodies, which are derived from the conversion of 
fat breakdown products, are increasingly used as a fuel as they can cross the blood-
brain barrier to be used by the brain cells for energy.  
While religious fasts are partaken mainly for spiritual purposes, they can potentially 
affect one’s physical health. In patients with diabetes, changes in meal frequency, 
daily physical activities and sleeping patterns during these religious fasts may 
influence the glycaemic and other biochemical parameters.   
Intermittent fasting occurs during Ramadan. Food and drink are abstained during 
daylight hours on repeated days for a month, with no restrictions on intake during the 
hours of darkness.  
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A change in the timings of meals during Ramadan is accompanied by changes in 
circadian pattern. Studies on sleep patterns have demonstrated significant delays in 
bedtime and wake-up time during Ramadan in healthy subjects17;18. Body 
temperature, as a marker of circadian pattern, normally falls during sleep and rises at 
wake time. During Ramadan, there is a significant rise in body temperature at 23:00 
and 00:00 hours and a significant reduction in daylight hours (09:00, 11:00, 13:00, 
and 16:00 hours), as compared to non-fasting period19. Melatonin, also a marker of 
circadian rhythm, has been shown to have a delayed night peak and a flatter slope of 
serum melatonin rise during Ramadan20, which may be due to prolonged exposure 
to artificial light during Ramadan.  
Changes in meal timing and daytime fasting have been shown to induce changes in 
the rhythmic patterns of various endocrine hormones, as compared to pre-Ramadan 
days20. During the non-Ramadan day (meals at 08:00, 12:00 and 19:00), serum 
cortisol levels rose during the early hours since midnight and peaked at 08:00, then 
gradually fell during the day. During the Ramadan day (meals at 19:00 and 01:00), 
there were two peaks, one at 8:00 and the other at 20:00 in the evening, i.e. at the 
time of the first meal following the daytime fasting period. In addition, there was a 
slower rise but higher morning peak during Ramadan than on the control day. This 
pattern is consistent with findings in subjects on a five-day total fast (water only), 
which showed a delayed maximum cortisol concentrations and increase in the mass 
of the glucocorticoid secretory bursts21. Prolactin also exhibited similar biphasic 
peaks at 08:00 and 20:00 during Ramadan20.  
Leptin, produced and secreted from fat adipocyte tissue, has a key role in regulating 
appetite and energy expenditure. It acts in the hypothalamus. When fat mass 
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increases, plasma leptin level increases, thus inhibiting food intake and increasing 
energy expenditure through integrated pathways of the hypothalamic neural circuits. 
Neuropeptide Y is one of the orexigenic hormones. Reduction in neuropeptide Y 
activity is associated with decrease in food intake. Fasting serum leptin levels were 
significantly raised and neuropeptide Y levels were reduced in healthy subjects 
fasting during Ramadan22. 
Periods of religious fasting are usually followed by celebratory feasting. Eid ul-Fitr 
marks the end of Ramadan and is usually celebrated with 3 days of prayers, family 
gatherings, and feasting with traditional Eid food such as murgh mussallam and 
mrouziya.  
1.3.1.4 Effects of fasting on glycaemic control 
Most Muslim religious authorities accept that if a person is advised by a trusted 
health professional, such as a doctor or nurse, that fasting is harmful to his or her 
health, then that person is exempted from fasting23. Several studies on people with 
diabetes, either diet controlled or on oral hypoglycaemic agents, have demonstrated 
no change in HbA1c or fructosamine levels24;25 during Ramadan. Others have shown 
improvement26 or deterioration27 in glycaemic control in people taking oral 
hypoglycaemics or insulin during Ramadan. However, it is the variation in glycaemia 
leading to severe hypo- and hyperglycaemia that is the main issue for people with 
diabetes fasting for Ramadan.     
1.3.1.5 Risks of fasting for people with diabetes 
The risks of fasting include hypoglycaemia, hyperglycaemia, and dehydration. The 
EPIDIAR study found that the change in eating patterns during Ramadan increased 
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the risk of severe hypoglycaemia 4.7-fold (from 3 to 14 events per 100 people per 
month) in type 1 diabetes and 7.5-fold (from 0.4 to 3 events per 100 people per 
month) in type 2 diabetes. It also found a fivefold increase in the incidence of severe 
hyperglycaemia in patients with type 2 diabetes during Ramadan. A small 
observational study (n=41) conducted in 1998 found an increase in symptomatic 
hypoglycaemia28, but other studies have not found a significant increase in the risk of 
hypoglycaemia during Ramadan in patients treated with oral hypoglycaemic 
medications or insulin27;29. One explanation for different findings among studies is 
that because Ramadan occurs in a different season every nine years, and the 
duration and temperature of fasting days change, rates of hypoglycaemia may vary 
according to the year in which the study was performed. The differences in methods 
and the small number of patients included in these studies would also explain the 
disparity of the results. Furthermore, the baseline HbA1c or fructosamine levels in 
the studies were not the same and the interventions instituted in the studies were 
different28-30. This would also explain the disparate results of hypoglycaemic rates. 
1.3.1.6 Effects of fasting on caloric intake 
Even though people abstain from any oral intake from sunrise to sunset, they take 
considerable amount of sweet and fried foods traditionally prepared for Ramadan 
during non-fasting hours, especially at the Iftar meal. An increase in daily caloric 
intake during Ramadan has been shown in healthy subjects31;32. However, some 
studies reported a decrease in daily caloric and carbohydrate intake in type 1 and 
type 2 diabetes patients26;33. These discrepancies between healthy and diabetes 
subjects may be due to diabetes patients being more health conscious about limiting 
their total food and carbohydrate intake. It could also be explained by the food habits 
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in different Islamic countries, as the former studies on healthy subjects were 
conducted in Tunisia and Algeria31;32, whereas the latter relating to diabetes patients 
were performed in Malaysia26;33. 
1.3.1.7 Effects of fasting on weight and body mass index  
In 120 well-controlled type 2 diabetes patients on diet or oral hypoglycaemic 
medications, weight and body mass index did not change before and fifteen days 
after Ramadan after receiving dietary advice and adjustment of the timing of their 
medications34. However, in type 2 diabetes women with high body mass index (BMI> 
30kg/m2), fasting during Ramadan resulted in a significant weight loss (-3.12 kg; p < 
0.01), a decrease in meal frequency (from 4.3 ± 0.4 before to 2.2 ± 0.3 meals during 
Ramadan) as well as in energy intake (1823 ± 262 to 1488 ± 118 Kcal/d; p < 
0.001)35. 
1.3.1.8 Effects of fasting on lipid profile 
It was postulated that physiological adaptations during the month of fasting lead to 
an increase in reliance on fat as a source of fuel during daytime fasting36. In obese 
type 2 diabetes women, dietary fat consumption increased (from 25.36% before to 
35.84% during Ramadan), especially saturated fats (231Kcal/d i.e. 43.25%) 35. Total 
cholesterol intake, as well as total and LDL cholesterol concentration, also increased 
significantly in non-obese type 2 patients (n = 57)37 and in type 2 patients with 
hyperlipidaemia on diet, fibrates or statins38.  
Over the coming decade, the number of fasting hours will progressively increase in 
the northern hemisphere as Ramadan falls in the summer months. This will have 
important implications for Muslims with diabetes who wish to fast. Hence, it is 
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important that both patients and their healthcare professionals are aware of the 
implications of Ramadan fasting in order to provide systematic advice on treatment 
adjustment to empower the patients in self-management of their disease.  
 
1.3.2 Judaism 
The world’s Jewish population was estimated at 13,428,300 in 2010. Israel and the 
United States accounted for 82% of the total39. Europe has the largest estimated 
core Jewish population outside of North America and Israel, with an estimated 2.2 
Jews per 1000 total population. The United Kingdom has a core Jewish population of 
292,000, which included people that identified themselves as Jews in socio-
demographic surveys; or who are identified as Jews by a respondent in the same 
household, and do not have another monotheistic religion.   
The prevalence of adult-onset diabetes (diabetes presenting at > 20 years of age) 
was 12% among Jews in Israel40. In the Ashkenazi Jewish population, single 
nucleotide polymorphisms (SNPs) in the hepatic nuclear factor 4A (HNF-4A) and 
Wolfram syndrome (WF1) genes were associated with predisposition for type 2 
diabetes41;42. The unadjusted odds of being affected with Type 2 diabetes were 3 
times greater in subjects with the HNF4A and WFS2 risk alleles than those without 
either42.  
Yom Kippur, the Day of Atonement, is one of the major annual fasting days in 
Judaism. No food and drink is consumed for twenty-five hours from sunset on the 
eve of the day to the dusk of the following day. All Jewish males 13 years or older 
and all females 12 years or older are required to fast. However, the Jewish law 
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exempts patients from fasting if it endangers their health43. Halakhic authorities 
(experts in Jewish law) recommend that all patients with diabetes who intend to fast 
should consult their doctors for assurance that fasting is safe and forbid type 1 
diabetes patients to fast on Yom Kippur44. Yom Kippur differs from other Jewish fast 
days in that drawing blood and using electrical devices (such as blood glucose 
meters) are prohibited, unless needed to preserve sanctity of life45. If patients with 
diabetes decided to fast during Yom Kippur, it has been suggested that blood 
glucose monitoring should be done only if there are hypoglycaemic symptoms or 
upon arising on the morning of fast if there is a history of hypoglycaemic 
unawareness. Nonetheless, recent recommendations from Rabbis and diabetes 
specialists advocated that the use of capillary blood glucose testing with electronic 
meters during Yom Kippur is permissible in type 1 and type 2 diabetes patients when 
performed appropriately for patients’ welfare and health45;46. Apart from the risk of 
hypoglycaemia, dehydration and subsequent hypotension may also compromise the 
25-hour fast in patients with diabetes. If a patient with diabetes feels strongly about 
proceeding to fast despite physicians’ advice not to, a compromise position may be 
recommended by the rabbi, whereby small quantities of food or drink can be taken at 
specified intervals throughout the day of Yom Kippur, rather than three daily meals45. 
Many Jews also observe additional fasts (tzomot) throughout the year. In Tisha B’Av, 
the ninth day of the month of Av in the Hebrew calendar, fasting also occurs for 25-
hours from sunset to sunset. The other fasting days observed during the year mainly 
last from sunrise to sunset, i.e. daytime-only fast, namely the 10th of Tevet (Asarah 
B’Tevet); the fast of Tammuz; the fast of Gedaliah; and the fast of Esther. 
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1.3.3 Hinduism 
Hinduism is the religion of over 900 million adherents worldwide with the majority in 
India and Nepal47. There are many festivals in Hinduism, with periods of feasting and 
fasting from one to nine days based on the lunar calendar. Fasting also varies from 
total abstinence of food and drink to omitting certain meals of the day or limiting 
some types of food. For instance, Monday is dedicated to the God Shiva when 
devotees of Shiva observe a fast all night and break the fast the next morning, and 
eat the food offerings (made from fruits of the season, root vegetables, and 
coconuts) offered to Shiva. Fasting on Tuesdays honours the Goddess Mariamman 
in Southern India, when devotees only have liquid, but not solid food, from sunrise to 
sunset. In Northern India, Tuesday fast is dedicated to Lord Hanuman, when only 
milk and fruit are allowed to be consumed between sunrise and sunset (Table 1.2).  
The 2001 U.K. census recorded 559,000 Hindus, around 1% of the population in 
Britain. The prevalence of diabetes mellitus has rapidly increased in India in the past 
decades and a similar trend has been observed in South Asian migrants compared 
with other ethnic groups in host countries48. Understanding of the cultural practices 
of fasting and feasting is important to manage these people with diabetes or with 
high risk of developing diabetes and to prevent acute complications. For instance, 
appropriate advice about hypoglycaemia to patients who only takes beverages 
during fasting days is important to improve self-management of diabetes. Morning 
insulin doses may need to be reduced if the lunchtime meal is omitted when fasting 
for these festivals and evening doses may be increased during post-fast meals.  
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1.3.4 Buddhism 
The two major sects of Buddhism are Theravada (mainly in Thailand, Cambodia and 
Sri Lanka) and Mahayana Buddhism (mainly in Tibet, China, Korea and Japan). All 
branches of Buddhism practice some periods of fasting, usually on full-moon days, 
as a method of purification. On the days of observance, the Uposatha days, lay 
Buddhists and monks observe the eight precepts usually once a week, which 
includes abstaining from eating after noon until the following day. High scores for  
Buddhist values were found to be correlated with better medication and dietary self-
care in non-insulin dependent diabetes patients in Thailand49.  
 
1.3.5 Christianity 
The largest proportion of religious affiliates in the U.K. still belonged to the Church of 
England, representing 20% of the respondents of the British social attitudes survey50.  
Fasting usually occurs in Lent; a forty-day period to commemorate the fast observed 
by Jesus Christ during his temptation in the desert and is marked by the period 
between Ash Wednesday and Easter. In the Roman Catholic Church, abstinence 
from meat is observed on Ash Wednesday and every Friday during Lent. For 
Eastern Orthodox and Greek-Catholic Christians, fasting during Lent includes 
refraining from all animal and dairy products for the entire period of Lent.  
 
 
31 
 
Religion When they fast How they fast Why they fast 
Islam Ramadan, 9th month of 
the Muslim calendar 
Abstain from food and 
drink from sunrise to 
sunset for the month of 
Ramadan 
Commemorates 
when the Koran was 
first revealed to the 
Prophet Muhammad 
Judaism Yom Kippur and Tisha 
B’Av are the major days 
of fasting. Other days 
include Asarah B’Tevet, 
Tzom Tammuz, Tzom 
Gedaliah, Tzom Esther 
On Yom Kippur and 
Tisha B’Av, food and 
drink is prohibited for a 
25-hour period, from 
sunset to sunset. On 
other fast days, food 
and drink is prohibited 
only from sunrise to 
sunset. 
Yom Kippur is the 
day of Atonement; 
Tisha B’Av is the 
day of the 
destruction of 
Jewish Temples 
Hinduism On days of new moon 
and during various 
festivals, e.g. Shivaratri, 
Saraswati Puja, and 
Durga Puja 
Fasting varies from 
total abstinence from 
food and drink for 24-
hours to abstinence 
from solid food, or 
particular food, e.g. 
meat or eggs 
For the purpose of 
purification, 
meditation and 
sacrifice 
Buddhism On days of full moon and 
other days in general, 
depending on different 
sects of Buddhism  
Abstain from solid food For the purpose of 
purification and 
meditation 
Christianity Ash Wednesday, Good 
Friday, and all Fridays in 
Lent 
Abstain from meat Lent is the period 
between Ash 
Wednesday to 
Easter Sunday. 
Good Friday 
commemorates the 
day Christ died 
Eastern 
Orthodox 
Lent, Apostles’ Fast, 
Dormition Fast (1st – 14th 
August), and the Nativity 
Fast (15th November – 
24th December), and 
several fast days (Every 
Wednesday and Friday 
is a fast day) 
Abstain from meat, 
dairy products and 
eggs on the day of fast. 
Fish is forbidden on 
some fast days. 
Fast strengthens 
resistance to 
gluttony 
Baha’i Ala, the 19-day fast, from 
March 2 - 20 
Abstain from food from 
sunrise to sunset 
To reinvigorate the 
soul and bring a 
person closer to God 
Table 1.3 A summary of the major fasting days across different religions 
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1.4 Aims 
 To review the current evidence for optimum management of diabetic patients 
who wish to fast during Ramadan and to draw up recommendations for 
optimal diabetes management during Ramadan (chapter 2). 
 To examine the practice of fasting amongst specific groups of Muslim patients 
with diabetes, in particularly pregnant women (chapter 3).  
 To evaluate the impact of the pre-Ramadan assessment on glycaemic 
variability using continuous glucose monitoring (chapter 4). 
 To evaluate the safety and efficacy, in terms of hypoglycaemic events and 
glycaemic control, of using the newer diabetic agents, including glucagon-like 
peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, as well as 
insulin treatments for patients with type 2 diabetes during Ramadan (chapter 
5 and 6). 
 To review the advances and challenges in the research on Ramadan fasting 
(chapter 7). 
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Chapter 2: Review of Diabetes Management during Ramadan 
The evidence for optimum management of diabetic patients who wish to fast during 
Ramadan is reviewed in this chapter, drawing on a small evidence base comprising 
randomised trials, non-randomised comparison studies, and observational studies. 
This is combined with recommendations based on expert consensus.  
 
2.1 Management of people with diabetes planning to fast during Ramadan 
2.1.1 Assessment before Ramadan 
Expert opinion recommends that if a patient has made it clear that they wish to fast 
during Ramadan, their primary care physicians and/or diabetes care specialists 
should assess whether they increase their health risk by doing so51. Table 2.1 
outlines how patients planning to fast during Ramadan may be categorised as high, 
moderate, or low risk of adverse events. Patients classed as high risk are advised 
not to fast as it can lead to worsening diabetes control, resulting in, for example, 
severe hypoglycaemia and diabetes ketoacidosis. Patients at moderate risk can 
reduce their level of risk if they see a healthcare professional several months before 
Ramadan and make necessary changes to their diabetes treatment. Those at low 
risk can fast without healthcare advice. Patients who choose to fast despite advice 
not to do so need support to help them fast as safely as possible. It is worth noting 
that the ADA pre-Ramadan risk stratification is mainly based on expert opinions, 
rather than evidence-based research. More studies on the safety of fasting on 
subgroups of Muslims, such as patients with renal transplant or cardiac disease52;53, 
are emerging and will help to refine the risk stratification profile for specific groups of 
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Muslims and to provide more evidence-based pre-Ramadan advice for these 
patients.      
In case patients miss the opportunity for assessment before Ramadan, discussion 
with patients and provision of information packs that include advice on Ramadan 
fasting can be made available at diagnosis and also at annual diabetic review.  
High risk patients  
Severe and recurrent episodes of hypoglycaemia and unawareness 
Patients with sustained poor glycaemic control 
Ketoacidosis within the last 3 months prior to Ramadan 
Hyperosmolar hyperglycaemic coma within the 3 months before Ramadan 
Those with acute illness 
Those who perform intense physical labour 
Pregnant women 
Those with comorbidities such as advanced macrovascular complications, renal disease on dialysis, 
cognitive dysfunction, uncontrolled epilepsy (particularly precipitated by hypoglycaemia) 
Moderate risk 
Well-controlled patients treated with short-acting insulin secretagogue, sulphonylurea, insulin, or on 
combination oral or oral plus insulin therapy  
Low risk 
Well-controlled patients treated with diet alone, monotherapy with metformin, DPP4 inhibitor or 
thiazolidinedione who are otherwise healthy 
Table 2.1 Expert recommendations for risk stratification in patients with type 1 or type 2 diabetes who 
fast during Ramadan
51;54
. 
 
2.1.2 Ramadan focused education  
Structured education interventions have been endorsed by the National Institute for 
Health and Clinical Excellence as important in empowering patients to improve their 
journey with diabetes55. In a observational study, patients who fasted during 
Ramadan without attending a structured education session had a fourfold increase in 
hypoglycaemic events, whereas those who attended an education programme 
focusing on Ramadan had a significant decrease in hypoglycaemic events56. It is 
therefore recommended that Muslim patients with diabetes attend some form of 
structured education intervention to increase their chance of being well when fasting 
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during Ramadan. Patients at high risk who plan to fast despite medical advice not to 
are also invited to attend structured education to support their self-management and 
decision to fast. Table 2.2 outlines suggested content of Ramadan focused 
education.  
Table 2.2 Four key areas in Ramadan-focused education 
Meal planning and 
dietary advice 
 The diet during Ramadan should not differ from that of a 
healthy balanced diet 
 Slow energy-release foods (such as wheat, semolina, 
beans, rice) should be taken before and after fasting, 
whereas foods high in saturated fat (such as ghee, samosas 
and pakoras) should be minimised  
 Advise patients to use only a small amount of 
monounsaturated oils (such as rapeseed or olive oil) in 
cooking  
 Before and after fasting include high fibre foods such as 
wholegrain cereals, granary bread, brown rice; beans and 
pulses; fruit, vegetables, and salads  
 
Exercise  Light and moderate exercise on a regular basis is safe in 
Type 2 diabetes patients  
 Rigorous exercise is not recommended as the risk of 
hypoglycaemia is increased, particularly in patients taking 
sulphonylureas or insulin 
 Patients should be encouraged to continue their usual 
physical activity, especially during non-fasting periods 
 Tarawaih prayers (multiple prayers after the sunset meal) 
should be considered as part of the daily exercise regimen. 
Blood glucose 
monitoring 
 Blood glucose monitoring does not constitute the break of 
fast  
 All patients who fast should be provided with the means to 
monitor their blood glucose    
 Capillary blood glucose testing should be done when:  
 The patient suspects they have symptoms of 
hypoglycaemia (subjective to the individual). Patients 
should be advised to break their fast if hypoglycaemia is 
confirmed on blood glucose testing 
 The patient is unwell (e.g. has a fever) 
 Testing at other times may be useful only if patients are able 
and willing to adjust their diabetes treatment regimens, such 
as insulin dosage titration 
 
Recognising and 
managing 
complications 
 Patients should be aware of the warning symptoms of 
dehydration, hypoglycaemia and hyperglycaemia, and 
should stop the fast as soon as any complications or acute 
illness occur 
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2.2  Managing type 2 diabetes patients fasting for Ramadan 
2.2.1 Patients taking oral hypoglycaemic agents 
2.2.1.1 Metformin 
Hypoglycaemia occurs in patients with type 2 diabetes taking metformin who are not 
fasting8. One of the mechanisms which metformin reduces hepatic gluconeogenesis, 
lowering blood glucose levels and potentially causing hypoglycaemia, is by inhibiting 
the expressions of hepatic gluconeogenic genes, phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), via AMP protein 
kinase (AMPK)-mediated upregulation of the transcription of the Small Heterodimer 
Partner (SHP) gene57. Metformin-induced increase in AMPK activity is also 
implicated in the stimulation of glucose uptake in skeletal muscle by directly 
phosphorylating the GLUT4 enhancer factor (GEF), increasing the transcription of 
the skeletal muscle glucose transporter, GLUT458. Metformin also reduces fatty acid 
oxidation, thereby enhancing glucose oxidation and reducing the energy supply for 
gluconeogenesis via the glucose fatty acid (Randle) cycle59. Furthermore, the 
glucose-lowering effect of metformin may be explained by its local inhibition of 
intestinal glucose absorption via the AMPK-mediated pathway59 involving intestinal 
glucose transporters, Sodium-dependent glucose transporter-1 (SGLT1) and 
GLUT2.  
A systematic review reported that levels of risk for hypoglycaemia among people 
taking metformin who are not fasting range from 0% to 21%60. No data exist for the 
incidence of hypoglycaemia in people who fast for prolonged periods and take only 
metformin.  
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As iftar is usually the largest meal during Ramadan, expert consensus suggests that 
the metformin dose should be split such that two thirds of the dose is taken at iftar 
and one third at suhur (as the lunchtime dose during the daytime fast is not allowed). 
So for a regimen of, for example, metformin 500 mg three times a day, we 
recommend 500 mg at suhur and 1000 mg at iftar54.  
2.2.1.2 Acarbose 
Acarbose inhibits the action of intestinal brush border alpha-glucosidases, which 
retards glucose absorption and modifies the secretion of insulin61. A randomised 
double-blind study showed that the risk of hypoglycaemia is low with this class of 
drugs62, although we could not find any evidence that this is so during Ramadan. We 
suggest that it is acceptable to continue with the prescribed dose(s) of acarbose 
taken only with meals during fasting.  
2.2.1.3 Rapid acting insulin secretagogues 
An open label, multicentre, randomised study showed that repaglinide, a rapid acting 
insulin secretagogue, contributed to improved glycaemic control, with a lower 
number of hypoglycaemic events among fasting patients during Ramadan when 
compared with glibenclamide. Patients taking repaglinide lowered their fructosamine 
levels from baseline, and there were 0.03 hypoglycaemic events per patient per 
month in this group versus 0.05 events per patient per month in the glibenclamide 
group63.  
A small study compared repaglinide (n=27) with a group of patients taking a 
sulphonylurea [glimepiride (n=23) or gliclazide (n=17)]. Fructosamine, HbA1c, and 
body weight did not change significantly in either group from before to after 
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Ramadan. Hypoglycaemia was documented in only one patient who took glimepiride 
during Ramadan25. The evidence cited suggests that rapid acting insulin 
secretagogues taken at suhur and iftar are a safer alternative than glibenclamide for 
patients who fast. Both sulphonylureas and rapid acting insulin secretagogues act by 
increasing insulin secretion via the ATP-sensitive K+ channels of the pancreatic β-
cells, activating the voltage-gated calcium channels to increase cytoplasmic calcium 
concentration and thereby stimulate the exocytosis of insulin. The difference is that 
they act on different binding sites and therefore, differs in their duration of action64. 
Repaglinide has been shown to enhance early phase insulin secretion more 
effectively than glimepiride and gliclazide MR65 in a non-Ramadan study, without 
prolonging insulin secretion beyond the early phase. Repaglinide has a fast onset 
(peak in 30 – 60 minutes) and short duration of action of 1 hour, compared to 
gliclazide MR (gradual onset in 6 hours, duration of action of 24 hours). Therefore, it 
may be preferable in targeting the post-prandial hyperglycaemia without additional 
hypoglycaemia during fasting periods. However, comparison between repaglinide 
and long-acting gliclazide has not been performed during Ramadan. 
2.2.1.4 Sulphonylureas 
A large prospective observational study (n=332) by the GLIRA study group showed 
that changing once daily glimepiride from a morning dose taken with breakfast 
before Ramadan to an evening dose taken at iftar during Ramadan did not alter 
rates of hypoglycaemia or glycaemic control30. However, the rate of hypoglycaemia 
in patients taking glimepiride in the mornings during Ramadan was not studied, so 
whether that rate was higher than the rate in those taking glimepiride in the evenings 
was unknown. The incidence of hypoglycaemic events did not differ between a group 
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of patients taking once daily glimepiride (n=21) and a group taking twice daily 
repaglinide (n=20) (taken at suhur and iftar)66.  
A recent observational study has shown that 20% of patients on sulphonylurea and 
metformin experienced one or more symptomatic hypoglycaemic events during 
Ramadan. The hypoglycaemic risk varied across agents within this class, with 
incidences observed in subjects treated with glibenclamide (26%), glimepiride (17%), 
and gliclazide (14%), respectively67.  
If a sulphonylurea is being used during Ramadan, slow release preparation may 
have a better safety profile than glimepiride. In a non-Ramadan-related study, the 
GUIDE study (a double-blinded comparison of once-daily gliclazide MR and 
glimepiride), gliclazide MR demonstrated about 50% fewer hypoglycaemic events in 
comparison with glimepride68. In a Ramadan-related study, 136 type 2 diabetes 
males, with well-controlled diabetes and evening administration of gliclazide MR 
60mg as monotherapy during fast, have been shown to have no weight gain or 
increase in hypoglycaemic events during Ramadan (5 episodes before and 3 
episodes during Ramadan)69.  
Based on the above evidence, gliclazide or gliclazide MR appeared to have the 
lowest hypoglycaemic risk. During Ramadan, the recommendation would therefore 
be to change the timing of the once daily dose of sulphonylurea (such as glimepiride 
or gliclazide MR) from the usual morning dose to the evening (at iftar). With regard to 
gliclazide, patients are recommended take a larger dose at iftar than at suhur and 
that clinicians should consider reducing the prescribed dose for suhur if the patient’s 
glycaemic control before Ramadan is stable (for example, change gliclazide 160 mg 
twice daily to 80 mg in the morning and 160 mg in the evening)54.  
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2.2.1.5 Thiazolidinediones 
A randomised controlled trial that compared pioglitazone 30 mg once daily with 
placebo in patients already taking other oral hypoglycaemic agents or alone, found 
no increase in hypoglycaemia during Ramadan fasting70. No studies have been 
reported on the use of rosiglitazone use during Ramadan. Continuing with 
thiazolidinediones during fasting is considered safe.  
2.2.1.6 Dipeptidyl peptidase-4 inhibitors 
A prospective non-interventional study conducted on Muslim patients with type 2 
diabetes showed that adding vildagliptin to metformin treatment was associated with 
a reduced incidence of hypoglycaemic events and improved glucose control 
compared with patients treated with gliclazide and metformin during Ramadan71. 
This suggests that it may be safer to combine dipeptidyl peptidase-4 inhibitors, rather 
than sulphonylureas, with metformin in patients who are not well controlled when 
taking metformin alone and are planning to fast during Ramadan. The findings have 
since been confirmed in a randomised open-labelled study72.  
2.2.1.7 Glucagon-like peptide-1 receptor agonists 
Glucagon-like peptide-1 receptor agonists are currently used in combination with 
other oral hypoglycaemic agents. In non-Ramadan studies, hypoglycaemic events 
associated with glucagon-like peptide-1 receptor agonists occurred primarily in 
patients taking a sulphonylurea73. Our findings (Chapter 5) suggested that its dosage 
does not need to be adjusted during Ramadan but that other agents, such as 
sulphonylureas, may need dose reductions when used as a combination treatment74.  
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2.2.2 Patients taking insulin  
2.2.2.1 Single basal insulin and oral combined treatment 
A multicentre, prospective, observational study compared fasting patients taking 
metformin combined with glimepiride (n=21), repaglinide (n=18), or glargine (n=10)27.  
Although the rate of hypoglycaemia was higher in the glimepiride group (14.3%) than 
in the repaglinide (11%) and glargine (10%) groups, the increased rate was not 
significant. Glimepiride was given before iftar; repaglinide was given with both meals; 
and glargine at 10.00 pm. No studies have compared the incidence of 
hypoglycaemic events in patients taking insulin detemir or isophane insulin (NPH) 
(such as Insulatard or Humulin I).  
In a small prospective non-randomised study of 19 patients who had type 2 diabetes, 
were at low risk of diabetic complications, and had a pre-Ramadan HbA1c 
concentration of less than 8% (64 mmol/mol), neither fasting (n=11) nor non-fasting 
(n=8) patients who were taking repaglinide three times a day and glargine 
experienced hypoglycaemic events, and both groups maintained stable glycaemic 
control29. Those who fasted took repaglinide at iftar, at midnight, and at suhur, and 
the doses of repaglinide and glargine remained unchanged throughout Ramadan. 
We advise patients who take long acting basal insulin, such as glargine, to reduce 
the dose by 20% to avoid hypoglycaemia. Patients taking repaglinide and single 
dose glargine may continue taking the same doses of repaglinide. The timing of 
repaglinide can be rearranged to coincide with suhur and iftar. Even though 
significant hypoglycaemia did not occur when the dose of basal insulin, glargine 
remained the same29, a more cautious approach to avoid hypoglycaemia would be to 
consider reducing glargine by 20% during Ramadan. However, insulin dosage can 
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be highly variable in different individuals, therefore, the 20% reduction would only be 
a suggestion recommended by expert opinions. 
2.2.2.2 Premixed insulins 
A randomised, open labelled, crossover study comparing Humalog Mix25 (25% short 
acting insulin lispro and 75% intermediate acting neutral lispro protamine) and 
Humulin M3 (human insulin 30% soluble, 70% isophane) given in identical doses 
showed that the former offered better control of postprandial blood glucose after Iftar 
and a lower occurrence of hypoglycaemic events75. We performed an observational 
study (Chapter 6), which suggested that using Humalog Mix50 at Iftar instead of 
Mix30/70 reduced hypoglycaemia without compromising the overall blood glucose 
control76. Patients taking twice daily insulin may reduce the suhur dose by 30% if 
they are well controlled, and consider switching to a Mix50 preparation if their 
postprandial glucose remains elevated.  
 
2.3 Fasting during pregnancy 
Pregnant women with diabetes, including gestational diabetes, are exempted from 
fasting and are strongly cautioned against fasting because clear maternal and foetal 
risks are associated with poor glycaemic control in pregnancy77. However, no 
outcome study of women with diabetes specifically related to Ramadan fasting has 
been conducted. We conducted a survey to assess the habit of Ramadan fasting in 
pregnant women with diabetes (Chapter 3). Preconception counselling for diabetic 
Muslim women should include education about the substantial risks associated with 
poor glycaemic control to help to dissuade them from trying to fast.  
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2.4 Managing type 1 diabetes patients fasting for Ramadan 
A small study examined the use of glargine and insulin lispro or aspart, divided in a 
6:4 ratio of the total 24 hour insulin dose in nine patients with type 1 diabetes78. Of 
seven patients who started to fast, five continued for the whole month, and two broke 
the fast owing to hypoglycaemia. None of the patients had any episodes of severe 
hypoglycaemia or diabetic ketoacidosis requiring hospital admission, and the 
patients’ HbA1c concentrations remained stable at the end of Ramadan. As the 
insulin requirement in this study group decreased by 28% from baseline (p=0.002), 
the authors suggested a reduced dose (70% of a patient’s usual dose) during the 
fast.  
An open label, comparative, crossover study of 64 patients with type 1 diabetes 
found significantly lower (p=0.026) two hour, postprandial glucose concentrations 
after iftar and fewer hypoglycaemic events with insulin lispro than with regular human 
insulin79. In both arms isophane insulin (Humulin I) was given as the basal insulin.  
Most studies of patients with type 1 diabetes have comprised small numbers of 
patients and some have excluded adolescents, elderly patients, or patients with 
comorbidities such as renal impairment. Suggested treatments, therefore, may not 
be generalised to all fasting patients with type 1 diabetes, and no good evidence 
exists to allow us to give clear guidance for those who are not on a basal bolus 
regimen.  
Patients with type 1 diabetes who are on a basal bolus regimen four times daily 
should be discouraged from fasting owing to the risks of poor glycaemic control54. If 
patients choose to fast despite medical advice, it will help if they are familiar with 
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carbohydrate counting.  A suggested insulin reduction would be to decrease their 
total daily insulin by  approximately 30% based on the above studies on Type 1 
diabetes78;79 and to omit the midday rapid acting insulin if their capillary blood 
glucose concentration is ≤7 mmol/l. If their blood glucose concentration is >7 mmol/l, 
patients will need to calculate their insulin correction dose as determined by their 
specialists.  
 
In summary 
Table 2.3 summarises the recommendations discussed, based on the best available 
and current evidence and on expert opinions in managing patients who fast during 
Ramadan.  
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Table 2.3 An approach to oral treatment of type 2 diabetes in Ramadan 
 
Type 2 diabetes – planning to fast during Ramadan 
2-4 months before Ramadan 
Medical assessment 
 
Individualised approach 
Review of overall glycaemic control, BP & lipids, renal 
function.  
Body weight and BMI 
Change to diabetes medication regimens, i.e. therapy choice, 
timing and dosage adjustment 
Ramadan focused structured education 
 
To educate patients and carers on the effects of fasting on 
diabetes, including: 
Meal planning and dietary advice with dietician 
Appropriate levels of exercise 
Blood glucose monitoring 
How to recognise and manage acute complications e.g. hypo-, 
hyperglycaemia, dehydration, and when to break fast 
Diet-controlled patients 
 Split daily calories over 2-3 
smaller meals during the non-
fasting interval 
 Eat complex carbohydrates, 
e.g. oatmeal, bran, brown rice 
at Suhur (predawn meal); 
with simple carbohydrates at 
Iftar (sunset meal) 
 Avoid food high in fat & sugar 
 Ensure adequate fluid intake 
during non-fasting interval 
Oral hypoglycaemic agents 
 Choice of treatment should 
be individualised 
 DPP4 inhibitors, rapid acting 
insulin secretagogues and 
TZD may be used at meal 
times without dose 
adjustments 
 Ensure adequate fluid intake  
Injectables Therapies 
Insulin 
 In general, use an overnight intermediate acting 
insulin, plus a rapid acting insulin before meals 
 Adjustment to therapy necessary, e.g. 1) reduce 
insulin glargine dose by 20%; 2) use Mix 50 in the 
evening instead of Mix 30 to avoid postprandial 
hyperglycaemia;  
 
GLP-1 analogues 
No treatment adjustment required 
Metformin 
Modify timing of doses: 
 2/3 daily dose at Iftar 
 1/3 daily dose at 
Suhur 
 If on modified release 
once daily, take dose 
before Iftar (pm) 
rather than Suhur 
(am) 
Sulphonylureas 
Consider dose adjustment, e.g. 
 Reduction in Suhur dose if 
taking twice daily SU, e.g. 
gliclazide 80mg bd – to 
change gliclazide 80mg at 
Iftar (pm) and 40mg at Suhur 
(am)  
Consider timing adjustment, 
e.g. 
 If on once daily SU, switch to 
Iftar meal, e.g. glimepiride 
4mg od – change to 4mg at 
Iftar (pm). 
DDP4 inhibitors 
Consider DDP4 inhibitors 
as an alternative to SU if 
the risk of hypoglycaemia 
is high 
TZDs 
No treatment 
adjustment 
required 
Oral insulin 
secretagogues 
e.g. repaglinide  
 Short-acting 
 Take twice 
daily before 
Suhur (am) 
and Iftar 
(pm) 
Follow-up essential post-Ramadan 
HbA1c, weight, BP, lipids 
Readjustment of medications where appropriate  
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Chapter 3: Fasting among pregnant women with diabetes during Ramadan 
3.1  Health beliefs of Muslim women about Ramadan fasting during 
pregnancy 
Islamic law exempts menstruating, breastfeeding and pregnant women who are 
worried about their health, and/or pregnancy, from fasting during Ramadan80. Many 
Ramadan-related published sources also confirm the belief that Muslim women, who 
believed that fasting will endanger either their own or their foetuses/neonates’ health, 
are exempted from fasting during pregnancy81-84. The Koran14 states that “…fasting 
for a limited number of days. So whoever among you is ill, or on a journey, then an 
equal number of other days are to be made up. And upon those who are able to fast 
but with hardship, a ransom for substitute of feeding a poor person each day”. It is 
believed that fasting during pregnancy causes hardship the same way as illness, 
hence, is exempted with a ransom for substitute or deferred, as illness and travelling 
do80. The Hadith Sharif, a collection of sayings of the Prophet Muhammad, also 
stated that “if a pregnant woman fears for herself or the breast-feeding women fears 
for her child in Ramadan, they should break their fast and feed a poor person for 
each day and they do not have to make up the fast”85.  
3.1.1 Fasting during Ramadan amongst healthy pregnant women 
Although pregnant women are allowed to defer fasting until after the pregnancy, as 
compensational fasting ‘qada’ after pregnancy, pregnant women prefer to share the 
social and religious experience of Ramadan fasting with their families in Middle 
Eastern and African countries86;87. It was observed that 90% of pregnant women in a 
rural West African village fasted throughout the period of Ramadan86.  
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A retrospective study on Muslim pregnant women in Singapore has shown that 87% 
of total respondents (n = 182) fasted during Ramadan81. Among the 158 women who 
fasted, 57% of women fasted more than 21 days, 17% fasted for 11 to 20 days, and 
13% fasted for 1 to 10 days. About two-thirds of women believed that fasting during 
Ramadan is essential and compulsory in a healthy pregnancy and all women were 
aware that compensational fasting can be repaid after pregnancy. 55 out of 158 
women experienced nausea and vomiting, giddiness during fasting but 80% 
overcame the adverse reactions and continued to fast.  30% of primagravidas did not 
fast at all, compared to only 3% of multigravidas. The Mufti, religious leaders in 
Singapore, agreed that if a pregnant woman is worried for her and her foetus’ health, 
she is exempted from fasting. However, if a healthy pregnant woman does not feel 
any worry about her or her foetus and is capable to fast, she is required and 
expected to fast81. The latter is less clear in other Ramadan-related published 
sources but may explain the high prevalence of Ramadan fasting in some countries. 
The joint medical and religious guidance from the Islamic Organisation for Medical 
Sciences and the International Islamic Fiqh Academy agreed that patients with high 
risk of serious complications from fasting are exempted from Ramadan fasting. 
These patients include women with diabetes during pregnancy, patients with 
frequent hypoglycaemia or hypoglycaemic unawareness, and patients known to 
have difficulty in controlling diabetes. On the other hand, patients with low risk of 
complications of fasting are not permissible to break the fast. These include diabetic 
patients with stable situations and controlled by diet and/or the appropriate oral 
hypoglycaemic agents (sulphonylureas, metformin or thiazolidinediones)88.  
Figure 3.1 showed the percentage of healthy women that fasted during pregnancy in 
various countries. In Iran, 65% of pregnant Muslim women (n = 284) fasted for at 
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least 10 days for 13 daylight hours during Ramadan89. In southeast Michigan, United 
States, a total of 32 pregnant women, recruited by leaflet and word-of-mouth from 
Muslim communities, participated in a focus-group discussion about fasting during 
pregnancy. It showed that 28 of them fasted whilst pregnant for at least one day90. In 
United Kingdom, a small study of 44 women showed that 20 women (45%) fasted for 
17 hours in 1987 during Ramadan91.   
 
Figure 3.1 Percentage of healthy women fasted during pregnancy
81;86;89-91
.  
(The studies were conducted at different years and had different study protocols; therefore the diagram cannot be used as a direct comparison of the percentages). 
 
3.2 Effects of fasting in pregnancy in the non-diabetic population 
The physiology of fasting in normal pregnancy was studied in the setting of overnight 
fast. Plasma glucose levels were significantly lower in pregnant women in their third 
trimester after 12 hours of overnight fast (from 18:00 to 06:00 the next morning), 
equivalent to skipping breakfast. Glucose levels fell further during the subsequent 6 
hours of fasting. Plasma alanine levels, one of the sources of circulating fuels, also 
declined significantly during the same time interval, with concurrent rises in plasma 
free fatty acids and beta-hydroxybutyrate and fall in plasma insulin level. In 
Singapore Iran US UK Rural west
african village
87% 
65% 
88% 
45% 
90% 
Percentage of healthy women fasted during pregnancy
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comparison, the plasma levels of these gluco-regulatory hormones (insulin and 
glucagon) and food source (glucose, alanine, free fatty acids and beta-
hydroxybutyrate) in non-pregnant women remained stable after 18 hours fast92. 
Hence, ‘accelerated starvation’ was noticed in pregnant women compared with non-
pregnant women even with minor dietary deprivation in common clinical 
circumstances, such as omitting breakfast. Women who ate fewer than three meals 
and two snacks per day also had a 30% higher risk for delivering pre-term in 
comparison to pregnant women who had met the meal frequencies93. Prolonged 
periods without food lasting 13 hours or longer were associated with elevated 
maternal corticotropin-releasing hormone concentrations compared with those 
without food for periods less than 13 hours. Elevated maternal corticotropin-releasing 
hormone levels were associated with pre-term birth94. Skipping meals and sustaining 
periods without food may stimulate neuroendocrine hormones that lead to pre-term 
labour.  
The question of whether Ramadan fasting is safe in healthy non-diabetic pregnant 
women remains unclear. Some studies on Ramadan fasting have found detrimental 
maternal and foetal effects in pregnant women who fasted. Excessive vomiting and 
hyperemesis gravidarum was found to be associated with fasting in the first month of 
pregnancy95.  
The frequency of foetal breathing movement was significantly less during fasting 
periods compared to post-prandial periods in healthy primagravidas of 30 weeks’ 
gestation or more (n = 63). Foetal breathing movements comprised of normal foetal 
breathing activity and sporadic breathing patterns that resembled sighs, gasps, 
coughs and panting, can affect foetal circulation by influencing the rate of umbilical 
artery blood flow96. The time needed to detect breathing movements was also 
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significantly longer due to the low level of blood glucose concentration during fasting 
than post-prandial periods97.  
Foetal biophysical score is a standard method to assess foetal well-being and 
includes criteria for foetal breathing movements, foetal movements, foetal tone and 
amniotic fluid volume. More foetuses of fasting pregnant mothers (30 out of 81 
foetuses) had a low foetal biophysical score of 6/8 compared with non-fasting 
controls (11 out of 81) matched for age, gestational age and parity (37% versus 
13.6%, p = 0.001). Foetuses in both groups with a biophysical score of 6/8 showed 
no breathing movements98. Reduced foetal breathing movements in fasting pregnant 
women were related to low maternal glucose levels during fasting period. Following 
maternal ingestion of glucose, foetal movements were shown to be increased 99, with 
maximum movements one hour following the peak maternal plasma glucose 
concentration100. 
Despite significant difference in the foetal breathing movements between fasting and 
non-fasting pregnant women, other components of the foetal biophysical score, 
namely gross body movements, foetal tone and amniotic fluid volume remained 
similar between fasting and non-fasting groups98. Other foetal and maternal 
outcomes were not included in the study and it was unclear whether transient 
reduction in foetal breathing movements would have any long-term effects to the 
mother and child.      
Other studies demonstrated that Ramadan fasting has no harmful effect on the 
unborn baby. In a case-control study comparing fasting (for at least 20 days during 
Ramadan) and non-fasting women, there were no significant differences between 
the two groups with regards to the intrauterine growth rate in the second trimester, 
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neonatal mean birth weight and the amniotic fluid volume84.  There was also no 
significant effect of Ramadan fasting on maternal blood pressure and weight in the 
101 women who fasted84. An analysis of twenty-year trends of birth weights of full-
term babies (n = 13 351) to Asian Muslim women in comparison to non-Muslim Asian 
and Caucasian births showed that Ramadan had no effect on the birth weights of 
babies born at full-term in the United Kingdom. However, there was no indication of 
how many of the women included in the study adhered to Ramadan during 
pregnancy and the study did not take into account the difference in the length of time 
between sunrise and sunset in the twenty year period101. A retrospective cohort 
study from Iran showed that there was no significant difference in the birth weight of 
neonates from mothers with a history of Ramadan fasting during pregnancy 
compared to neonates of non-fasting women89. In a prospective study of 36 Turkish 
women with uncomplicated pregnancy, maternal fasting of 13 – 14 hour each day for 
at least 18 days during Ramadan did not lead to significant ketonaemia or ketonuria. 
The change in measurements of foetal biparietal diameter, foetal femur length, foetal 
biophysical profile, amniotic fluid index and umbilical artery systole/diastole ratio in 
the beginning and the end of Ramadan were not significantly different between the 
fasting and non-fasting women102. Transient ketonuria may occur during healthy 
pregnancy as a result of dehydration and caloric restriction or prolonged starvation. 
Ketones has been shown to alter the amniotic fluid volume in ewes in response to 
maternal dehydration103. The results indicated that fasting for about 13 -14 hours 
each day did not cause significant ketonaemia in the pregnant women102, in contrast 
to the earlier studies92;94. Moreover, there was no difference in ketone levels 
between fasting and non-fasting women at more than 20 weeks gestation. The 
fasting pregnant women were given advice to drink at least two litres of water when 
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they ‘break’ fast after sunset, which may prevent the build-up of ketones in these 
fasting subjects.  
Despite the short-term reduction on foetal breathing movements, Ramadan fasting 
did not appear to have any effects on intrauterine growth and neonatal birth weight at 
full term. It seems that the newborns of fasting women are able to withstand 
intermittent and short durations of hypoglycaemia without affecting its glycogen 
storage. Some authors have suggested that fasting for less than 15 hours may not 
be metabolically different from a physiological overnight fast during sleep for the 
healthy pregnant women90. Although the research to date is reassuring, there is still 
insufficient evidence to conclude that fasting during pregnancy is safe. Table 3.1 
showed a summary of the studies on the effect of Ramadan fasting in healthy 
pregnant women and their neonates. 
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Study Study Design Gestation Comparison Neutral Outcomes Detrimental 
Outcomes 
Mirghani et 
al. 2007 
Cross-
sectional 
observational 
study 
20-24 
weeks 
53 fasting vs. 53 non-
fasting women 
Similar uterine arterial blood 
flow velocity 
 
Mirghani et 
al. 2004 
Cross-
sectional 
observational 
study 
30 weeks 
or more 
81 fasting vs. 81 non-
fasting women 
Similar mean umbilical 
artery pulsatility index, 
vertical amniotic pool depth, 
and foetal bladder volume 
Reduced foetal 
biophysical score 
in fasting women 
Mirghani et 
al. 2003 
Observational 
study 
30 weeks 
or more 
63 women during 
fasting and post-
prandial periods 
 Reduced foetal 
breathing 
movement; 
Longer time 
needed to detect 
breathing 
movement 
Cross et al. 
1990 
Retrospective 
study 
n/a 13,351 babies to 
Asian Muslim 
mothers (assumed to 
be fasting during 
Ramadan) vs. 13,351 
white and 5106 non-
Muslim births from 
1964 - 1984 
Similar mean birth weight in 
Asian Muslim women 
 
Dikensoy et 
al. 2008 
Prospective  20 weeks 
or more 
36 fasting vs. 29 non-
fasting women 
Similar (the differences 
before and after Ramadan 
between groups) foetal 
biparietal diameter; foetal 
femur length; estimated 
foetal body weight; foetal 
biophysical profile; 
amniotic fluid index; and 
umbilical artery systole/ 
diastole ratio  
No change in urinary ketone 
concentration 
 
Kavehmanesh 
et al. 2004 
Retrospective 
cohort study 
n/a Neonates of 284 
women fasted during 
pregnancy vs. 255 
women who did not 
fast 
Similar neonatal birth 
weight, height and preterm 
delivery (adjusted for 
maternal body mass index) 
 
Naderi et al. 
2004 
Case-control 
study 
18 to 28 
weeks 
51 fasting vs. 50 non-
fasting women 
Similar maternal weight 
increase, intrauterine 
growth (in terms of fundal 
height increase, amniotic 
fluid volume) during 
Ramadan 
Similar neonatal birth 
weights (matched) 
 
Table 3.1 A summary of the effect of Ramadan fasting in healthy pregnant women and their neonates. 
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3.3 Effects of fasting in pregnant population with diabetes 
There is limited data on the effect of intermittent fasting in pregnant women with 
diabetes. In 10 insulin-dependent diabetic women (the type(s) of diabetes was not 
specified) of more than 5 years duration in their third trimester were consented and 
ethnically approved to undergo insulin-induced hypoglycaemia, achieved by lowering 
plasma glucose from 95 mg/dl (5.3 mmol/l) to 45 mg/dl (2.5 mmol/l) using insulin 
clamp technique at Yale Clinical Research Centre. The number of foetal limb and 
breathing movements, and foetal heart rate did not change significantly in spite of 
progressive lowering of blood glucose levels104.  
In the EPIDIAR study15, the largest multi-centred epidemiological survey on the 
prevalence of fasting during Ramadan and its implications on people with diabetes, 
half of the respondents were women with the mean age of 31 ± 12.7 (standard 
deviation, SD) years for type 1 and 54.0 ± 11.0 (SD) years for type 2 diabetes. The 
majority of the patients fasted during Ramadan and had a significant increase in 
severe hypoglycaemic and hyperglycaemic complications during Ramadan. Although 
the study did not mention the specific population of pregnant women with diabetes, it 
was speculated that some pregnant women with diabetes also fasted during 
Ramadan.  
 
3.4 The practice of Ramadan fasting in pregnant women with diabetes 
The aims of this survey were to examine the practice of fasting among pregnant 
Muslim women with diabetes and to explore the factors that influenced the decision 
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to fast in London, the United Kingdom. The roles of healthcare professionals and 
Imams (Muslim religious leaders) in the decision to fast were also examined.  
3.4.1  Methods 
Standardised questionnaire-based one-to-one interviews were conducted on Muslim 
women with diabetes, who received antenatal care at 4 specialist antenatal centres 
in Northwest London from the start of Ramadan 2010 to the end of December 2010.  
Setting 
The survey was carried out in conjoint antenatal endocrine clinics run by 
obstetricians and diabetes specialist doctors in 4 London hospitals: Northwick Park 
Hospital, Central Middlesex Hospital, Hammersmith Hospital, and West Middlesex 
University Hospital.  Patients attending the clinics were invited to participate in the 
survey if they had any type of diabetes mellitus, Muslim, and pregnant. The 
consulting specialist diabetes doctors or midwives identified the patients, obtained 
verbal consent and conducted the questionnaire survey during the clinic 
consultations. The doctors and midwives agreed to take part in the survey and were 
briefed about the questionnaire before the start of Ramadan 2010. The questionnaire 
served as part of the consultation to assist the doctors and midwives with issues 
regarding fasting during Ramadan. 
Questionnaire 
The participants were invited to fill in the standardised one-page questionnaire 
(Appendix 1) requiring mainly ‘yes’ or ‘no’ answers. The questionnaire covered the 
following topics: 
1) Types of diabetes mellitus: type 1 (T1DM), type 2 (T2DM), gestational (GDM) 
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2) Prevalence of fasting for Ramadan during pregnancy 
3) Discussion of fasting for Ramadan with healthcare professionals and/or 
Imams 
4) Prevalence of glycaemic complications (hypo- and hyperglycaemia) 
associated with fasting during pregnancy 
The questionnaire was developed following the questions asked in the EPIDIAR 
study15. The questionnaire was piloted on non-pregnant Muslim patients with 
diabetes at Central Middlesex Hospital and was reviewed by two consultant 
diabetologists. No changes were made to the questionnaire following the pilot.  
Local National Health Service Trust Clinical Audit and Effectiveness committee 
approval to conduct the survey was sought before it was undertaken. 
3.4.2 Results 
A total of 48 women were invited and completed the questionnaire. Mean age (+ SD) 
was 32 + 5 years.  31 (65%) women had gestational diabetes (GDM), 15 (31%) had 
type 2 diabetes (T2DM), and 2 had type 1 diabetes (T1DM). 21 (44%) were diet-
controlled, 12 (25%) were on oral hypoglycaemic agent(s), 10 (21%) on insulin, and 
5 (10%) were taking insulin and metformin. Participant characteristics are shown in 
Table 3.2.  
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Characteristics Number of patients Percentage 
Age (years) 
20 - 29 14 29% 
30 - 39 21 44% 
Not stated 13 27% 
Type of Diabetes 
Type 1  2 4% 
Type 2  15 31% 
Gestational diabetes 31 65% 
Diabetes treatment* 
Diet 21   
(4 T2DM; 17 GDM) 
44% 
Metformin 12   
(6 T2DM; 6 GDM) 
25% 
Insulin 10 
(2 T1DM; 2 T2DM; 6 GDM) 
21% 
Insulin and metformin 5 
(3 T2DM; 2 GDM) 
10% 
Table 3.2 Characteristics of the pregnant women with diabetes  
* Diabetes treatment at the time of the questionnaire interview 
 
Five out of forty eight pregnant women fasted during Ramadan. Three of the five 
women fasted for the entire month of Ramadan without experiencing hypoglycaemia. 
Two of them had gestational diabetes on insulin and/or metformin; the third patient 
had type 2 diabetes on diet-control at the time of interview.  Table 3.3 showed the 
characteristics of women who fasted during pregnancy. 
 
 
Table 3.3 Characteristics of the women who fasted during pregnancy 
 
 
Patient Type of 
diabetes 
Diabetes 
treatment 
Fasting whilst 
Pregnant 
previously 
Number of days 
fasted during 
Ramadan 
Discussion with 
healthcare 
professional 
Discussion 
with Imam 
1 T1DM Insulin N 14 Y Y 
2 T2DM Diet N 30 N N 
3 T2DM Oral Y 5 N Y 
4 GDM Insulin + 
metformin 
Y 30 N Y 
5 GDM Insulin Y 30 N Y 
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One of the patients with type 2 diabetes (patient number 3) fasted for 5 days only as 
there was a history of hypoglycaemia before the month of Ramadan (Table 3.4). The 
patient was on oral medication(s). However, the type of oral hypoglycaemic agent(s) 
was not documented. She discussed the issue of fasting with an Imam but not a 
healthcare professional. Patient Number 2 also had type 2 diabetes, but diet-
controlled. She did not have hypoglycaemic complications associated with fasting 
and completed a whole month of fasting. She did not seek medical or religious 
advice prior to fasting. 
The patient with type 1 diabetes fasted for 14 days and experienced hypoglycaemia 
during the fast. She had not been pregnant during previous Ramadan periods but 
had discussed with both healthcare professionals and her community religious 
leaders whether it was safe to fast.  
3 of these women had fasted previously whilst pregnant during Ramadan and had 
only consulted their Imams, but not healthcare professionals, regarding whether it 
was safe for them to fast.  
 
 
Table 3.4 Glycaemic control in the women who fasted during pregnancy 
*glucose readings indicated capillary blood glucose levels in mmol/l 
Patient Type of 
diabetes 
History of 
hypoglycaemia 
before Ramadan 
Hypoglycaemia 
during fasting 
periods of 
Ramadan 
Frequency of 
hypoglycaemia 
during fasting 
hours 
Hyperglycaemia 
during Ramadan: 
highest glucose 
readings* during 
Ramadan 
1 T1DM Y Y 4 19 
2 T2DM N N 0 Not recall high 
readings 
3 T2DM Y N 0 13 
4 GDM N N 0 Not recall high 
readings 
5 GDM N N 0 11 
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The majority of pregnant women did not fast during Ramadan. Of the forty-three non-
fasting pregnant women, ten (23%) had a history of hypoglycaemia during Ramadan. 
Seven of these women were on insulin treatment: five had type 2 diabetes, one had 
GDM, and one had type 1 diabetes. Their hypoglycaemic experiences were not 
specifically related to fasting whilst pregnant in previous Ramadan, as no non-fasting 
women who had hypoglycaemia had been pregnant whilst fasting during Ramadan 
(Table 3.5).  
During previous Ramadan  No. of non-fasting women who had hypoglycaemia 
pregnant and fasted  0 
never pregnant and not fasted  1 
fasted but never pregnant 2 
pregnant but not fasted 1 
not documented 6 
total 10 
Table 3.5 Experience of hypoglycaemia during previous Ramadan periods in non-fasting women  
 
Among the 43 non-fasting women, 4 consulted both their Imam and healthcare 
professionals. 9 had consulted healthcare professionals only and 3 had discussed 
with their Imam only. Thirteen patients (33%) had consulted their doctors or nurses 
about the issue of fasting, and seven (18%) had discussed with their Imams (table 
3.6).  
Table 3.6 Comparison between the pregnant women with diabetes who fasted and who did not fast 
during Ramadan  
 
Fasting women 
No. (%) 
Non-fasting women  
No. (%) 
  Glycaemic control during Ramadan: 
    Hypoglycaemia  1 10 
    Hyperglycaemia  3 4 
  Ramadan discussions with: 
    Healthcare professionals 0 9 
    Imams 3 3 
    Both 1 4 
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The majority of non-fasting women (39/43) did not recall any hyperglycaemia, 
whereas 3 of the 5 fasting women recorded hyperglycaemia during Ramadan period. 
The highest capillary blood glucose readings ranged from 11 – 19 mmol/l (Table 
3.3).  
3.4.3 Discussion 
From our survey of pregnant women with diabetes, 10% fasted during Ramadan. 
This is in contrast to previous studies on healthy pregnant women who did not 
specifically have diabetes, where 45 – 90% of pregnant Muslim women fasted81;89-91. 
Moreover, 52 – 99% of non-diabetic Muslim adults in Asia, Africa and Europe 
observed fast. Although the specific proportion of non-diabetic Muslim women who 
fasted were not unknown, Muslim men and women were found to be equally 
committed to their religious belief105. The lower percentage of fasting in our group of 
high-risk women reflects the widely accepted belief that a women should not fast if it 
would hurt her or the baby. This was the sole reason for not fasting during pregnancy 
in a group of Muslim women in America90. Higher education level (English-speaking) 
and the urban background of these women may also have influenced their decision 
not to fast, as immigrant Muslims and women from rural areas tended to choose to 
fast86;91. Most of the women in the study (65%) had gestational diabetes which would 
be a new diagnosis in pregnancy. Women appeared to give up Ramadan fasting 
sooner after a diagnosis of diabetes than did men106, suggesting that a new 
diagnosis of gestational diabetes may make these women give up fasting.  
Twenty-three per cent of the women that did not fast had a history of hypoglycaemia. 
Seven out of ten women with a history of hypoglycaemia were on insulin treatment, 
which can be the cause of hypoglycaemia on prolonged fasting. One of the 
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limitations was that the questionnaire did not elaborate on previous experience of 
pregnancy and fasting, six of the ten women did not have documentation regarding 
previous history of pregnancy and fasting.  
As mentioned, Muslim women who believed that fasting will endanger either their 
own, or their foetuses or neonates’ health, are exempted from fasting during 
pregnancy. Having diabetes with the risk of hypoglycaemia may be the reason that 
these women did not fast during Ramadan, in comparison to healthy pregnant 
women who have been shown to be keen to fast despite adverse reaction81. The 
high incidence of hypoglycaemia (23%) in the population that did not fast may be the 
inhibiting factor towards fasting.  
Even though 62% (27 out of 43 women) did not consult healthcare professionals or 
religious leaders for advice, they made conscious decisions themselves not to fast 
for Ramadan whilst pregnant. Women may consult other people apart from religious 
advisors and healthcare professionals, such as family members107 and, in 
particularly, their husbands who tended to discourage fasting when they felt that the 
women were endangering themselves90.   
Three of the five women in the fasting group had fasted previously whilst pregnant 
and had only consulted their Imams, but not healthcare professionals. Two of these 
patients had gestational diabetes; and one had type 2 diabetes. These patients may 
not have diabetes prior to current pregnancy and may feel well enough to fast during 
previous pregnancy. None of the patients with type 2 diabetes or gestational 
diabetes had discussed the issue of fasting during pregnancy with healthcare 
professionals, as they may not be aware of the implications of diabetes in 
association with fasting during pregnancy.  
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For those who seek perinatal advice about fasting, more women in the non-fasting 
group discussed with their healthcare professionals than their Imams regarding 
fasting during Ramadan, whereas the fasting women mainly discussed Ramadan 
with their Imams. Overall, women were just as likely to discuss fasting with their 
Imams as they were with healthcare professionals (11 discussed with Imams and 14 
discussed with healthcare professionals; within each group 5 discussed with both).  
In comparison, a study in the south of France with large Muslim communities 
evaluated attitudes in hospital inpatients towards Ramadan fasting and diabetes 
(n=101). 65 patients had discussed the feasibility of fasting with their general 
practitioner (GP), and 25 patients sought advice from the local Imam. All the patients 
that had counselling from their Imam followed his advice, whereas more than half of 
those who were advised by their GPs not to fast did so anyway107. The role of 
religious advisors are as important, and sometimes, even more important, in 
deciding to fast or not. Some GPs may lack the specific medical knowledge and 
cultural competence to provide appropriate counselling to Muslim pregnant women 
regarding Ramadan fasting.  
One of the limitations of the survey was that it relied on the retrospective recall of 
patients’ past experience of Ramadan fasting. The small overall number of 
participants and the number of women with hyperglycaemia may represent under-
reporting. This survey mainly focused on understanding the current practice of 
Ramadan fasting among pregnant women with diabetes in London. It would be 
useful to further extend the questions to directly include ‘reasons for fasting or not 
fasting’. Information of the parity would also be helpful to delineate the factors that 
influence fasting, as more multiparous women has been shown to fast compared to 
primiparous women81. Information on the length of stay in London and U.K. would 
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also be helpful to assess the effect of different generations of immigrants on their 
commitment to fast. In addition, as London is the most ethnically diverse city in the 
UK108, the sample may not be representative of all Muslim women with diabetes in 
other regions of the UK. Extending the survey beyond London, to other UK cities and 
other countries would provide a more comprehensive view of Muslim women with 
diabetes. Further research will be helpful to determine whether women in utero 
during Ramadan affect maternal and foetal outcomes.  
As the questionnaire served as part of the antenatal clinic consultation, all of the 
women agreed to answer the questions. Appropriate advice and management plan 
were given accordingly by the consulting healthcare professionals. Although each 
clinic visit appeared to have a reasonable number of Muslim patients, these women 
were seen in the clinics frequently every 1 – 2 weeks. This may explain the small 
overall number of participants across the four clinics as each woman was only 
interviewed once even though they attended the clinic repeatedly during the studied 
period.    
In conclusion, the majority of Muslim women, who were both pregnant and had 
diabetes during pregnancy, did not fast for Ramadan. A history of hypoglycaemia and 
the presence of medical illness, namely diabetes, were the deterrent factors for 
fasting. For those who planned to fast whilst pregnant, medical and religious advice 
are both important to ensure that the mother, pregnancy and foetus will not be 
compromised by the fast and that the mother is able to make an informed decision to 
fast.  
Pre-Ramadan assessment and education about the potential complications of fasting 
is essential to stratify the risk of fasting and to provide adequate advice for people 
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with diabetes109. In this specific population of Muslim women with diabetes, pre-
conception care should include education on the risks of fasting during Ramadan.  
Further education for our healthcare professionals is important to understand the 
cultural behaviour and dilemmas faced by these Muslim women and to provide 
appropriate advice specific to Ramadan fasting. Further research is required to 
determine whether there are changes in the maternal and foetal complication rates, 
such as still birth rates, preterm delivery, macrosomia and other structural 
abnormalities, if the women are pregnant during Ramadan.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
Chapter 4: Low glycaemic variability in type 2 diabetes subjects following pre-
Ramadan assessment and adjustments for fasting during Ramadan  
4.1 The role of continuous glucose monitoring for fasting people with diabetes  
Ramadan is the ninth month of the Islamic Lunar calendar, during which Muslims 
abstain from food and fluid intake between dawn and sunset. Major changes to 
dietary patterns occur during Ramadan as meals are taken before dawn, known as 
Suhur, and immediately after sunset, known as Iftar. People with type 2 diabetes 
fasting during Ramadan have large increases in glycaemic excursions with a 7.5-fold 
increased frequency of severe hypoglycaemia and a 5-fold increase in severe 
hyperglycaemia15.  
During Ramadan, it is difficult to study glucose excursions using HbA1c as it does 
not reflect short-term glucose variations during the month of fasting. Even though 
studies did not demonstrate any significant changes in HbA1c24 or fructosamine 
levels110,37 during Ramadan in people with type 2 diabetes, it is the glycaemic 
variability leading to severe hypoglycaemia and hyperglycaemia that matters for 
these patients to fast safely for prolonged period. As diabetes patients undergo 
major changes in their dietary habits during Ramadan, continuous glucose 
monitoring (CGM) may be a better tool to examine the glycaemic variability in 
patients with diabetes who fast during Ramadan, particularly in patients with 
hypoglycaemia. CGM is helpful in detecting subclinical hypoglycaemic episodes111 
and provides additional indices for the assessment of GV that are not captured by 
HbA1c112.  
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4.1.1 Glucose variability and diabetes complication risk 
In patients with similar HbA1c values in the Diabetes Control and Complications trial 
(DCCT), the rates of retinopathy were significantly lower in the intensive cohort, 
suggesting that additional factors, such as glycaemic variations, may play a role in 
complication risk113.  
Glycaemic variability is implicated in the increased mortality risk amongst adults in 
the critical care setting114, as is hypoglycaemia115. An increase in glycaemic 
variability probably also increases the risk of severe hypoglycaemia116. As both 
factors are closely related to the risk of mortality, it would be difficult to tease out 
either’s contribution to mortality.  
Excessive glycaemic excursions can induce oxidative stress leading to endothelial 
dysfunction117,118. Oscillating blood glucose concentrations have been shown in 
clamp studies to have a worse effect on endothelial function than stable 
hyperglycaemia119 and endothelial dysfunction has been implicated in the preclinical 
stages of atherosclerosis120.  
In terms of microvascular endpoints, the fasting plasma glucose variation coefficient, 
as a measurement of glycaemic variability, was considered as a risk factor for 
diabetic retinopathy in patients with type 2 diabetes121.  
As for macrovascular complications, the Diabetes Interventional Study 
demonstrated, after an 11-year follow up of 1139 newly diagnosed type 2 diabetes 
individuals, that postprandial, but not fasting, hyperglycaemia was a significant 
predictor of myocardial infarction and mortality122. However, the trial was criticised for 
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calculating the prediction of myocardial infarction from the baseline plasma glucose 
rather than that during the time course of the trial.  
On the other hand, the A1C-Derived Average Glucose (ADAG) study showed that 
indices of glycaemic variability, namely standard deviation, mean amplitude of 
glucose excursion (MAGE), and continuous overlapping net glycaemic action 
(CONGA), and 2-hour post-prandial hyperglycaemia, were not significantly 
associated with known cardiovascular risk factors (lipids, high-sensitivity C-reactive 
protein and blood pressure). In comparison, mean blood glucose and HbA1c were 
stronger associations with the cardiovascular risk factors in patients with type 1 or 2 
diabetes123. Nonetheless, there are still no direct conclusions regarding the impact of 
postprandial glucose levels and glucose variability on actual cardiovascular events. 
Moreover, the aforementioned studies were performed in diabetes subjects on 
normal diet, rather than during prolonged fasting and feasting of Ramadan.  
Whilst the relationship between glucose excursions and the aetiology of vascular 
complications in diabetes is complicated, severe hypoglycaemia and hyperglycaemia 
are associated with increased hospital admissions, reduced quality of life124 and a 
decrease in the quality of glycaemic control125 in people with type 2 diabetes. 
Therefore, targeting glycaemic variability is essential in the management of diabetes 
during Ramadan to empower people with diabetes to fast safely for prolonged 
periods.  
The American Diabetes Association (ADA) has published recommendations on 
diabetes management during Ramadan, focusing on individualised care and pre-
Ramadan structured education to minimise the risks of severe glycaemic 
excursions109;126. The objective of this study was to implement the ADA 
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recommendations for the management of diabetes during Ramadan, focusing on 
pre-Ramadan assessment, and to evaluate the impact of the guidelines on 
glycaemic variability using continuous glucose monitoring in fasting and non-fasting 
hours.  
 
4.2 Impact of pre-Ramadan assessment on glycaemic variability: Methods 
4.2.1 Subject characteristics 
Muslim subjects over 18 years old with type 2 diabetes attending a specialist 
diabetes clinic in Brent, and planning to fast for Ramadan with a history of 
hypoglycaemia (symptomatic or documented capillary blood glucose (BG) < 4.0 
mmol/L), were invited to undergo a five-day glucose profile using the Abbott 
Freestyle Navigator (Abbot Diabetes, Alameda, CA) continuous glucose monitoring 
system as part of their clinical investigation. They were treated according to the 
American Diabetes Association’s recommendations for management of diabetes 
during Ramadan109. Timing and dosage of diabetes medications were adjusted at 
their pre-Ramadan clinic visits when clinically indicated according to the ADA 
recommendations.  
4.2.2 Study procedure and data collection 
The continuous glucose monitoring (CGM) device was implanted for a random 5-day 
period during the month of Ramadan 2010 in the United Kingdom. Daily fasting 
duration ranged from 13 to 16 hours. Data from the CGM device were downloaded 
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using CoPilot® Healthcare Management System 4.0 (Abbot Diabetes, Alameda, 
CA). 
4.2.3 Outcome measures 
The following outcome measures were evaluated:  
1) Glucose control: mean glucose, percentage of time in low (<4.4 mmol/L), normal 
(4.4 – 10.0 mmol/L) and high (>10.0 mmol/L) glucose ranges.  
2) Glycaemic variability (GV): standard deviation of mean blood glucose (SD), M-
value, mean amplitude of glycaemic excursion (MAGE), lability index (LI), J index, 
continuous overlapping net glycaemic action (CONGA), average daily risk ratio 
(ADRR), low blood glucose index (LBGI), high blood glucose index (HBGI). These 
indices were calculated using EasyGV software (available free at www.easygv.co.uk) 
and have been extensively reviewed127.  
As the continuous glucose monitoring was conducted as part of clinical service 
without reference to a standard. The choice of using the continuous glucose 
monitoring was that of the clinicians and the patients according to professional 
standards and patients’ preference, central ethics committee approval was not 
sought for the study. 
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4.3 Results 
4.3.1 Individual glycaemic variability 
A total of nine subjects participated. 6 of them completed the 5-day monitoring. 
Three patients failed due to insufficient sensor data collections.  Sensors/transmitters 
were detached from 2 subjects during the monitoring period without the participants’ 
knowledge, and the remaining subject did not calibrate the sensor adequately. 
However, no adverse events related to the use of the CGM device were reported.  
Mean age of the participants (n=6) was 53.7 ± 2.3 years, mean duration of diabetes 
7.3 ± 2.8 years and HbA1c pre-Ramadan was 7.6 ± 1.1% (60 ± 1.1 mmol/mol) (Table 
4.1).  The presence of diabetic complications were documented in the diabetic 
patient database and updated during each clinic consultations. Retinopathy was 
assessed by community retinal screening programme; nephropathy was assessed 
using urinary albumin:creatinine ratio performed annually or as clinically required; 
painless and painful neuropathy was assessed during history taking and examination 
using the 10g monofilament test. All subjects fasted for more than fifteen days during 
Ramadan and fasted from dawn to sunset during the whole interval of their CGM. 
Table 4.1 The baseline characteristics of the 6 participants who completed the continuous glucose 
monitoring during Ramadan.  
 
 
 
Participant 
HbA1c (%) 
pre-
Ramadan Age 
Duration of 
diabetes 
(years) BP (mm/Hg) Retinopathy Nephropathy Neuropathy 
1 6.3 53 10 138/74 N N N 
2 9.2 53 9 120/79 Y Y N 
3 8.4 57 6 126/72 N N N 
4 7.4 50 10 130/80 N N N 
5 7.7 55 6 135/82 N N N 
6 6.8 54 3 126/75 N N N 
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All participants had pre-Ramadan assessments and 3 required dose and time 
adjustments of their diabetes medications (Table 4.2). Patient 2 decided to fast 
despite high pre-Ramadan HbA1c, therefore, he had insulin dose increase during 
Ramadan, instead of insulin reduction according to the ADA recommendations. 
 
Table 4.2 The adjustments in timing and dosage of the participants’ medications pre-Ramadan, and 
the mean tissue glucose (BG) during continuous glucose monitoring. 
*Participant 4 had time and dose adjustments for metformin from thrice daily to twice daily. 
Participant Doses and timing of 
medications before 
Ramadan 
Doses and timing of 
medications during 
Ramadan 
Time 
adjust-
ment 
Dose 
adjust-
ment 
Mean BG 
(mmol/L) 
1 Metformin 500 mg od 
(lunchtime) 
Metformin 500 mg od 
(Iftar) 
Y N 7.8 
2 Humalog Mix 50 
(19 and 25 units), 
Metformin 1g tds, 
Sitagliptin 100 mg od 
Humalog Mix 50 
(21 and 28 units) 
Metformin 1g bd 
Sitagliptin 100 mg od 
Y Y 13.6 
3 Metformin 850 mg od 
Vildagliptin 50 mg bd 
 
Metformin 850 mg od 
Vildagliptin 50 mg bd 
(Suhur and Iftar) 
N N 7.6 
4 Metformin 850 mg tds 
Gliclazide 160 mg bd 
Metformin 850 mg bd* 
(Suhur and Iftar) 
Gliclazide 160 mg bd 
Y Y 10.4 
5 Metformin 500 mg 
(breakfast),1g 
(evening) 
Gliclazide 160 mg bd 
Metformin 500 mg 
(Suhur), 1g (Iftar) 
Gliclazide 160 mg bd 
N N 6.8 
6 Glimepiride 2 mg od 
(evening) 
Glimepiride 2 mg (Iftar) N N 7.4 
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4 participants had 84–95% of their glucose control within the target range (4.4 – 10.0 
mmol/L). Participant 2, who was on premixed insulin, metformin and dipeptidyl 
peptidase IV inhibitor, had 93% of the glucose control in the high glucose range (> 
10mmol/L), requiring insulin dose adjustments pre-Ramadan, as well as after CGM. 
Participant 4 spent 46% of the time in target and 54% above (Table 4.3).  
No severe hypoglycaemia requiring third party assistance was reported during the 5-
day monitoring period. Three subjects had documented glucose values of less than 
4.4 mmol/L (i.e. below %, Table 4.3). However, two of these participants had glucose 
value < 4.4 mmol/L for only 1 - 2% of the total monitored period. The 1% Below 
target reading in participant 3 constituted to spurious sensing by the CGM device at 
the end of the monitoring period. The 2% Below target reading in participant 4 
comprised of glucose levels between 4.1 – 4.3 mmol/L. They occurred during the 
first day of monitoring just before the breaking of fast at 17:40 – 18:50 in the evening. 
The patient was asymptomatic and did not require any intervention. There were no 
other clinically significant hypoglycaemic episodes of less than 4.4 mmol/L in 
subsequent days.  
The hypoglycaemic episodes were clinically significant in participant 5 who spent 
10% of their time with a tissue glucose value between 3.3 - 4.0 mmol/L, mainly less 
than an hour before Iftar (sunset meal) and before Suhur (sunrise meal). The 
gliclazide dose was halved to 80 mg bd after the CGM results were obtained and the 
patient continued to fast during the rest of the month without documented 
hypoglycaemia on capillary blood glucose monitoring.  
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Table 4.3 Percentage of time spent above (> 10.0 mmol/L), within (4.4 – 10.0 mmol/L) and below (< 
4.4 mmol/L) target glucose range.  
 
4.3.2 Glycaemic variability during fasting and non-fasting periods 
Although the resulting measures of glycaemic variability, as indicated by mean 
amplitude of glycaemic variability (MAGE), lability index, J index, continuous 
overlapping net glycaemic action (CONGA), and M-value were higher during non-
fasting hours when participants break their fast between sunset and dawn, there was 
no significant difference when compared to the fasting periods (Table 4.4).  
The risk of hypoglycaemia as measured by low blood glucose index (LBGI) was not 
significantly different between the fasting hours compared with the non-fasting hours 
(9.45 ± 18.96 vs. 1.21 ± 1.12; p=0.35).  
High blood glucose index (HBGI), an indicator of hyperglycaemic risk, was also 
similar across the two periods (6.41 ± 7.21 vs. 10.46 ± 10.99; p=0.15).  
The average daily risk ratio (ADRR), a predictor of future hypoglycaemia (< 
4.0mmol/L) and hyperglycaemia (> 10.0mmol/L), was 21.82 ± 12.53. An ADRR 
Participant Above % Within % Below % 
1 8 92 0 
2 77 23 0 
3 9 90 1 
4 52 46 2 
5 6 84 10 
6 5 95 0 
74 
 
between 20 and 40 is considered moderate risk for future low and high glucose 
excursions128. 
Table 4.4 The parameters of blood glucose control and glycaemic variability of the participants during 
the fasting (daylight hours from sunrise to sunset) and non-fasting hours of Ramadan. Values are 
mean ± SD (mmol/L). 
 
 
 
 
 
 
 
 Total periods Fasting periods Non-fasting periods p-value 
Mean tissue glucose 8.92 + 2.76 8.56 + 2.42 9.68 + 3.46 0.17 
Measures of glycaemic variability 
SD  2.07 + 0.83  1.81 + 0.47 2.10 +  0.95 0.45 
MAGE 4.47 + 0.75 4.69 + 1.47 4.82 + 1.63 0.90 
CONGA 8.01 + 2.68 7.66 + 2.34 8.29 +  2.96 0.21 
J-Index 42.25 + 25.27 36.52 + 19.18 49.42  + 34.05 0.19 
M-value 10.21 + 13.96 7.34 + 11.17 14.95 +  19.53 0.17 
Risk measures - Predictors of extreme hypoglycaemia and hyperglycaemia 
LBGI 9.44 + 18.96 9.45 + 18.96 1.22 + 1.12 0.35 
HBGI 7.91 + 8.59 6.41 + 7.21 10.46 +  10.99 0.15 
ADDR 21.82 + 12.53    
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4.4 Discussion 
A considerable amount of food rich in refined carbohydrate is traditionally prepared 
for Ramadan and taken during non-fasting hours, especially at the Iftar meal. Dietary 
fat consumption has been shown to be higher in type 2 diabetes subjects during 
Ramadan35. Despite these dietary changes and previous reports of hypoglycaemic 
and hyperglycaemic excursions in Ramadan, when pre-Ramadan assessment and 
adjustments are implemented, the difference compared with fasting hours is not 
significant.  
Measures of GV calculated were measures of total variability (SD), within-day 
variability (MAGE), and between-day variability (CONGA24
127). Table 4.5 showed the 
interpretations of each measure of glycaemic variability.  
Each measure was greater during the non-fasting hours, but was not statistically 
significant, which may, in part, be due to the small number of participants.  However, 
despite the small sample size, the glycaemic variability assessed by MAGE during 
Ramadan (4.47 ± 0.75) is similar to the MAGE value in published series of non-
fasting subjects with type 2 diabetes (4.8 ± 2.1)129, suggesting a representative 
sample.  
With regard to hypoglycaemia, the value of the low blood glucose index (LBGI), as a 
predictor of extreme hypoglycaemia was higher during fasting interval than in non-
fasting interval. However, the difference was not significant (p=0.35). On an 
individual basis, CGM has identified hypoglycaemic episodes in participant 5. It is 
worth noting that this participant did not have any time or dosage adjustments before 
Ramadan and was taking a combination of metformin and sulphonylurea. This is 
consistent with the findings that hypoglycaemia is commoner in type 2 diabetes  
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Table 4.5 The pros and cons of each measure of glycaemic variability
127;130
 
 
 
 
Criterion Definition Advantages Disadvantages 
SD (Total) SD of all glucose values Simple 
Classical statistical 
method 
Does not address 
skewed asymmetrical 
distribution  
MAGE Mean of glucose 
excursions from peak 
to nadir (or nadir to 
peak) where the 
difference is greater 
than 1 SD 
 
- Assess intra-day 
glycaemic variability  
- Describes major 
fluctuations, e.g. due 
to meals 
- Directly proportional 
to and highly 
correlated with SD of 
all glucose values 
 
- Inter-operator 
dependent 
- Potential bias 
towards hyper-
glycaemic peaks  and 
insensitive to hypo-
glycaemic nadirs (as 
hypoglycaemic range is 
commonly narrower 
than hyperglycaemic 
range, i.e. < 1 SD) 
CONGAn SD of the differences 
between  
any glucose value and 
another one exactly n 
hours ago (or later) 
- Assess intra-day 
(CONGA1-23) and inter-
day (CONGA24) GV 
- Specifically developed 
for CGM 
- Unaffected by the 
asymmetry of a 
glycaemic profile  
- Independent of peaks 
or nadirs according to 
arbitrary definitions 
 
J-index Combination of 
information from 
mean and SD of all 
glucose values  
J = 0.324 x (mean+SD)2 
- Measures mean 
glucose and variability 
in one formula 
- Independent of an 
arbitrarily selected 
ideal glucose value 
- highly correlated with 
percentage of time in 
target range 
- Sensitive to 
hyperglycaemia but 
relatively insensitive to 
hypoglycaemia, similar 
to MAGE 
M-value Weighted average of 
transformed glucose 
values, using 1,000 x 
Ilog10 (glucose/100)I
3 
 
M(100) is M at glucose 
value 100mg/dL 
- Measures glycaemic 
variability relative to 
an arbitrary ‘ideal’ 
value 
- highly correlated with 
percentage of time in 
target range 
- Skewed emphasis on 
hypoglycaemic 
excursions than hyper-
glycaemic excursions  
- Requires glycaemic 
reference points (i.e. 
arbitrary ideal values) 
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subjects on sulphonylureas with or without metformin, fasting for Ramadan131. A 
preferable alternative would be the use of a DPP-4 inhibitor or GLP-1 agonist to 
those who do not have good glycaemic control on metformin alone; or to adjust the 
doses of the sulphonylurea during Ramadan54.  
Four of the participants (1, 3, 5 and 6) had 84% to 95% of their glucose values within 
4.4 – 10.0 mmol/L. All of these patients found that the CGM was useful in their self-
management of diabetes. They frequently checked their BG values and were more 
aware of their dietary intake in their Iftar (sunset meal). This may also be the reason 
why participant 4 had 2% of glucose values between 4.1 – 4.4 mmol/L on the first 
day of the monitoring period, who became more aware of projected low readings in 
subsequent days and thus, avoided more low CGM readings.  
Given the high pre-Ramadan HbA1c, participant 2 would generally be advised not to 
fast during Ramadan. 95% of his CGM readings were higher than 10mmol/L. The 
use of continuous glucose sensor allowed the patient to understand that his glucose 
control was not as satisfactory as the patient believed and to intensify his insulin 
treatment without increasing the risk of hypoglycaemia in order to continue fasting 
safely.  
The main limitations of the study are the small number of recruits and the lack of a 
control group. The lack of statistical significance may reflect the small number and 
high standard deviations in the parameters, particularly LBGI and HBGI. The trend 
towards higher variability in non-fasting in comparison to fasting periods may reflect 
insufficient power, leading to type 2 error. Recruitment of patients in a limited time 
can be challenging in Ramadan, particularly during a religious event of such 
importance, and further studies including a larger number and wider spectrum of 
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participants, are warranted. It would also be useful to compare the GV of these 
subjects in the non-fasting months with the GV in the month of Ramadan to assess 
the alterations in dietary and social habits during Ramadan, as compared to normal 
routine. However, the participants were not keen to have continuous glucose 
monitoring beyond the month of Ramadan. Further studies using other control 
groups of non-fasting diabetic patients and fasting non-diabetic people, as compared 
to fasting Muslim patients, would also be useful to assess the effects of fasting and 
diabetes on GV.  
Pre-Ramadan assessment and educational advice regarding healthy diet, adequate 
exercise and awareness of the risks of hypoglycaemia and hyperglycaemia play an 
important role in eliminating the damaging GV previously demonstrated in the 
EPIDIAR study15.  
 
4.5 Conclusion 
Continuous glucose monitoring is a useful tool for assessing glycaemic variability 
and risks of hypo- and hyperglycaemia during fasting for Ramadan. To individuals 
who have had pre-Ramadan assessment and adjustments in their diabetes 
regimens, the glycaemic variability is similar between fasting and non-fasting 
periods, the risk of severe hypoglycaemia is minimal and the risk of extreme glucose 
excursions as calculated by ADRR is also moderate. Our findings suggest that 
systematic pre-Ramadan assessment and appropriate therapeutic adjustment 
according to the ADA recommendations are important in negating the previously 
described glycaemic variability seen during Ramadan. 
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Chapter 5: Glucagon-like peptide-1 receptor agonist and Dipeptidyl peptidase-
4 inhibitor therapies in type 2 diabetes patients during Ramadan 
5.1 Incretin hormones: from physiology to therapeutic use during Ramadan 
Glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 
(DPP-4) inhibitors are new anti-diabetic therapies acting via incretin receptor 
signalling. The two incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic peptide (GIP) are gut hormones released from the intestinal 
L cells in the distal ileum and colon and the K cells in the duodenum and jejunum 
respectively132. The incretin hormones exert their actions via G-protein coupled 
receptors: 1) GIP receptors are expressed mainly on pancreatic islet β-cells, and to a 
lesser extent, in adipocytes and central nervous system; 2) GLP-1 receptors are 
expressed on islet α- and β-cells, in the heart, kidney, lungs, gastrointestinal tract, 
and peripheral and central nervous systems. Circulating incretin levels increase 
rapidly and transiently after food ingestion, activating the receptors on pancreatic β-
cells which lead to increase in cyclic AMP and intracellular calcium and subsequent 
insulin exocytosis, in a glucose-dependent manner133. GLP-1 also inhibits glucose-
dependent glucagon secretion from the α-cells, reducing hepatic glucose release. 
GLP-1 induces gene transcription and insulin biosynthesis to increase β-cell 
proliferation and decrease apoptosis. It slows gastric emptying, thereby promoting 
the feeling of satiety and reducing food intake. Animal studies have also showed that 
GLP-1 acts centrally to promote satiety134. 
Endogenous human incretins have short half-lives (in minutes) and are degraded by 
the enzyme, DPP-4. Exenatide, the synthetic GLP-1R agonist, is degradation-
resistant and has a longer half-life (2.4 hours in humans)135. Selective DPP-4 
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inhibitors (such as sitagliptin, vildagliptin and saxagliptin) extend the half-life of native 
incretins, thereby prolonging their effects136.  
In type 2 diabetes, the incretin hormone response is impaired137 and post-prandial 
glucagon secretion is not adequately suppressed138. Both GLP-1R agonists and 
DPP-4 inhibitors target the above mechanisms (Table 5.1), which depends on oral 
glucose intake to improve glycaemic control139. GLP-1R agonists achieve greater 
reduction in HbA1c than DPP-4 inhibitors and have additional effects on delaying 
gastric emptying, appetite suppression and weight loss140.  
 
Features in type 2 
diabetes 
Actions of 
endogenous GLP-1 in 
type 2 diabetes 
GLP-1R  agonist 
(exenatide) 
DPP-4 inhibitor 
Defective insulin-
stimulated insulin 
secretion 
Glucose-dependent 
stimulation of insulin 
secretion  
Yes Yes 
Inability to suppress 
postprandial glucagon 
secretion 
Suppression of 
glucagon secretion 
Yes Yes 
Abnormally high β cell 
apoptosis rate 
Inhibition of 
toxin-induced β-cell 
apoptosis 
Yes Probable 
Decrease in β cell 
mass 
Increase in β-cell mass  Yes Yes 
Normal, increase or 
decrease in gastric 
emptying 
Decrease in gastric 
emptying 
 
Yes No 
Hypercaloric energy 
intake and obesity 
Suppression of 
appetite and induction 
of satiety 
Yes Weight neutral 
Insulin resistance No immediate effect No No 
Table 5.1 Biological actions of endogenous GLP-1, GLP-1R agonist and DPP-4 inhibitor in relation to 
the pathophysiology of type 2 diabetes (adapted from Drucker et al.
132
). 
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These properties that GLP-1R agonists exhibit make them a suitable class to help 
moderate the changing dietary patterns during Ramadan. Its glucose-lowering effect 
is glucose-dependent, minimising hypoglycaemia both during prolonged fasting and 
irregular food intake in the month of Ramadan. Short-acting GLP-1R agonist, 
exenatide, can be taken before meals to reduce appetite; this would be useful at 
Suhur (pre-dawn meal) to promote satiety before the daylight fasting, and Iftar (post-
sunset meal) to prevent excessive feasting in the evening. Its moderate weight-
losing effect141 may also be advantageous in combating potential weight gain from 
overeating in the evenings during Ramadan.  
 
5.2 Glucagon-like peptide-1 receptor agonist and glycaemic control during 
Ramadan 
There are currently no published studies on the use of glucagon-like peptide-1 
receptor agonists during Ramadan. A retrospective evaluation was carried out on 
type 2 diabetes subjects taking exenatide, who fasted during Ramadan, to assess 
their HbA1c, weight and hypoglycaemic episodes. 
5.2.1 GLP-1R agonist: Method 
Muslim patients who fasted during Ramadan in 2009 were identified from the 
community diabetes clinic in Brent.  All of the patients were treated with exenatide 
10mcg twice daily.  Aside from metformin, all patients on other oral hypoglycaemic 
agents and insulin were excluded. The primary endpoints were the mean weight 
change and hypoglycaemic episodes before and during Ramadan and the mean 
HbA1c change before and after the month of Ramadan. Each hypoglycaemic 
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episode was defined as a self-monitored capillary blood glucose < 3.5 mmol/L with or 
without symptoms and recorded by the patients during the month before Ramadan 
and the month of Ramadan. 
A second group of type 2 diabetes Muslim subjects who fasted during Ramadan, but 
were taking gliclazide 80mg twice daily with or without metformin, acted as controls.  
Statistical analysis was performed using GraphPad Prism 5.01. A paired t-test was 
used to analyse weight and HbA1c changes before and after the month of Ramadan.  
5.2.2 GLP-1R agonist: Results 
In the exenatide group, mean baseline HbA1c was 8.05% (± 0.69 SD), mean age 
was 53.2 years (± 9.7 SD) and the duration of diabetes was 8.3 years (± 2.5 SD). 
There was no significant different in weight between the exenatide group and the 
gliclazide group before Ramadan (Table 5.2).  
Table 5.2 Baseline characteristics of the participants 
 Group 1 (Exenatide) Group 2 (Gliclazide) 
Participants (n) 26 26 
Men:Women [n (%)] 15(58%):11(42%) 8(31%):18(69%) 
Age [years, mean ± SD (range)] 53.2 ± 9.7 (33-73) 62.3 ± 9.8 (45-77) 
HbA1c (%, mean ± SD) 8.05 ± 0.69 8.95 ± 1.28 
Weight (kg, mean ± SD) 85.8 ± 7.2 89.4 ± 8.7* 
Ethnicity (n)   
       Pakistani [n (%)] 10 24 
       Middle Eastern [n (%)] 12 0 
       Other [n (%)] 4 2 
Duration of diabetes  
[years, mean ± SD (range)] 
8.3 ± 2.5 (4.5-15.3) 6.9 ± 1.4 (4.5-11.2) 
*p > 0.05 between group 1 and 2. SD = standard deviation 
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In the exenatide group, the total number of hypoglycaemic events was 9 episodes 
before Ramadan and 7 episodes during Ramadan (p=0.43). There was a small but 
non-significant increase in mean weight of 0.11 kg before and after Ramadan 
(p=0.55) (Table 5.3).  
In the gliclazide group, there was a significant increase in mean weight of 0.81 kg 
(p<0.001) before and after Ramadan (Table 5.3). There was also a significant 
increase in the total number of hypoglycaemic events from 7 to 24 (p<0.001). 
Although the mean change in HbA1c was significantly better in the gliclazide group 
in comparison to the exenatide group (-0.05% versus -1.20%, p<0.001) (Figure 5.1), 
the gliclazide group had a significant increase in hypoglycaemic events whilst the 
exenatide group had no significant change in hypoglycaemic events before and 
during Ramadan (Table 5.3). 
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Figure 5.1 The mean changes in 
HbA1c before and after Ramadan 
between exenatide and gliclazide (p 
< 0.001).  
84 
 
exenatide gliclazide
0.0
0.5
1.0
1.5
c
h
a
n
g
e
 i
n
 w
e
ig
h
t 
(k
g
)
 
The mean increase in weight was significantly less in the exenatide group than the 
gliclazide group (0.11kg versus 0.81kg; p=0.013) (Figure 5.2). 
Table 5.3 Change in outcome measures during Ramadan in participants taking exenatide 
(group 1) and gliclazide (group 2) with or without metformin 
 
Before 
Ramadan 
After 
Ramadan 
Mean change 
before and after 
Ramadan 
Standard error of 
mean 
p-value 
Hypoglycaemic events (mean ± SD) 
Exenatide 
(n=26) 
0.35 ± 0.49  0.27 ± 0.45 0.08   
Gliclazide 
(n=26) 
0.27 ± 0.45 0.92 ± 0.94 0.65   
HbA1c (%, mean ± SD)  
Exenatide 
(n=26) 
8.05 ± 0.69 8.00 ± 0.69 -0.05 1.304 P<0.001* 
Gliclazide 
(n=26) 
8.95 ± 1.28 7.75 ± 0.93 -1.20 0.256  
Weight (kg, mean ± SD) 
Exenatide 
(n=26) 
85.82 ± 7.20 85.93 ± 7.55 0.11 0.191 P=0.013* 
Gliclazide 
(n=26) 
89.39 ± 8.69 90.20 ± 8.92 0.81 0.187  
*p-value for comparisons between the mean changes in group 1 and 2.  
 
Figure 5.2 The mean changes in 
weight before and after Ramadan 
between exenatide and gliclazide (p 
= 0.013).  
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5.2.3 GLP-1R agonist: Discussion 
The number of hypoglycaemic events and mean weight remained stable before and 
during Ramadan in patients taking exenatide and metformin. In the gliclazide group, 
there was significant reduction in HbA1c, weight gain and an increase in 
hypoglycaemic events during Ramadan. The fall in HbA1c in the gliclazide group 
occurred in the expense of increased hypoglycaemia and weight gain. The reasons 
for such a large fall in HbA1c may be due to a combination of fasting, reduced meal 
frequencies, reduced caloric intake or food contents in the gliclazide group. 
However, details about food intake were not available for comparison.  
In a randomised, triple-blind, placebo-controlled, 30-week non-Ramadan study, 
exenatide has been shown to reduce HbA1c with no weight gain or change in the 
incidence of hypoglycaemia in patients with type 2 diabetes inadequately controlled 
on metformin alone141. Reported rates of mild-to-moderate hypoglycaemia of 5.3% 
were the same in both the group that received exenatide 10mcg twice daily with 
metformin and metformin alone (with placebo).  
Although this small audit lacked information regarding the duration of exenatide 
treatment, the length of fasting days and whether the timing of gliclazide or exenatide 
were altered during Ramadan, it corroborated the existing evidence that exenatide 
would be a safe addition, in terms of hypoglycaemic risk, for type 2 diabetes people 
fasting for Ramadan.  
Exenatide also reduced the post-prandial glucose rise to a greater extent than insulin 
glargine in a comparative study142. As it stimulates insulin secretion following an oral 
glucose load with a dose-dependent blunting effect on the post-prandial rise of 
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plasma glucose143, it provides possible benefits in moderating glucose excursions at 
Suhur and Iftar during Ramadan.  
Apart from hypoglycaemia, dehydration is another risk of fasting in patients with 
diabetes during Ramadan15. As exenatide is cleared renally, it is not recommended 
for use in patients with severe renal impairment (Creatinine Clearance < 30 mL/min), 
and the U.S. food and drug administration recommended caution when starting or 
increasing the dose of exenatide from 5mcg to 10mcg in patients with moderate 
renal impairment (Creatinine Clearance 30 to 50 mL/min)144. Moreover, 
gastrointestinal (GI) adverse events (nausea, vomiting and diarrhoea) are commonly 
reported with highest incidence at initiation of the GLP-1R agonist therapy. Nausea 
was mostly mild-to-moderate in intensity in metformin-treated participants started on 
GLP-1R agonist141, and generally subsided by 8 weeks after the initiation of 
exenatide treatment141;145.  
The potential impact of developing or worsening renal disease due to dehydration 
following prolonged fasting together with the known GLP-1R agonist-induced GI side 
effects should be considered when prescribing exenatide to the diabetic Muslim 
population, even in those with only mild renal impairment. The side effect profile 
would also indicate that exenatide should be initiated more than 8 weeks before 
Ramadan to allow potential GI symptoms to settle.  
Alternatively, liraglutide, a once-daily GLP-1R agonist, is not primarily eliminated by 
the kidneys, but is metabolised by proteolysis146. Its extended activity is achieved by 
modifying the structure of the human GLP-1 peptide to increase the circulating half-
life to 12 hours135. The GI side effects of liraglutide was also reported to be more 
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short-lived than exenatide, up to 4 weeks147. Therefore, it is a safe alternative for use 
in Ramadan.  
Once-weekly formulations of GLP-1R agonists, such as exenatide LAR and 
taspoglutide148 are being developed and further studies of these agents during 
periods of fasting with respect to their tolerability and efficacy will be eagerly 
anticipated.  
 
5.3 Dipeptidyl peptidase-4 inhibitor and glycaemic control during Ramadan  
5.3.1 Hypoglycaemia  
The addition of a DPP-4 inhibitor to metformin therapy during Ramadan in fasting 
Muslim patients with type 2 diabetes offers advantages over gliclazide primarily in 
the reduction in the incidence of hypoglycaemia71;72. One of the commonest causes 
of hypoglycaemia is diabetes medication, especially where the goal of treatment is 
intensive glucose control8 involving insulin therapy or insulin secretagogues, such as 
sulphonylureas, particularly in patients with irregular eating patterns or who miss 
meals (such as during Ramadan fast). In view of this, the American Diabetes 
Association recommends caution in the use of sulphonylureas during Ramadan126.  
DPP-4 inhibitor is associated with minimal risk of hypoglycaemia in combination with 
metformin, sulphonylurea or a thiazolidinedione149;150. In a 52-week non-Ramadan 
study, when added to metformin, vildagliptin significantly lowered the incidence and 
severity of hypoglycaemic episodes compared with glimepiride151. 
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This low hypoglycaemic risk may be because GLP-1 enhanced insulin secretion and 
inhibition of glucagon secretion are glucose-dependent152. Vildagliptin, a DPP-4 
inhibitor, prevents the rapid degradation of endogenous GLP-1 and glucose-
dependent insulinotropic peptide and increases plasma levels of their intact, active 
form. It acts by an enhancement of pancreatic islet function, with improved β- and α-
cell sensitivity to glucose153. The action of potassium channel-based insulin 
secretagogues, such as sulphonylureas, is non-glucose-dependent, which explained 
the higher hypoglycaemic risk during fasting. 
A prospective study comparing vildagliptin and gliclazide as an add-on to metformin 
during Ramadan showed that there was no hypoglycaemia in the vildagliptin group 
(n = 23), compared with 34 hypoglycaemic events (41.7%) in the gliclazide group (n 
= 36)71.  
A large randomised open-labelled study comparing sitagliptin and sulphonylureas 
(glibenclamide, gliclazide, and glimepiride) in type 2 diabetes Muslims who were 
treated with or without metformin, and fasted for Ramadan, also demonstrated that 
fewer patients experienced hypoglycaemic events in the sitagliptin group (n = 507) 
relative to the sulphonylurea group (n = 514) (6.7% versus 13.2%, respectively). And 
the risk of symptomatic hypoglycaemia was significantly lower with sitagliptin relative 
to sulphonylurea (Mentel-Haenszel relative risk ratio = 0.51; 95% CI, 0.34 - 0.75; 
p<0.001).  
The findings of these prospective observational and randomised studies71;72 indicate 
that these newer anti-diabetic agents have a beneficial role in the management of 
patients during Ramadan, particularly to reduce their risk of hypoglycaemia during 
the long daytime fasting periods. 
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5.3.2 Safety and adverse events  
The primary concern regarding these new therapies centres on their long-term safety 
profiles. Safety outcomes on these incretin-based therapies were reported in non-
Ramadan randomised control trials for a duration up to 52 weeks147;154;155. DPP-4 is 
a cell-membrane protein expressed in many tissues, including lymphocytes. This 
raised concerns about its long-term effect on the immune system. Upper respiratory 
tract infection and urinary tract infection have been reported as adverse events in 
patients treated with DPP-4 inhibitors156. Meta-analysis of clinical trials has found a 
significant increase in all-cause infection associated with sitagliptin but not with 
vildagliptin157. Although the relative risk is low (relative risk = 1.15; 95% CI, 1.02 – 
1.31; p=0.03), the clinical implication is still significant in millions of Muslim diabetes 
patients who are prone to urinary tract infection due to diabetes or dehydration 
associated with fasting.  
Moreover, during post-marketing surveillance, acute pancreatitis and severe allergic 
reaction were reported in 88 patients taking DPP-4 inhibitors158 and 6 reported cases 
of necrotising and haemorrhagic pancreatitis in patients taking exenatide159. Other 
factors can also predispose the individuals to pancreatitis, such as obesity and 
hypertriglyceridaemia, and the presence of type 2 diabetes. Analysis of pancreatitis 
in U.S. healthcare claims database of individuals with type 2 diabetes suggested that 
their risks were increased threefold over non-diabetic individuals160.  
With reference to Ramadan, there has been a case report of massive gastric 
dilatation and acute pancreatitis following ‘breaking’ the Ramadan fast at Iftar 
meal161, similar to that of acute pancreatitis associated with re-feeding syndrome in 
anorexia nervosa162. This case merely represents a single incident as there is 
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currently no evidence causally linking Ramadan fasting and acute pancreatitis-
associated refeeding syndrome. Nonetheless, Ramadan-focused education on a 
healthy balanced diet is essential to minimise overeating. 
5.3.3 Recommendations during Ramadan 
The National institute for clinical excellence (NICE) recommended exenatide as a 
third line agent following metformin and sulphonylurea when blood glucose control is 
inadequate [HbA1c > 7.5% (58 mmol/mol)]55. Our findings suggest that exenatide 
would be more suitable than gliclazide when considering an add-on to metformin for 
type 2 diabetes patients planning to fast for Ramadan. 
DPP-4 inhibitors are recommended by NICE as second-line therapy to first-line 
metformin or sulphonylurea when blood glucose control is inadequate [HbA1c > 
6.5% (48 mmol/mol)]55. This would also be an appropriate choice in people with type 
2 diabetes who are planning to fast for Ramadan.  
In the context of moderate to severe renal impairment, DPP-4 inhibitors are safe in 
reduced doses163 and provide a better alternative to GLP-1R agonists in patients 
with diabetic nephropathy.   
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Chapter 6: Insulin regimens in type 2 diabetes patients during Ramadan 
6.1 Different options of insulin regimens during Ramadan 
For people already on insulin, Ramadan fasting can represent a challenge to their 
glycaemic control. As mentioned in Chapter two, patients with well-controlled 
diabetes on insulin are considered as moderate risk to fast during Ramadan54;126. 
The EPIDIAR study primarily observed the effects of fasting in diabetes subjects 
without any intervention and reported that insulin dose was unchanged in more than 
64% of patients. The survey also reported increased risks of severe hypoglycaemia 
and hyperglycaemia associated with fasting, which may have contributed to their 
insulin dosage not being adjusted15. A recent study using continuous glucose 
monitoring reported no symptomatic hypoglycaemia when 20 – 30% of insulin 
requirement was reduced during Ramadan164. It is therefore important for these 
moderate-risk patients to have pre-Ramadan medical assessment to adjust their 
insulin treatment appropriately.  
6.1.1 Switching insulin doses Suhur to Iftar, and vice versa 
The Ramadan Prospective Diabetes Study initially suggested switching the full pre-
Ramadan morning dose of insulin to Iftar (sunset meal) and taking half of the pre-
Ramadan evening dose at Suhur (pre-dawn) (Table 6.1). However, the highest 
frequency of hyperglycaemic episodes (defined as > 11.11 mmol/l) with this regimen 
was seen at pre-dawn, followed by post-dusk, whilst most of the hypoglycaemic 
events also occurred at pre-dawn, followed by midday. Following this, the authors 
suggested further reduction in the pre-dawn insulin dose by 75%, rather than only 
50%, to help minimise the pre-dawn and midday hypoglycaemia165. 
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Table 6.1 Suggested changes in insulin regimens during Ramadan. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Pre-Ramadan  During Ramadan 
Authors Breakfast Lunch Dinner Bedtime Suhur Fasting 
Period 
Iftar Bedtime Midnight 
Ahmedani 
et al. 
2012165 
Morning 
insulin  
(e.g. 20 units 
Novomix 30) 
 Evening 
insulin  
(e.g. 30 units 
Novomix 30) 
 25% of 
evening 
insulin  
(e.g. 7.5 units 
Novomix 30) 
 Morning 
insulin  
(e.g. 20 units 
Novomix 30) 
  
Salti et al. 
2009166 
Glimepiride   Glargine   Glimepiride Glargine  
Bakiner et 
al. 200929 
Repaglinide Repaglinide Repaglinide Glargine Repaglinide  Repaglinide Glargine Repaglinide 
Mattoo et 
al. 200375 
Humulin 
30/70 
 Humulin 
30/70 
 Lispro 
Mix25/75 
 Lispro 
Mix25/75 
  
Hui et al. 
201076 
Human 
Mixtard 
30/70 
 Human 
Mixtard 
30/70 
 Human 
Mixtard 
30/70 
 Humalog 
Mix 50/50 
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6.1.2 Long-acting insulin and oral hypoglycaemic agents 
In an open, multi-centre, prospective study, glimepiride (given at Iftar, mean dose 
4.3mg ± 1.0mg SD per day) in combination with glargine (given any time before 
bedtime, but at the same time every day, mean dose 29.2 ± 16.1 SD units/day) 
conferred a significant increase in the total number of hypoglycaemic episodes 
during Ramadan, as compared to pre- and post-Ramadan periods, despite a stable 
HbA1c and mean fasting blood glucose during the fasting periods166. Whilst a shorter 
acting sulphonylurea, such as gliclazide, with glargine may help ameliorate part of 
the hypoglycaemia risk7, alternative regimens should be considered67;167.   
In a small prospective study (n = 19), repaglinide (taken at suhur, iftar and midnight 
meals) plus single-dose glargine (at bedtime) (Table 6.1) has been shown to be safe 
in well-controlled type 2 diabetic patients when compared to non-fasting controls 
(repaglinide taken with regular meals three times a day and glargine at bedtime). 
Fructosamine, fasting and post-prandial glucose levels were similar between fasting 
and control group, with no reported hypoglycaemia29. However, this regimen 
required taking an extra meal at midnight and may not be ideal for patients with 
suboptimal HbA1c. Similarly, for patients on maximally tolerated doses of metformin 
and sulphonylurea, the addition of a single basal analogue insulin, detemir, was not 
sufficient to achieve an HbA1c of < 6.5% (48 mmol/mol) in as many patients when 
compared to the addition of a biphasic or prandial analogue insulin aspart168.  
Other possibilities include a DPP-4 inhibitor and glargine or DPP-4 and detemir or 
using exenatide at suhur and iftar meals and glargine at bedtime; however, further 
research is necessary before these combinations can be fully endorsed.  
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6.1.3 Once or twice daily neutral protamine hagedorn (NPH) insulin 
Intermediate-acting NPH insulin has an onset of action within 1.5 hours and a 
maximum duration of 12 hours. In one of the earliest Ramadan studies, patients on 
once or twice daily NPH insulin tried a variety of ways to self-manage their glycaemia 
whilst fasting. These options included either omitting the morning dose or evening 
dose when taking twice daily regimen, or switching the once-daily dose from morning 
to evening. The outcomes of these measures were not clearly reported169.  
More recently, pregnant women with diabetes (all types) treated with NPH insulin 
whilst fasting for Ramadan had stable fructosamine and HbA1c before and after 
Ramadan170. Unfortunately, insulin requirements in pregnant diabetic women are 
very different and the findings cannot be extrapolated to non-pregnant diabetes 
subjects.  
Nonetheless, NPH insulin is cheaper compared to basal analogues, such as glargine 
and detemir. This approach may be more practical and sustainable in developing 
countries. Indeed, NICE guidance stated that the first insulin treatment for type 2 
diabetes should be NPH insulin at bedtime or twice daily55. 
6.1.4 Basal Bolus regimen 
Studies on Ramadan fasting using basal bolus regimens were primarily performed 
on type 1 diabetes subjects78;171;172. The sample sizes were small and the selected 
patients in these studies were usually well controlled [HbA1c < 7.5% (58 mmol/mol)], 
with no history of hypoglycaemia or diabetic ketoacidosis. Although the use of 
glargine was found to be safe and maintained sufficient plasma insulin levels over 
the fasting periods, this was achieved via a strict regimen of meticulously adjusted 
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insulin dosage and close monitoring of blood glucose levels171;172 that may be difficult 
to realise in practice. Children with type 1 diabetes who chose to fast during 
Ramadan were liable to hypoglycaemia during fasting unless the dose of basal 
insulin was reduced by 10 – 20%173.  
For people with type 2 diabetes, it would seem reasonable that basal bolus regimen 
would provide the flexibility during Ramadan. Reduction of the basal insulin dose will 
probably be necessary, but further studies will be needed to quantify that. 
6.1.5 Mixed insulin regimens 
For patients already on twice daily mixed insulin before Ramadan, omitting lunchtime 
meals during Ramadan can result in low glucose levels at midday and postprandial 
glucose rises pre-dawn and after sunset.  
In a randomised, open-label, crossover study, patients initially taking human insulin 
30/70 (Humulin® 30/70) pre-Ramadan instead received insulin lispro Mix 25 at Suhur 
and Iftar for the first two weeks during Ramadan and then switched back to Humulin® 
30/70 for the remaining 2 weeks, and vice versa. The insulin doses were not 
changed. There was a small, but significant improvement in 2-hour post-prandial 
mean blood glucose in the Mix 25 group compared to the human insulin 30/70 group 
at iftar75. It was attributed to the rapid peak concentration following subcutaneous 
administration of the analogue insulin (Cmax 90 minutes) compared to the human Mix 
30/70 (Cmax 130 minutes).  
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6.1.6 Proposed Insulin regimen – Mixtard 30 at suhur, Humalog Mix 50 at iftar 
For patients who cannot achieve good glycaemic control with twice daily human 
Mixtard 30 insulin, the evening dose at Iftar is switched from Mixtard 30 to Humalog 
Mix 50. The greatest variability with nadir and peak glucose occurred before and 
after Iftar, respectively164. Hence, the rationale for the switch is to provide patients 
with a more rapid-acting insulin that has shorter time of onset and peak time for the 
large meal in the evening, to improve the post-prandial glucose control without 
increasing the risk of hypoglycaemia. Since a smaller proportion of the daily caloric 
intake is usually consumed at suhur (pre-dawn meal), the morning insulin is kept with 
Mixtard 30 before the daylight fasting begins.  
 
6.2 Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 
diabetes patients during Ramadan 
6.2.1 Aim 
We undertook an observational study to evaluate hypoglycaemic events (defined as 
a blood glucose < 3.5 mmol ⁄ l with or without symptoms), HbA1c and weight change 
in Muslim patients with type 2 diabetes who fasted and whose HbA1c was 
insufficiently controlled with twice daily Mix 30 insulin regimen (Human Mixtard 
30/70) before Ramadan. The evening dose was therefore changed to Mix 50 
(Humalog Mix 50/50) based on clinical judgement.  
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The aim is to compare the effect of Mix 30 and Mix 50 insulin regimes on HbA1c, 
weight and hypoglycaemic events in type 2 diabetes patients who fasted during the 
month of Ramadan. 
6.2.2 Methods 
Participants 
This was an observational study of Muslim patients with type 2 diabetes treated in 
accordance with the American Diabetes Association’s recommendations for the 
management of diabetes during Ramadan126. Participants who were 18 years or 
over and fasted for more than 15 days were included. Patients attended six primary 
care practices in the London boroughs of Brent, Ealing and Harrow, which had taken 
part in a workshop to educate healthcare professionals on issues surrounding 
diabetes and fasting. All participants received Ramadan-focused education about the 
management of their diabetes and the identification and management of 
hypoglycaemia. Patients were already on Mix 30 insulin twice daily before attending 
the education. They either continued on Mix 30 insulin twice daily or their evening 
insulin dose was changed to Mix 50 two weeks before Ramadan. Patients who 
continued on Mix 30 used their usual pre-study injection-to-meal time interval. 
Patients who had Mix 50 insulin in the evening were advised to inject immediately 
before meals. Allocation to treatments was based on clinical judgement prior to 
inclusion and was not randomised. Indications for changing to Mix 50 included an 
elevated 2-hour postprandial capillary blood glucose greater than 10mmol/l in the 
evenings.  
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Assessments 
All participants were seen two weeks before the start of Ramadan and seen again 
ten days after the last day of Ramadan. All participants were instructed to monitor 
their symptoms closely and record daily pre-prandial and 2-hour postprandial blood 
glucose, hypoglycaemic events and weight. An Ascensia Contour glucose meter 
(Bayer Healthcare, U.K.) was provided to participants. Before Ramadan, participants 
were asked to provide any documentation of hypoglycaemia from either a blood 
glucose meter or glucose diary records. During Ramadan, participants were asked to 
check their blood glucose levels if they had any symptoms of dizziness, visual 
blurring, palpitations, nausea, sweating, confusion, tremor or intense hunger. Both 
the blood glucose diary and the blood glucose meter were analysed for episodes of 
hypoglycaemia. Patients were also asked to notify their general practitioner if they 
had any episodes of hypoglycaemia, and they were told to attend the daily rapid 
access clinics in Brent if they had any concerns about their diabetes. Severe 
hypoglycaemia was defined as a low blood sugar (< 3.5 mmol/l) requiring assistance 
to treat the hypoglycaemic event. In addition, participants were asked to document 
the total number of days they had fasted. 
Statistical Analysis 
Changes between pre- and post-fasting HbA1c and weight were analysed using 
analysis of covariance (ANCOVA) models to adjust for the effects of age, gender, 
and ethnicity, duration of diabetes and baseline values. ANOVA can firstly be used to 
add precision in comparisons between datasets by accounting for the variability (i.e. 
how scatter the data points around the mean) on prognostic variables. Secondly, the 
purpose of using ANOVA in this context was to ‘adjust’ comparisons between the 
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groups for imbalances in the prognostic variables (referred to as covariates) between 
these groups, e.g. to determine whether there was a difference between the pre- and 
post-fasting HbA1c, independent of any age or gender differences between the 
groups. The ‘adjustment’ was made based on fitting a particular kind of regression 
line. By doing so, it eliminates variation due to each covariate and therefore provides 
a more precise analysis.   
Patients were asked to record the total number of hypoglycaemic events 4 weeks 
prior to the start of Ramadan and subsequently asked to record hypoglycaemic 
events during the month of Ramadan. Least squared (adjusted) means (LSM) were 
presented for treatment differences. For hypoglycaemic events, in addition to the 
total number per patient, the data were also dichotomised into groups of patients 
who experienced no events during fasting and those who experienced at least one 
event during fasting. 
As a result of the non-interventional nature of this study according to the Medicines 
and Healthcare products Regulatory Agency guidance on what constitutes a clinical 
trial, central ethics committee approval was not sought for the observational study. 
6.2.3 Results 
Fifty-two patients were included. The Mix 50 group (n=26 patients) received Mix 30 
at the meal before sunrise and Mix 50 after sunset. The Mix 30 group (n=26 patients) 
received Mix 30 twice daily. The baseline demographics of the two groups are shown 
in Table 6.2. The mean age was 62.3 ± 9.8 years in Mix 50 group and 61.9 ± 9.2 
years in Mix 30 group (p=0.90). The mean duration of diabetes was approximately 
9.5 years in each group. The mean baseline HbA1c values were similar between the 
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two groups (9.05 ± 0.43% versus 8.98 ± 0.37%; p=0.22). ANCOVA models were 
used to adjust for baseline imbalances due to the non-randomised allocation to 
treatment. 
Mix 50 was associated with a small reduction of 0.04 (p=0.81) in the mean number of 
hypoglycaemic events during Ramadan compared with before Ramadan (Table 
6.3a), whereas Mix 30 was associated with an increase of 0.15 (p=0.43) (Table 
6.3b). These differences between the groups were not statistically significant 
following adjustment for baseline factors [LSM difference between groups = 0.135, 
p=0.36, 95% confidence limits (-0.16, 0.43)].  
The Mix 50 group had a mean HbA1c reduction of 0.48% (p=0.0001) (Table 6.3a) 
whereas the Mix 30 group had a mean HbA1c increase of 0.28% (p=0.007) (Table 
6.3b).  These differences, adjusting for baseline factors, were statistically significant 
[LSM difference 0.40%, p=0.0004, 95% confidence limits (0.19%, 0.62%)].  
In the Mix 50 group, there was a significant increase in mean body weight before and 
after Ramadan (mean weight change = 0.81kg, p=0.0002) (Table 6.3a). There was a 
small, but non-significant increase in mean weight in the Mix 30 group of 0.33kg 
(p=0.082) after Ramadan (Table 6.3b). These differences however, adjusting for 
baseline imbalances, were not statistically significant [LSM difference -0.09, p=0.62, 
95% confidence limits (-0.47, 0.28)]. 
However, direct comparison between the groups can be biased due to the non-
randomised nature of the groups in that patients with higher post-prandial glucose 
values were pre-selected to the Mix 50 group. In summary, the Mix 50 group had no 
significant change in hypoglycaemic events, but had a significant reduction in mean 
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HbA1c (Figure 6.1) and an increase in mean body weight (Figure 6.2) before and 
after Ramadan. In the Mix 30 group, there were no significant changes in 
hypoglycaemic events and mean body weight (Figure 6.4), but a significant increase 
in mean HbA1c (Figure 6.3) before and after Ramadan. 
 
Table 6.2 Baseline characteristics of the participants 
 Group 1 (Mix 50) Group 2 (Mix 30) 
Participants (n) 26 26 
Men:Women [n (%)] 8 (30.8%):18 (69.2%) 10 (38.5%):16 (61.5%) 
Age [years, mean ± SD (range)] 62.3 ± 9.8 (45-77) 61.9 ± 9.2 (44-77)* 
HbA1c (%, mean ± SD) 9.05 ± 0.43 8.98 ± 0.37* 
Weight (kg, mean ± SD) 89.4 ± 8.7 85.8 ± 7.2* 
Ethnicity (n)   
       Pakistani [n (%)] 24 (92.3%) 10 (38.46%) 
       Middle Eastern [n (%)] 0 (0%) 12 (46.15%) 
       Other [n (%)] 2 (7.7%) 4 (15.4%) 
Duration of diabetes  
[years, mean ± SD (range)] 
9.8 ± 2.8 (4.6-16.5) 9.5 ± 3.3 (4.5-16.5)* 
*p > 0.05 between group 1 and 2.  SD = standard deviation  
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Table 6.3a Change in outcome measures during Ramadan in participants receiving Mix 30 
before sunrise and Mix 50 after sunset (the Mix 50 group)  
 
Before Ramadan After Ramadan 
Least squares mean 
change 
Hypoglycaemic events (n ± SD) 
Mix 50 0.46 ± 0.65 0.42 ± 0.58 0.058 
HbA1c (%, mean ± SD) 
Mix 50  9.05 ± 0.43 8.56 ± 0.62 -0.100 
Body weight (kg, mean ± SD) 
Mix 50  89. 4 ± 8.7 90.2 ± 8.9 0.57 
Analysis of covariance (ANCOVA) including terms for treatment group, gender and ethnicity as factors and age and duration of 
diabetes and baseline values for weight, HbA1c and hypoglycaemic events. SD = standard deviation, SEM = standard error. 
 
Table 6.3b Change in outcome measures during Ramadan in participants receiving Mix 30 
twice daily (the Mix 30 group) 
 
Before Ramadan After Ramadan 
Least squares mean 
change 
Hypoglycaemic events (n ± SD) 
Mix 30  0.42 ± 0.58 0.58 ± 0.81 0.193 
HbA1c (%, mean ± SD) 
Mix 30  8.98 ± 0.37 9.27 ± 0.59 0.303 
Body weight (kg, mean ± SD) 
Mix 30  85.8 ± 7.2 86.1 ± 7.7 0.47 
Analysis of covariance (ANCOVA) including terms for treatment group, gender and ethnicity as factors and age and duration of 
diabetes and baseline values for weight, HbA1c and hypoglycaemic events. SD = standard deviation, SEM = standard error. 
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Figure 6.1 HbA1c (%) of the Mix 50 
group before and after Ramadan (9.05 
± 0.43 vs. 8.56 ± 0.62; p = 0.0001).  
Figure 6.2 Weight (kg) of the Mix 50 
group before and after Ramadan (89.4 
± 8.7 vs. 90.2 ± 8.9; p = 0.0002). 
Figure 6.3 HbA1c (%) of the Mix 30 
group before and after Ramadan (8.98 
± 0.37 vs. 9.27 ± 0.59; p = 0.007). 
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6.2.4 Discussion 
Humalog Mix 50 is a premixed insulin analogue containing 50% of lispro and 50% 
neutral protamine lispro (NPL, an intermediate-acting insulin), whereas human 
Mixtard 30 is a mixture of 30% dissolved human insulin (rDNA) and 70% isophane 
insulin (NPH) (Table 6.4). The pharmacokinetics of analogue premixed insulin is 
considered to be more akin to the normal pattern of insulin secretion than premixed 
human insulin174. The former has a quicker time to onset of 5-15 minutes versus 30-
60 minutes and a shorter time to peak (Tmax) of 115 minutes versus 173 minutes in 
premixed human insulin. 
6.2.4.1 Hypoglycaemia 
Although hypoglycaemia tends to be less frequent in type 2 compared to type 1 
diabetes, it remains a considerable risk, particularly in patients treated with  insulin 
for years and in those who have  significant beta-cell failure and insulin deficiency126. 
Hypoglycaemia may be exacerbated by the inappropriate response of counter-
80
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Figure 6.4 Weight (kg) of the Mix 30 
group before and after Ramadan (85.8 
± 7.2 vs. 86.1 ± 7.7; p = 0.082). 
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regulatory hormones and the defect in epinephrine secretion due to autonomic 
neuropathy171.  
In this report, there were no significant differences in the mean number of 
hypoglycaemic episodes before and during Ramadan in both Mix 50 and Mix 30 
groups. In the crossover, comparative trial, Mattoo et al.75 have also shown no 
change in the mean number of hypoglycaemic episodes in patients on Humalog Mix 
25/75 and human insulin Mix 30/70. These four regimens are tolerated during 
Ramadan in their risk of hypoglycaemia. 
The focus of both studies was mainly on the change in the type and composition of 
the premixed insulins, rather than on dosage adjustments, which can also affect 
hypoglycaemic rate, weight and overall glycaemic control. There were only a few 
studies during Ramadan focusing on the appropriate dose adjustments, mainly on 
type 1 diabetes. Further studies taking into account the amount of food intake, 
titration regimens and total insulin requirements would guide clinicians on 
appropriate insulin adjustments of the commonly used premixed insulins, such as 
Novomix 30, in type 2 diabetes patients during Ramadan.     
6.2.4.2 Weight change 
Previous studies have shown no change in body mass index or weight during the 
fasting period in type 2 diabetes patients treated with once daily insulin compared to 
controls that were on repaglinide or sulphonylureas27;29. In the crossover study with 
Humalog Mix 25/75 and human insulin Mix 30/70, there was also no significant 
change in body weight for all patients for the duration of the study (mean 0.08, SD 
1.5, p=0.607). Information about calorie intake and exercise are not available in this 
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study. These would be important factors that may have contributed to the weight 
increase in the Mix 50 group.  
6.2.4.3 Glycaemic control 
Changing to Humalog Mix 50 in the evening during Ramadan resulted in an 
improvement in glycaemic control without increasing the incidence of 
hypoglycaemia. In reviews of comparative trials, premixed insulin analogues and 
premixed human insulin provided similar glycaemic control in terms of decreasing 
HbA1c, fasting blood glucose and hypoglycaemia175;176. Therefore, the main 
advantage of using analogue insulin during Ramadan is to provide a more 
physiologic and predictable time-action profile. Premixed insulin analogues, such as 
Humalog Mix 50, have quicker onset and peak shorter than human Mixtard 30 (Table 
6.4). It produces greater reductions in the magnitude of postprandial glucose 
excursions than human insulin 30/70177, helping to tackle the large meal at Iftar. 
The predawn meals are usually smaller. Keeping the morning insulin to Human 
Mixtard 30 has not resulted in a higher incidence of hypoglycaemia, which can be 
expected with the slower onset of action of the human premixed insulin. As Human 
Mixtard 30 is no longer available in the U.K., future studies will be useful to explore 
other viable options including Humalog Mix 50 or Novomix 30 twice daily, and other 
treatment approaches, such as basal analogues at bedtime and bolus insulin at iftar 
and suhur. As the duration of action of glargine is longer than detemir (median 
duration of action for glargine = 24 hours; median for detemir = dose-dependent: 12 
hours for 0.2 units/kg, 20 hours for 0.4 units/kg)178;179, using detemir as the basal 
insulin during Ramadan may have lower risk of hypoglycaemia, particularly just 
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before breaking the fast (before Iftar in the afternoon or early evening depending on 
seasonal changes).  
The duration of the study (7.5 weeks) was too short to firmly conclude that the 
groups achieved their maximum HbA1c. An alternative measurement for glycaemic 
control, such as serum fructosamine, would have been useful in this study as a more 
appropriate marker to evaluate the glycaemic control during this short interval. Due 
to the observational nature of the study, patients were not randomised. Further 
studies with ethics approval in which patients were randomised to different groups of 
insulin treatments with a crossover design after 2 weeks during Ramadan would be 
preferable. An additional limitation of the study is that complete post-prandial glucose 
measurements were not available from the participants, which would have been 
useful in evaluating the contribution of HbA1c in the Mix 50 group.  
In conclusion, our findings demonstrated that switching to analogue Mix 50 insulin in 
the evening has a role in the management of type 2 diabetes patients already on 
twice daily mixed insulin in order to improve their glycaemic control without 
compromising their risk of hypoglycaemia during Ramadan.   
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         Table 6.4 The onset and duration of different insulins (adapted from Diabetes UK insulin wall chart)180. 
 
NAME SOURCE TAKEN ONSET, PEAK AND DURATION 
   0 2 4 6 8 10 12 14 16 18 20 22 24 
RAPID ACTING ANALOGUE              
NovoRapid Analogue Just before / with / just after food              
Humalog Analogue Just before / with / just after food              
SHORT-ACTING INSULINS/NEUTRAL INSULIN              
Actrapid Human 30 mins before food              
Humulin S Human 20-45 mins before food              
MEDIUM AND LONG-ACTING INSULINS              
Insulatard Human About 30 mins before food or bed              
Humulin I Human About 30 mins before food or bed              
MIXED INSULINS              
Mixtard 30 Human 30 mins before food              
Humulin M3 Human 20-45 mins before food              
ANALOGUE MIXTURE              
Humalog Mix 25 Analogue Just before / with / just after food              
Humalog Mix 50 Analogue Just before / with / just after food              
NovoMix 30 Analogue Just before / with / just after food              
LONG-ACTING ANALOGUE              
Lantus Analogue Once a day, anytime (but at same time each day)              
Levemir Analogue Once or twice daily              
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Chapter 7: Advances, Challenges and future directions in Ramadan research 
7.1 Advances in research on Ramadan  
7.1.1 Increasing awareness of Ramadan in medical conditions 
There has been an exponential increase in the number of studies based on fasting 
during Ramadan in the last few years.  Using ‘Ramadan’ as a title or abstract search 
term on PubMed revealed 43 articles published from 1960 – 1990. From 1991 – 
2000, there were 90 published articles and since 2001, there were about 330 
Ramadan-related articles with diabetes being the focus in the majority. However, in 
recent years, there has been a growing interest in the effects of Ramadan on health 
as global awareness of fasting for Ramadan increases. In both Muslim and non-
Muslim countries, there is now increasing awareness of the influence of Ramadan 
not only on healthy individuals or people with diabetes, but also on people with other 
illnesses. Recent research on other conditions have centred on cancer181, multiple 
sclerosis (MS)182, asthma183 and psychiatric disorders184;185. Consequently, clinicians 
are starting to address issues such as adherence to medications and potential 
exacerbations of these conditions. Prospective studies have not shown any rise in 
MS relapse rate or deterioration in the lung function of asthmatics during the month 
of fasting when compared to non-fasting months182;186. Changes in the sleep/wake 
cycle and social routine during Ramadan can precipitate relapses in manic 
disorder184. One group were able to minimise the chance of relapses in bipolar 
affective disorder using measures such as giving advice about adequate sleep, 
assessment of mood at least 3 months before Ramadan, and careful monitoring of 
lithium levels, electrolyte and fluid balance during Ramadan185.  
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We predict that research on other medical conditions and public health efforts will 
increase in the near future. 
7.1.2 Increasing awareness in Muslim and non-Muslim countries 
In countries with a Muslim majority, the normal routine of an entire nation changes 
during Ramadan: working hours are from 8 am to 3 pm; nocturnal sleep is 
shortened187; and daytime sleeping hours increase during Ramadan188. The effect of 
such social and behavioural modifications during Ramadan were assessed in recent 
studies from Morocco, United Arab Emirates, Turkey, Pakistan and other Muslim 
countries34;165;189-191. Collectively, three themes have emerged: 1) the need for pre-
Ramadan assessment for patients intending to fast for Ramadan; 2) the need to 
support clinicians with both medical and religious knowledge of Ramadan; 3) 
demonstration that Ramadan is safe in various patient groups, e.g. cardiac, renal, 
and obese and diabetes patients. Raising the awareness of Ramadan helps 
clinicians to understand the act of fasting and to avoid medically unjustified negative 
advice for fasting to patients. 
Addressing ethnic populations on their religious practices can be a challenge in 
countries with a Muslim minority for healthcare professionals, who often have 
different religious and language backgrounds. For that reason, interview-based 
studies from Sweden, France, Belgium, and Canada were carried out to evaluate the 
attitudes of Turkish, Somali and Bangladeshi Muslims and their physicians towards 
Ramadan fasting and diabetes care107;192-194. Many healthcare professionals in these 
countries were not familiar with the fasting practices, whilst more than half of the 
Muslim patients in France disagreed with the advice given by their physicians107. 
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We have shown that, in a specific sub-group of pregnant women with diabetes, 
fasting during Ramadan was rare and the influence of religious leaders was as 
important as medical advice195. In overall, women were just as likely to discuss 
fasting with their Imams as they were with healthcare professionals. Pre-conception 
care in Muslim women with diabetes should include education on the potential risks 
of fasting during Ramadan and healthcare professionals should work together with 
Imams to address the medical and religious aspects of fasting. 
The updated ADA recommendations for management of diabetes during 
Ramadan109 also recognised the importance of global awareness of Ramadan in 
educating healthcare professionals and including religious and community leaders 
when providing guidance on health maintenance during fasting. The challenge now 
is for healthcare and faith communities to engage patients together both on an 
individual and population level.  
Adolescents, pregnant women, patients who have had bariatric surgery, 
geographically isolated patients of low socioeconomic background, and immigrants 
with language difficulty all deserve more attention.  
7.1.3 Advances in diabetes research 
7.1.3.1 Structured education for both healthcare professionals and patients 
We have demonstrated that Ramadan-focused structured education on Muslim 
diabetes patients minimised hypoglycaemic risk and weight gain during Ramadan56. 
A number of studies have also shown the benefits of structured patient education to 
empower people with diabetes to improve their health during Ramadan34;165;196. In 
Pakistan, pre-Ramadan assessment, education and adjustment of dietary control 
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and diabetes medications prepared type 2 diabetes patients on all treatment groups 
(oral agents and insulin) to fast safely during Ramadan, resulting in a reduction in 
hypoglycaemic events over the course of the month and no major hyperglycaemic 
complications, such as diabetes ketoacidosis and hyperglycaemic hyperosmolar 
state165.  
The ADA recommended that Muslim patients with diabetes intending to fast should 
have structured education, preferably in patients’ own languages, from well-informed 
healthcare professionals109. Accordingly, healthcare professionals are now seeking 
to understand more about the religious perspective of fasting and the medical 
options to fast safely, as demonstrated by an increase in the BMJ article usage 
meter (in blue squares) of a review about diabetes management during Ramadan 
around the months leading up to Ramadan54 (Table 7.1).   
 
Table 7.1 Article metrics: an indication of how often the Ramadan review article has been accessed 
month by month
197
.  
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By following the ADA recommendations for pre-Ramadan assessment and 
therapeutic adjustments, we showed that the glycaemic variability between fasting 
and non-fasting periods during Ramadan were similar198. Even though each 
measure of glycaemic variability was non-significantly higher during the non-fasting 
hours, which may be due to the small number of participants, the glycaemic 
variability assessed by mean amplitude of glycaemic excursion (MAGE) during 
Ramadan was similar to the MAGE value in published series of non-fasting subjects 
with type 2 diabetes129, suggesting a representative sample. 
7.1.3.2 Evidence-based recommendations to Muslims with diabetes 
Our findings suggested that exenatide, the GLP-1R agonist, is safe during Ramadan 
by minimising hypoglycaemia and significant weight gain. From the observational 
study, Humalog Mix 50 injection at Iftar in addition to Human Mixtard 30 at Suhur is 
as good as twice-daily Human Mixtard 30 in achieving stable weight with no 
significant differences in the mean number of hypoglycaemic events before and 
during Ramadan. Changing to Humalog Mix 50 in the evening during Ramadan 
resulted in a modest but significant improvement in glycaemic control without 
increasing the incidence of hypoglycaemia. 
Large multicentre studies have provided more answers regarding optimal diabetes 
treatment during Ramadan. A five-country observational study showed that nearly 
20% of sulphonylurea-treated Muslims with type 2 diabetes had symptomatic 
hypoglycaemia during the month of fasting. Among all the sulphonylurea 
medications, gliclazide had the least incidence of hypoglycaemia67. A randomised, 
multicentre open-label study revealed that sitagliptin reduced the risk of 
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hypoglycaemia compared with a sulphonylurea in patients who were fasting during 
Ramadan72.  
There are no further randomised controlled trials on premixed insulins in recent 
years. Earlier, crossover studies comparing analogue insulins (Humalog Mix 25 and 
Humalog) and human insulins (human insulin 30/70 and human soluble insulin 
Humulin I) suggested that analogue insulins were better in lowering post-prandial 
hyperglycaemia following the sunset meal75;199. However, the debate of analogue 
versus human insulin is not resolved. A randomised trial has been proposed to 
compare once-daily detemir and NovoMix 30/70 to standard patient care. Further 
randomised controlled studies on commonly used insulin regimens, such as basal 
bolus regimes, are warranted. 
 
7.2 Challenges in Ramadan studies 
7.2.1 Geographical and cultural differences  
There is a vast amount of work on the effects of fasting during Ramadan in relation 
to anthropometric indices, including weight and body mass index; metabolic markers, 
such as lipid profile, high-sensitivity CRP (hs-CRP), HbA1c, glucose; and dietary 
intake with respect to protein, carbohydrate and fat. The findings often varied from 
one study of practising Muslim populations to another. For instance, studies on 
healthy Muslims in Turkey and Morocco demonstrated an increase in total energy 
intake200;201, whilst Jordanian and Emirati Muslims had no change in total energy 
consumption before and during Ramadan202;203. These differences have been partly 
attributed to the unique food habits of different Islamic countries, and also due to the 
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differing beliefs and practices among the various denominations in Islam204. For 
instance, Sunni Muslims are allowed to eat shellfish but some Shiite sects are not. 
We have not taken into account the different sects of Islam in our study but the 
information will be helpful in future works.  
Moreover, the daylight hours and the length of daily fast vary depending on the 
month Ramadan falls on and the geographical location. It is, therefore, important to 
bear in mind these changing variables when conducting multicentre trials on 
Ramadan.  
7.2.2 Physiological adaption during the month of fasting 
Another variable that is not usually accounted for in Ramadan studies is that people 
fasting for the whole month undergo physiological and psychological adaptations. 
Changes experienced at the start of Ramadan may be different to the end of the 
month. By completing an appetite rating questionnaire every week throughout 
Ramadan, the average fasting levels of hunger was higher for women than men 
during the early days of Ramadan. As the month progressed, the women showed a 
decline in hunger and the average levels of hunger became similar for both sexes205. 
Interestingly, the women were often involved in preparing food before sunset, whilst 
the men were usually at work, away from this external cue of hunger. There may be 
changes in food consumption patterns throughout Ramadan35. Alternatively, 
unreinforced exposure to food cues during intermittent daily fasting may have led to 
a progressive decrease in the capacity of these cues to stimulate hunger205.  
We demonstrated that one participant ‘corrected’ his low glucose readings (4.1 – 4.4 
mmol/L) during days of continuous glucose monitoring198, and Muslim students also 
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adapted during Ramadan to avoid daytime somnolence by increasing daytime sleep 
hours188. To account for these variations, assessments should be performed 
throughout the month of Ramadan when evaluating the effects of medical treatment.  
7.2.3 Limitations and Bias  
Limitations in our research include: 1) selection bias of the study participants (mainly 
from diabetes community clinics and specialist clinics in North West London) and 
small sample sizes, which may not be representative to the whole Muslim type 2 
diabetes population in the U.K. We intended to include other parts of London with 
high proportion of Muslims. Unfortunately, the plan was abandoned due to the 
inability to arrange Bangladeshi interpreters; 2) reporting bias of the hypo- and 
hyperglycaemic events by the participants. Downloading data from glucometers 
would minimise recall bias of symptomatic events. More studies using continuous 
glucose monitoring would be helpful to capture the temporal differences of glycaemic 
control; 3) assessment of glycaemic variability – we have used a range of measures 
to assess glycaemic variability. Each of them has its own advantages and 
disadvantages. As there is currently no consensus as to the best method for 
assessing glycaemic variability from continuous glucose monitoring data206, we 
aimed to display a comprehensive assessment using the currently available 
measures. 
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7.3 Future directions in Ramadan research 
7.3.1 The ‘Ramadan-model’: initiation of lifestyle modification 
Globally, an estimated 50 million people with diabetes fast during Ramadan each 
year109. The ability to suppress hunger daily for long periods and subsequent weight 
loss in some Muslim populations35;202;207 are fascinating topics that are worth 
exploring. Fasting and reduced meal frequency during Ramadan resulted in a 3.7% 
weight loss in obese women with diabetes (before versus mid-Ramadan, 84.26 ± 
8.84kg vs. 81.14 ± 6.34kg respectively; p<0.01)35. Fasting during Ramadan serves 
as a great opportunity to initiate healthy lifestyle changes and to lose weight, 
especially in obese people with diabetes.  
Maintaining weight loss after Ramadan is equally important. The obese women 
regained their weight after Ramadan as they returned to their pre-Ramadan 
lifestyle35. The goal of pre-Ramadan assessment with dietary and therapeutic 
adjustments should not only be restricted to the Ramadan period, but should ideally 
provide a sustainable weight and lifestyle modification, and improvement in 
glycaemic control beyond Ramadan.  
Further research on the physiology of fasting and the role of gut hormones is needed 
to help understand the complex hormonal and metabolic changes that occur during 
Ramadan, which may help to provide novel solutions to maintain weight loss after 
Ramadan. 
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7.3.2 Ramadan and other diabetes complications 
We have primarily focused on the short-term effects of Ramadan fasting, namely 
hypo- and hyperglycaemia, glycaemic variability, HbA1c and weight change to 
ensure safety during Ramadan. The impact of fasting on other diabetes 
complications also needs attention: 
1) Nephropathy: The risk of dehydration, particularly when Ramadan occurs during 
summer months in the Northern hemisphere with long daylight hours, is potentially 
high. Kidney-transplant recipients, with or without diabetes, had stable estimated 
glomerular filtration rate and urinary protein excretion before and after Ramadan in 
the Middle East where the duration of fasting was shorter ; however, the sample size 
of the studies were small52;208;209.  
Current evidence revealed that hospital admissions for urolithiasis in a Saudi hospital 
did not increase during the months of Ramadan in three consecutive years210. 
Further studies will be helpful to address whether Ramadan is safe in patients with 
moderate to severe nephropathy and in patients on dialysis, and whether Ramadan 
fasting has an effect on the prevalence of urinary tract infections. Randomised 
controlled studies on therapeutic regimens or adjustments, such as GLP-1R agonist 
and insulin, is greatly needed to risk-stratify patients with diabetic nephropathy who 
choose to fast. 
2) Neuropathy: About a quarter of the EPIDIAR population (n=12,243) of type 1 and 
2 diabetes patients had pre-existing neuropathy15. Hypoglycaemic unawareness and 
gastroparesis associated with autonomic neuropathy and acute hyperglycaemia are 
likely to produce grave consequences for those who are keen to fast. Continuous 
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glucose monitoring would be useful in this group of patients with hypoglycaemic 
unawareness. Continuous glucose monitoring also demonstrated that glucose 
excursions occurred more frequently and glycaemic control, as indicated by M-value 
and mean glucose, was worse in patients with painful neuropathy compared to those 
with painless neuropathy211. Glycaemic variability with multiple glucose excursions 
may have a biochemical effect on nociceptive afferent fibres and exacerbate painful 
symptoms. Studies to assess its prevalence are greatly needed and fasting in these 
patients should not be recommended and should be assessed on an individual 
basis.  
Apart from Ramadan, diabetes and its complications can also affect other aspects of 
Islamic practice. For instance, diabetic neuropathy may affect Muslims who travel to 
Hajj, the pilgrimage to Mecca. In a large population-based study in Northwest 
England, painful neuropathy symptoms were greater in South Asians compared with 
other ethnic groups, even in the absence of clinical neuropathy212. This would have 
an impact on the South Asians in the U.K., which comprised of the largest group of 
British Muslims predominantly of Pakistani and Bangladeshi origins213.  
3) Retinopathy: Apart from a report on the increased incidence of retinal vein 
occlusion during Ramadan due to dehydration in Saudi Arabia214, there are currently 
no published data about the effects of Ramadan on diabetic retinopathy. Preliminary 
evidence has shown that acute hyperglycaemia increased blood flow to the retina 
associated with the progression of retinopathy215. The link between retinopathy and 
acute hyperglycaemia associated with fasting and feasting has yet to be established.  
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7.3.3 Ramadan and cardiovascular outcomes 
By reviewing the hospital admissions of ACS to a district general hospital in Brent 
during the month of Ramadan in 2009, we observed that only one patient, out of a 
total of 30 patients admitted with ACS, was fasting. The patient did not have diabetes 
and had a normal fasting glucose during the hospital stay216. Two patients with 
diabetes were admitted with ACS during the month, but they did not fast. From this 
small single-centred study, hospital admissions for acute coronary syndrome did not 
appear to be a major problem in Muslims with diabetes who fasted in the London 
borough of Brent. Larger studies are needed to determine the incidence of ACS 
during Ramadan in the U.K, including centres with facilities for primary angioplasty to 
capture the incidences of both ST-elevation and non-ST elevation myocardial 
infarctions. 
Retrospective reviews of hospital admissions over 10 years showed no increase in 
the incidences of acute coronary syndrome (ACS) in Qatar217, congestive heart 
failure218 or stroke219 during Ramadan. A prospective study on stable cardiac 
outpatients with no or mild symptoms classified as congestive heart failure with New 
York Heart Association class I and II, patients with stable angina, atrial fibrillation or 
prosthetic valves concluded that these patients were safe to fast53.  
Serum leptin and hs-CRP, biomarkers of vascular inflammation, were also 
unchanged in stable cardiac patients who fasted. Twenty-nine per cent of these 
patients felt that their symptoms improved and none of them felt worse during 
Ramadan189. 
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Spiritually, Ramadan is the month of self-purification. From a medical point of view, 
Ramadan may have a cardioprotective effect on certain patients. Additional research 
is needed to clarify the safety profile of fasting in patients with multiple comorbidities 
or those with coronary artery disease.  
 
7.4 Summary and Conclusion 
 10% of pregnant women with diabetes fasted during Ramadan in our survey. 
Both Imams and healthcare professionals were important to these women in 
making the decision to fast. 
 Therapeutic adjustments in relation to the type of insulins, timing and/or 
dosage of medications, as well as education focused on Ramadan issues in 
the period preceding Ramadan, are beneficial in minimising large glycaemic 
excursions during fasting and non-fasting intervals of Ramadan. 
 New therapeutic strategies, including glucagon-like peptide-1 receptor 
agonists, for patients with type 2 diabetes should incur less hypoglycaemia 
and weight gain during Ramadan fasting.  
 Global awareness on the impact of religious fasting would bridge the gap in 
the cultural differences between the patients and their healthcare providers. 
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Chapter 8: Appendix 1 
Ramadan & Diabetes Questionnaire  (delete when appropriate) 
Age:                   
What type of diabetes do you have?  Type 1/Type 2/gestational  
How long have you had diabetes?   ………months……….years 
Do you take tablets or insulin or both for your diabetes?   
Please write down the names of your diabetes medications:  
 
 
Were you pregnant during any previous Ramadan periods? Yes/No 
Did you fast during Ramadan?    Yes/No 
- If yes, how many days (of the month of Ramadan)?  
Are you taking your tablets/insulin at different times or 
different doses during Ramadan, when compared to other 
months?      
Yes/No 
- if yes, is your tablets/insulin: increased/ decreased/ 
maintained/ stopped  
 
Have you ever discussed with a health care professional 
(doctor/nurse) if it is safe to fast? 
Yes/No 
Did you consult with an Imam or representative from the 
Mosque regarding whether to fast or not?   
Yes/No 
Did you check your blood sugars during Ramadan? Yes/No 
Did you have any low blood sugars (BM less than 4) during 
Ramadan or experienced symptoms of low blood sugars – 
e.g. feeling faint, dizziness, palpitations, sweating, hunger 
pains, disorientated?   
Yes/No 
How many times did you have low blood sugars (BM less 
than 4) during Ramadan? 
 
Did the low blood sugars occur during fasting time? Yes/No 
When your sugars are low, did you stop fasting?    Yes/No 
- If not, what happened? 
 
 
Did you have low blood sugars BEFORE Ramadan? Yes/No 
- if Yes, how many times a month?  
What was your highest blood sugar reading during 
Ramadan? 
Yes/No 
What did you do when the blood sugar was high?   
Were you admitted to hospital because of diabetes during 
Ramadan?   
Yes/No 
- if Yes, what was the cause(s)? 
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QRisk superior in diverse South Asian groups - response to Robson
et al.
To the Editor:
We thank Robson et al., for their comments
(1). We agree that the differences in calculated
vascular risk that we documented are relevant
to patient management. Also, it is very likely
that QRisk2 is a better predictor of risk in Cau-
casians and ⁄ or South Indian Asians (1).
Because South Indian Asians have a greater
risk of vascular events (2), it is imperative to
validate a risk engine specifically aimed at this
population living in India and in other coun-
tries where substantial migration has occurred
(e.g. UK, USA). It is also possible that risk
calculations will differ between South Asian
populations (e.g. Pakistanis, Bangladeshis, Sri
Lankans and even in Indians with different
dietary habits, faiths and geographical origins
within India).
In this context, it is of interest that we
found that the estimated glomerular filtration
rate (eGFR) calculated using different equa-
tions varies substantially in South Indian
Asians (3). These equations have not been
validated in South Asian populations despite
the fact that a low eGFR is a predictor of vas-
cular risk (4). This situation is similar to that
discussed above regarding the need for vali-
dated risk engines specifically designed for
South Asians.
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LETTER
Fasting among pregnant women with diabetes during Ramadan
To the Editor:
Islamic law exempts pregnant women from
fasting during Ramadan [1,2]. Although
women can defer fasting until after pregnancy,
they prefer to share the experience during Ram-
adan. A total of 45–90% of healthy pregnant
women fasted during Ramadan [3–5]. Our
aims were to examine the practice of fasting
among pregnant Muslim women with diabetes
and to explore the roles of healthcare profes-
sionals and Imams in the decision to fast.
Standardised questionnaire-based inter-
views, based on questions in the EPIDIAR
study [6], were conducted at four specialist
antenatal centres in London. Forty-eight
women completed the questionnaire. Mean
age (± SD) was 32 ± 5 years. Sixty-five per
cent had gestational diabetes, 31% had type 2
and the remainder had type 1 diabetes. Forty-
four per cent were diet-controlled, 25% on
oral hypoglycaemic agent(s), 21% on insulin
and 10% on insulin and metformin.
Ten per cent of women fasted during preg-
nancy (Table 1). Twenty-three per cent of
women who did not fast, had a history of
hypoglycaemia. Having diabetes with risk of
hypoglycaemia may be why these women did
not fast, compared with healthy pregnant
women who were keen to fast despite adverse
reaction [2]. Urban background may have
influenced their decision not to fast, as immi-
grants and women from rural areas tended to
fast [3,5]. Family members may have been
consulted instead, as 63% did not consult
healthcare professionals or religious leaders
for advice [7]. Husbands tended to discourage
fasting when they felt that the women were
endangering themselves [4].
In overall, women were just as likely to dis-
cuss fasting with their Imams as they were with
healthcare professionals (Table 2). Preconcep-
tion care in Muslim women with diabetes
should include education on the risks of fasting
during Ramadan and healthcare professionals
should work together with Imams to address
the medical and religious aspects of fasting.
Table 1 Characteristics of the five women (n = 48) who fasted during pregnancy
Patient
Type of
diabetes
Diabetes
treatment
Fasting
whilst Pregnant
previously
Number of days
fasted during
Ramadan
Discussion with
healthcare
professional
Discussion
with Imam
1 T1DM Insulin N 14 Y Y
2 T2DM Diet N 30 N N
3 T2DM Oral Y 5 N Y
4 GDM Insulin + metformin Y 30 N Y
5 GDM Insulin Y 30 N Y
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Extending the survey beyond London
would provide a more comprehensive view of
Muslim women with diabetes. Further
research is needed to determine whether fast-
ing during Ramadan affect maternal and foe-
tal outcomes.
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Table 2 Comparison between the pregnant women with diabetes who fasted and who did not fast
during Ramadan
Fasting women No. Non-fasting women No.
Glycaemic control during Ramadan:
Hypoglycaemia 1 10
Hyperglycaemia 3 4
Ramadan discussions with:
Healthcare professionals 0 9
Imams 3 3
Both 1 4
ª 2012 Blackwell Publishing Ltd
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Low glycaemic variability in subjects with
Type 2 diabetes following pre-Ramadan
assessment and adjustments for fasting
Diabet. Med. 29, 828–829 (2012)
Ramadan is the 9th month of the Islamic lunar calendar, during
which Muslims abstain from food intake between sunrise and
sunset. Major changes to dietary patterns occur duringRamadan
as meals are taken before dawn and immediately after sunset.
People with Type 2 diabetes fasting during Ramadan have large
increases in glycaemic excursions, with a 7.5-fold increased
frequency of severe hypoglycaemia and a 5-fold increase in
severe hyperglycaemia [1]. Glycaemic excursions are disruptive
to the individual and measures of variability are associated
with subsequent hypoglycaemia [2]. Therefore, diabetes
management in Ramadan should target glycaemic variability to
empower people with diabetes to fast safely for prolonged
periods.
The American Diabetes Association has published
recommendations on diabetes management during Ramadan,
focusing on individualized care and pre-Ramadan structured
education [3]. Our objective was to implement the American
Diabetes Association recommendations for the management
of diabetes during Ramadan, focusing on pre-Ramadan
assessment, and to evaluate the impact of the guidelines on
glycaemic variability using continuous glucose monitoring in
fasting and non-fasting hours.
Muslim subjects over 18 years old with Type 2 diabetes
attending a specialist diabetes clinic, and planning to fast for
Ramadan, with a history of hypoglycemia (symptomatic or
documented capillary blood glucose £ 4.0 mmol ⁄ l) were invited
to undergo a 5-day glucose profile using the Abbott Freestyle
Navigator (Abbot Diabetes, Alameda, CA, USA) continuous
glucose monitoring system as part of their clinical investigation
during Ramadan. Data from the continuous glucose monitoring
device were downloaded using the CoPilot Healthcare
Management System 4.0 (Abbott Diabetes Care Inc, Alameda,
CA, USA). Timing and dosage of diabetes medications were
adjusted at the patients’ pre-Ramadan clinic visits when clinically
indicated according to the American Diabetes Association
recommendations.
The following outcome measures of glycaemic variability were
evaluated: standard deviation of mean blood glucose, M-value,
mean amplitude of glycaemic variability (MAGE), lability index,
J-index, continuous overlapping net glycaemic action
(CONGA), average daily risk ratio, low blood glucose index,
high blood glucose index. These indices were calculated using
EasyGV software (available free at http://www.easygv.co.uk)
and have been extensively reviewed [4].
Mean age of the participants (n = 6) was 53.7  2.3 years,
mean duration of diabetes 7.3  2.8 years and HbA1c
pre-Ramadan was 60  1.1 mmol ⁄mol (7.6  1.1%). Daily
fasting duration ranged from 13 to 16 h. All participants had
pre-Ramadan assessments and three patients required dose
and time adjustments of their diabetes medications in line
with American Diabetes Association recommendations.
Although the resulting measures of glycaemic variability, as
indicated by MAGE, lability index, J-index, CONGA and
M-value, were higher during non-fasting hours when
participants break their fast between sunset and dawn, there
was no significant difference when compared with the fasting
periods (Table 1).
The risk of hypoglycaemia as measured by low blood glucose
index was not significantly different between the fasting hours
compared with the non-fasting hours (9.45  18.96 vs.
1.21  1.12; P = 0.35) and high blood glucose index, an
indicator of hyperglycaemic risk, was the same across the two
periods (6.41  7.21 vs. 10.46  10.99; P = 0.15).
The average daily risk ratio, a predictor of future hypo-
glycaemia (< 4 mmol ⁄ l) and hyperglycaemia (> 10 mmol ⁄ l),
was 21.82  12.53. An average daily risk ratio between 20 and
40 is considered moderate risk for future low and high glucose
excursions [5]. No severe hypoglycaemia requiring third-party
assistance was reported for any of the participants.
A considerable amount of food rich in refined carbohydrate is
traditionally prepared for Ramadan and taken during non-
fasting hours. Despite dietary changes and previous reports of
hypo- and hyperglycaemic excursions in Ramadan, when pre-
Ramadan assessment and adjustments are implemented, the
difference compared with fasting hours is not significant.
Measures of glycaemic variability calculated were measures of
total variability (sd), within-day variability (MAGE) and
between-day variability (CONGA). Each measure was greater
during the non-fasting hours, but was not statistically significant,
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which may, in part, be attributable to the small number of
participants. However, despite the small sample size, the
glycaemic variability assessed by MAGE during Ramadan
(4.47  0.75) is similar to the MAGE value in published series
of non-fasting subjects with Type 2 diabetes (4.8  2.1) [6],
suggesting a representative sample. Recruitment of subjects in a
limited time can be challenging in Ramadan, particularly during
a religious event of such importance, and further studies
including a larger number and wider spectrum of participants
are warranted. It would also be useful to compare the glycaemic
variability of these subjects in the non-fasting months with that in
the month of Ramadan to assess the alterations in dietary and
socialhabits duringRamadan,as comparedwithnormal routine.
We acknowledged that the lack of such a control group and that
the continuous glucose monitoring was not blinded may have
reduced the glycaemic variability.
In conclusion, our findings suggest that systematic pre-
Ramadan assessment with appropriate therapeutic adjustments
and educational advice regarding healthy diet, adequate exercise
and awareness of the risks of hypo- and hyperglycaemia are
important in negating the previously described glycaemic
variability seen during Ramadan [1].
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Death rate of residents with diabetes
in nursing homes
Diabet. Med. 28, 829–830 (2011)
In our paper published in Diabetic Medicine in July 2011 [1]
entitled ‘People living with diabetes resident in nursing
homes—assessing levels of disability and nursing needs’, we
made the assertion that it was likely that the majority of
individualsdescribed inthis studycouldbeclassifiedas terminally
ill. This assertion came from the definition of terminal illness that
is based on a negative answer to the question, ‘would I be
surprised if my patient were to die in the next 12 months?’.
Table 1 The parameters of blood glucose control and glycaemic variability of the participants during the fasting (daylight hours from sunrise to sunset) and
non-fasting hours of Ramadan
Total periods Fasting periods Non-fasting periods P-value
Mean tissue glucose 8.92  2.76 8.56  2.42 9.68  3.46 0.17
Measures of glycaemic variability
Standard deviation (sd) 2.07  0.83 1.81  0.47 2.10  0.95 0.45
Mean amplitude of glycaemic variability (MAGE) 4.47  0.75 4.69  1.47 4.82  1.63 0.90
Continuous overlapping net glycaemic action (CONGA) 8.01  2.68 7.66  2.34 8.29  2.96 0.21
Lability index 2.90  1.09 2.39  0.79 5.38  4.54 0.17
J-index 42.25  25.27 36.52  19.18 49.42  34.05 0.19
M-value 10.21  13.96 7.34  11.17 14.95  19.53 0.17
Risk measures—predictors of extreme hypoglycaemia and hyperglycaemia
Low blood glucose index 9.44  18.96 9.45  18.96 1.22  1.12 0.35
High blood glucose index 7.91  8.59 6.41  7.21 10.46  10.99 0.15
Average daily risk ratio 21.82  12.53
Values are mean  sd (mmol ⁄ l)
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Comparison of Humalog Mix 50 with human insulin Mix
30 in type 2 diabetes patients during Ramadan
E. Hui,1 V. Bravis,1,2 S. Salih,3 M. Hassanein,4 D. Devendra1,2,3
Introduction
Ramadan is the ninth month of the Islamic lunar
calendar. Healthy Muslims are obliged to abstain
from all food and drink during daylight hours
throughout this month and can do so with little
long-term impact on their health (1). As the lunar
year rotates from season to season, Ramadan can
occur in any month. Its duration varies between 29
and 30 days and the hours spent in fasting range
from only a few hours to more than 20 h per day
depending on season and geographical location (2).
The EPIDIAR study showed that 78.7% of patients
with Type 2 diabetes chose to fast for at least 15 days
during Ramadan (3). Although several studies have
shown that Ramadan fasting did not affect overall
glycaemia in balanced Type 2 patients treated with
diet and oral hypoglycaemic agents (4–6), acute met-
abolic complications are thought to be important
concerns for patients with diabetes during Ramadan.
Increased frequencies of hypoglycaemia have been
reported during Ramadan fasting (3,7,8). There was
a 7.5-fold increased risk of hypoglycaemia in Type 2
diabetes patients (3).
There is no consensus regarding the most appropri-
ate insulin therapy for Muslim diabetes patients
during Ramadan. Risk of hypoglycaemia did not differ
significantly during Ramadan in patients treated with
either repaglinide, glimepiride or insulin glargine (9).
Repaglinide plus single-dose insulin glargine regimen
has been shown to be safe in low-risk Type 2 diabetic
patients as compared with non-fasting controls. There
SUMMARY
Aims: To compare hypoglycaemic events, glycated haemoglobin (HbA1c) and
changes in body weight in Muslim patients with Type 2 diabetes receiving Humal-
og Mix 50 and human Mixtard 30 twice daily during Ramadan fasting. Meth-
ods: Data were collected from Muslim patients with Type 2 diabetes attending
primary care practices in North-West London, who were on Mixtard 30 insulin
twice daily before Ramadan. Group 1 had their evening insulin changed to Humal-
og Mix 50 (n = 26) 2 weeks before Ramadan, i.e. taking Mixtard 30 at predawn
meal and Humalog Mix 50 at the sunset meal during Ramadan. As the major pro-
portion of the daily caloric intake was consumed at the sunset meal, the rationale
of switching the evening dose from human Mixtard 30 to Humalog Mix 50 was to
provide more rapid-acting insulin that has shorter time of onset and peak time for
the large evening meal to improve the postprandial glucose control without
increasing the risk of hypoglycaemia. Group 2 continued on Mixtard 30 twice daily
(n = 26). All patients received structured education about how to identify and
manage hypoglycaemia during Ramadan. Results: Group 1 had a mean HbA1c
reduction of 0.48% (p = 0.0001) before and after Ramadan, whereas group 2
had a mean HbA1c increase of 0.28% (p = 0.007). Group 1 was associated with
a small reduction of 0.04 (p = 0.81) in the mean number of hypoglycaemic events
during Ramadan compared with before Ramadan, whereas group 2 was associated
with an increase of 0.15 (p = 0.43), although these differences between the
groups were not statistically significant following adjustment for baseline factors
[LSM difference between groups = 0.135, p = 0.36, 95% confidence limits
()0.16, 0.43)]. Conclusion: Changing to humalog Mix 50 during Ramadan
resulted in improvement in glycaemic control without increasing the incidence of
hypoglycaemia.
What’s known
• There are risks, such as hypoglycaemia, in
patients who choose to fast during Ramadan,
especially for those taking insulin.
• There are only a few studies about the use of
premixed insulin regimens during Ramadan fast:
• Short-acting analogue insulin lispro has been
shown to have less hypoglycaemic episodes
during Ramadan compared with soluble human
insulin, when both given with NPH (neutral
protamine Hagedorn). Humalog Mix 25, given
twice daily, has been shown to have less
postprandial glucose excursion than human
insulin Mix 30 ⁄ 70.
What’s new
• Muslims fast between sunrise and sunset during
the month of Ramadan, which varies according
to the lunar calendar. The long daylight hours in
countries in the Northern hemisphere will have
large implications, e.g. hypoglycaemia, on
diabetes patients who wish to fast during
Ramadan.
• This is the first study looking at the risks of
hypoglycaemia and glycaemic control of twice
daily premixed insulin regimens in the UK during
Ramadan.
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were no reported hypoglycaemic events and no signi-
ficant differences in metabolic parameters including
fasting and postprandial blood glucose and fructo-
samine levels before and after Ramadan (10).
However, changes in dietary habits during Ramadan
can result in extreme postprandial glucose rises and
difficulty in maintaining glycaemic control in patients
taking twice daily insulin.
As part of a larger programme of diabetes-focused
education and interventions during Ramadan in
North-west London, we undertook an observational
study to evaluate hypoglycaemic events (defined as
blood glucose < 3.5 mmol ⁄ l with or without symp-
toms), glycated haemoglobin (HbA1c) and weight
change in Muslim patients with Type 2 diabetes who
fasted and whose HbA1c was insufficiently controlled
with twice daily Mix 30 insulin regimen (Human
Mixtard 30 ⁄ 70) before Ramadan. As a larger propor-
tion of the daily caloric intake was usually consumed
at the evening meal (at sunset, Iftar) (11), the even-
ing dose was therefore changed to Mix 50 (Humalog
Mix 50 ⁄ 50) based on clinical judgement.
In this study, we aimed to compare the effect of
Mix 30 and Mix 50 insulin regimes on HbA1c,
weight and hypoglycaemic events in Type 2 patients
who fasted during the month of Ramadan.
Patients and methods
Participants
This was an observational study of Muslim patients
with Type 2 diabetes treated in accordance with the
American Diabetes Association’s recommendations
for the management of diabetes during Ramadan (2).
Participants who were 18 years or over and fasted
for ‡ 15 days were included. Patients attended six
primary care practices in the London boroughs of
Brent, Ealing and Harrow, who had taken part in a
workshop to educate healthcare professionals on
issues surrounding diabetes and fasting. All partici-
pants received Ramadan-focused education about the
management of their diabetes and the identification
and management of hypoglycaemia. Patients were
already on Mix 30 insulin twice daily before attend-
ing the education. They either continued on Mix 30
insulin twice daily or changed their evening insulin
dose to Mix 50 2 weeks before Ramadan. Patients
who continued on Mix 30 used their usual prestudy
injection-to-meal time interval. Patients who had
Mix 50 insulin in the evening were advised to inject
immediately before meals. Allocation to treatments
was based on clinical judgement prior to inclusion
and was not randomised. Indication for changing to
Mix 50 includes elevated 2-h postprandial capillary
blood glucose > 10 mmol ⁄ l in the evenings.
Assessments
All participants were seen 2 weeks before the start
of Ramadan and seen again 10 days after the last
day of Ramadan. All participants were instructed to
monitor their symptoms closely and record daily
preprandial and 2-h postprandial blood glucose,
hypoglycaemic events and weight. An Ascensia Con-
tour glucose meter (Bayer Healthcare, UK) was
provided to participants. Before Ramadan, partici-
pants were asked to provide any documentation of
hypoglycaemia from either a blood glucose meter
or glucose diary records. During Ramadan, partici-
pants were asked to check their blood glucose levels
if they had any symptoms of dizziness, visual blur-
ring, palpitations, nausea, sweating, confusion,
tremor or intense hunger. Both the blood glucose
diary and the blood glucose meter were analysed
for episodes of hypoglycaemia. Patients were also
asked to notify their general practitioner if they
had any episodes of hypoglycaemia, and they were
told to attend the daily rapid access clinics in Brent
if they had any concerns about their diabetes.
Severe hypoglycaemia was defined as a low blood
sugar (< 3.5 mmol ⁄ l) needing assistance to treat the
hypoglycaemic event. In addition, participants were
asked to document the total number of days they
had fasted.
Changes between prefasting and postfasting HbA1c
and weight were analysed using analysis of covari-
ance (ANCOVA) models to adjust for the effects of
age, gender, ethnicity, duration of diabetes and base-
line values. Patients were asked to record the total
number of hypoglycaemic events 4 weeks prior to
the start of Ramadan and subsequently asked to
record hypoglycaemic events during the month of
Ramadan. Changes between prefasting and intra-fast-
ing occurrence of hypoglycaemic events were also
analysed using ANCOVA models to adjust for the
effects of age, gender, ethnicity, duration of diabetes
and baseline values. Least squares (adjusted) means
(LSM) are presented for treatment differences. For
hypoglycaemic events, in addition to the total num-
ber per patient, the data were also dichotomised into
groups of patients who experienced no events during
fasting and those who experienced at least one event
during fasting.
As a result of the non-interventional nature of this
study according to the Medicines and Healthcare
products Regulatory Agency guidance on what con-
stitutes a clinical trial, central ethics committee
approval was not sought for the observational study.
However, local National Health Service Trust
Research and Development committee approval to
conduct the study was sought before the study was
undertaken.
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Results
Fifty-two patients were included in this observational
study. The Mix 50 group (n = 26 patients) received
Mix 30 at the meal before sunrise and Mix 50 after
sunset. The Mix 30 group (n = 26 patients) received
Mix 30 twice daily. The baseline demographics of the
two groups are shown in Table 1. The mean age was
62.3 ± 9.8 years in Mix 50 group and
61.9 ± 9.2 years in Mix 30 group (p = 0.90). The
mean duration of diabetes was approximately
9.5 years in each group. The mean baseline HbA1c
values were similar between the two groups
(9.05 ± 0.43 vs. 8.98 ± 0.37; p = 0.22). ANCOVA
models were used to adjust for baseline imbalances
because of the non-randomised allocation to treat-
ment.
Table 2 shows the difference in outcome measures
(hypoglycaemic events, HbA1c and weight) between
the start and end of Ramadan and between the two
treatment groups.
Mix 50 was associated with a small reduction of
0.04 (p = 0.81) in the mean number of hypoglycae-
mic events during Ramadan compared with before
Ramadan, whereas Mix 30 was associated with an
increase of 0.15 (p = 0.43), although these differences
between the groups were not statistically significant
following adjustment for baseline factors [LSM dif-
ference between groups = 0.135, p = 0.36, 95%
confidence limits ()0.16, 0.43)].
The Mix 50 group had a mean HbA1c reduction
of 0.48% (p = 0.0001), whereas group 2 had a mean
HbA1c increase of 0.28% (p = 0.007). These differ-
ences, adjusting for baseline factors, were statistically
significant [LSM difference 0.40%, p = 0.0004, 95%
confidence limits (0.19%, 0.62%)].
In the Mix 50 group, there was a significant increase
in mean body weight before and after Ramadan (mean
weight change = 0.81 kg, p = 0.0002). There was a
small but non-significant increase in mean weight
in the Mix 30 group of 0.33 kg (p = 0.082) after
Ramadan. These differences, however, adjusting for
baseline imbalances, were not statistically significant
[LSM difference )0.09, p = 0.62, 95% confidence
limits ()0.47, 0.28)].
Discussion
Ramadan represents a period when there is a major
change in dietary patterns. People take considerable
quantities of sweet foods specially prepared for Ram-
adan and carbohydrate rich meals during non-fasting
hours (12). A considerable proportion of food intake
usually occurs at the meal after sunset. In healthy
subjects, 65% of the daily caloric intake was observed
after this meal (11).
Humalog Mix 50 is a premixed insulin analogue
containing 50% of lispro and 50% neutral protamine
lispro (NPL, an intermediate-acting insulin), whereas
human Mixtard 30 is a mixture of 30% dissolved
human insulin (rDNA) and 70% isophane insulin
(NPH). The pharmacokinetics of analogue premixed
insulin was more akin to the normal pattern of insu-
lin secretion than premixed human insulin (13). The
former has a quicker time to onset of 5–15 min vs.
30–60 min and a shorter time to peak (Tmax) of
115 min vs. 173 min in premixed human insulin.
The rationale of switching the evening dose from
human Mixtard 30 to Humalog Mix 50 was to pro-
vide patients with more rapid-acting insulin that has
shorter time of onset and peak time for the large
meal in the evening to improve the postprandial
glucose control without increasing the risk of hypo-
glycaemia. Although hypoglycaemia tends to be less
frequent in Type 2 than in Type 1 diabetes, it is still
a considerable risk, particularly in patients who
Table 1 Baseline characteristics of the participants
Group 1 (Mix 50) Group 2 (Mix 30)
Participants (n) 26 26
Men:women [n (%)] 8 (30.8%):18 (69.2%) 10 (38.5%):16 (61.5%)
Age [years, mean ± SD (range)] 62.3 ± 9.8 (45–77) 61.9 ± 9.2 (44–77)*
HbA1c (%, mean ± SD) 9.05 ± 0.43 8.98 ± 0.37*
Weight (kg, mean ± SD) 89.4 ± 8.7 85.8 ± 7.2*
Ethnicity (n)
Pakistani [n (%)] 24 (92.3%) 10 (38.46%)
Middle-Eastern [n (%)] 0 (0%) 12 (46.15%)
Other [n (%)] 2 (7.7%) 4 (15.4%)
Duration of diabetes [years, mean ± SD (range)] 9.8 ± 2.8 (4.6–16.5) 9.5 ± 3.3 (4.5–16.5)*
*p > 0.05 between groups 1 and 2. SD, standard deviation.
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required insulin for years and had significant beta-
cell failure and insulin deficiency (2). Hypoglycaemia
may be exacerbated by the inappropriate response
of counter-regulatory hormones and the defect in
epinephrine secretion caused by autonomic neuro-
pathy (14). In this report, there were no significant
differences in the mean number of hypoglycaemic
episodes before and during Ramadan in the Mix 50
and the Mix 30 groups after adjusting for baseline
factors. In a crossover, comparative trial, Mattoo
et al. (15) has also shown no change in the mean
number of hypoglycaemic episodes in patients on
Humalog Mix 25 ⁄ 75 and human insulin Mix 30 ⁄ 70.
Previous studies have shown no change in body
mass index or weight during the fasting period in
Type 2 diabetes patients treated with once daily insu-
lin compared with controls who were on repaglinide
or sulphonylureas (9,10). Information about calorie
intake and exercise is not available in this study.
These would be important factors that may contrib-
ute to the weight increase in the Mix 50 group,
which is not significant after adjusting for baseline
imbalance.
Changing to humalog Mix 50 during Ramadan
resulted in an improvement in glycaemic control
without increasing the incidence of hypoglycaemia.
However, the duration of the study (7.5 weeks) is
rather short to conclude firmly that the groups
achieved their maximum HbA1c. Alternative mea-
surement for glycaemic control, such as serum
fructosamine, would be useful in this study, as serum
fructosamine would be more appropriate to evaluate
the glycaemic control of this short interval. Addi-
tional limitation of the study is that complete
postprandial glucose measurements were not avail-
able from the participants, which would be useful in
evaluating the contribution of HbA1c in the Mix 50
group. This was an observational study of a relatively
small number of Muslim patients with Type 2 diabe-
tes in North-west London. There is a need for larger,
prospective studies to investigate the appropriate
insulin regimens that may enable patients with Type
2, and even Type 1, diabetes who wish to fast with
minimal complications.
If a person with diabetes chooses to fast during
Ramadan, his or her decision needs to be respected
and an appropriate care plan needs to be devised,
taking into account the individual dietary and sleep-
ing patterns during the month and any treatment
modifications that may be needed. It is critical that
patients with diabetes should be counselled about the
need to adjust their insulin regimen before the start
of Ramadan as part of a focused education on meal
planning, glucose monitoring and dietary require-
ments (2). In an audit of 123 Muslim patients with
diabetes, patients who fasted without attending a
structured education session (n = 54) had a fourfold
increase in hypoglycaemia (p < 0.001), whereas those
who attended the Ramadan-focused education pro-
gramme had a significant decrease in hypoglycaemic
events (16).
Switching to analogue Mix 50 insulin in the even-
ing may have a role in the management of Type 2
diabetes patients during Ramadan, particularly to
minimise their risk of hypoglycaemia without com-
promising their glycaemic control and weight.
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Summary
Abstinence from food and liquid during daylight hours is observed by Muslim
individuals during the month of Ramadan. Even though the Koran exempts
the sick from fasting, many people with diabetes still fast during this religious
period. It is essential for patients, family and healthcare professionals to
be aware of the religious attitude to and health implications of fasting.
Major changes in dietary habits, daily physical activities and sleeping patterns
during Ramadan have significant impact on the glycaemic control, lipid
profile, weight and dietary intake. Hence, the patient is encouraged to have
appropriate pre-Ramadan assessment and education in order to stratify and
modify his or her risk with fasting. Dose and timing adjustments to insulin
and to some oral hypoglycaemic agents, especially sulphonylureas, may well
be necessary during Ramadan. Copyright  2010 John Wiley & Sons, Ltd.
Keywords diabetes; Ramadan; fasting; hypoglycaemia
Introduction
Ramadan is the ninth month of the Islamic calendar, when Muslims fast
during daylight hours. It is based on a lunar calendar; therefore, the duration
of daily fast and the overall period of the month of Ramadan vary each
year depending on the geographical location and season. Two main meals
are usually consumed during Ramadan, before sunrise, known in Arabic as
‘Sohur’, and after sunset, known as ‘Iftar’. Changes in meal frequency, daily
physical activities and sleeping patterns during Ramadan may influence the
glycaemic and other biochemical parameters in patients with diabetes [1–3].
Although the Koran exempts sick people from fasting, many Muslims with
diabetes may not perceive themselves as sick and choose to fast, despite
medical advice to the contrary.
Effects of fasting on lipid profile and weight
Caloric intake
Even though people abstain from any oral intake from sunrise to sunset, they
eat considerable amounts of sweet and fried foods traditionally prepared for
Ramadan during non-fasting hours, especially at the Iftar meal. An increase in
daily caloric intake during Ramadan has been shown in healthy subjects [1,4].
However, some studies reported a decrease in daily caloric and carbohydrate
intake in patients with type 1 and type 2 diabetes [5,6].
Copyright  2010 John Wiley & Sons, Ltd.
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Weight and body mass index
Weight and body mass index did not change before
and 15 days after Ramadan in 120 patients with type
2 diabetes well controlled on diet or oral hypoglycaemic
medications after receiving dietary advice and adjustment
of the timing of their medications [7]. In women
with type 2 diabetes and a high body mass index
(34.63 ± 3.29 kg/m2), fasting during Ramadan resulted
in significant weight loss (−3.12 kg; p < 0.01), a decrease
in meal frequency (2.2 ± 0.3 versus 4.3 ± 0.4) as well as in
energy intake (1488 ± 118 versus 1823 ± 262 kcal/day)
[8].
Lipid profile
It was postulated that physiological adaptations during
the month of fasting lead to an increase in reliance
on fat as a source of fuel during daytime fasting [9].
In obese patients with type 2 diabetes, dietary fat
consumption increased (35.84 versus 25.36%), especially
the saturated fats (231 kcal/day or 43.25% of total
fat [8]). Total cholesterol intake, as well as total
and low-density lipoprotein cholesterol concentrations,
increased significantly in non-obese patients with type
2 (n = 57) (p < 0.03) [10] and in type 2 patients with
hyperlipidaemia on diet, fibrates or statins [11].
Effects of fasting on cardiovascular
endpoints
A large population-based study conducted in Qatar, where
95% of the adult population fast for Ramadan, has
shown no significant difference in hospital admissions
for acute coronary syndrome between Ramadan and non-
fasting months (p < 0.05) [12]. A 13-year review of a
stroke database also showed no significant difference
in the number of hospitalizations for stroke during the
fasting month of Ramadan as compared to other months
(p < 0.05) [13].
Effects of fasting on glycaemic control
Several studies have demonstrated no change in
haemoglobin A1c [14] or fructosamine levels [10,15]
during Ramadan. However, it is the variation in gly-
caemia leading to severe hypo- and hyperglycaemia that
is the main issue for patients with diabetes fasting for
prolonged periods during Ramadan. A large epidemiolog-
ical study, the Epidemiology of Diabetes and Ramadan
study, showed that daytime fasting during Ramadan
increased the risk of severe hypoglycaemia by 4.7-fold
(from 3 to 14 events/100 people/month) in type 1
diabetes and 7.5-fold (from 0.4 to 3 events/100 peo-
ple/month) in type 2 diabetes. The incidence of severe
hyperglycaemia in patients with type 2 diabetes also
increased fivefold [16]. In a multicentre observational
study (n = 1374), symptomatic hypoglycaemia occurred
in about 20% of diabetic patients on sulphonylurea
with or without metformin who fast during Ramadan
[17], whilst other studies have not shown a significant
increase in the risk of hypoglycaemia during Ramadan in
patients treated with oral diabetic medications or insulin
[18,19].
Management of diabetes during
Ramadan
Blood glucose monitoring and the
potential role of continuous glucose
monitoring
Blood glucose monitoring does not constitute a break of
fast [20]. All patients who fast should be provided with
the means to monitor their blood glucose [21].
Continuous glucose monitoring has been shown
to improve overall mean glucose, reduce glycaemic
excursions and reduce time spent in hyperglycaemia in
non-fasting type 2 diabetes subjects [22]. Although it has
not been studied, continuous glucose monitoring may be
a useful tool in studying the glycaemic variability during
Ramadan in patients with a history of hypoglycaemia and
in raising an alarm if there is rapid decrease in glucose or
pending hypoglycaemia.
Pre-Ramadan assessment
A pre-Ramadan assessment of patients who wish to fast
during Ramadan is recommended to assess whether their
health risk increases by doing so [23]. Other opportunities
for discussions about fasting during Ramadan can be at
the time of diagnosis and at an annual diabetes review.
Consensus guidelines have categorized patients according
to their health risks [23,24]. Patients in the high-risk
category should be advised not to fast while those in the
low risk can be allowed to fast. Those in the medium
category should discuss with healthcare professionals
their management of Ramadan several months before
Ramadan to reduce their risks.
Muslim religious leaders also play an important role
in the education regarding religious fasting, especially
for patients with diabetes who are keen to fast but
overlook the risks involved, and also for patients who
do not wish to fast but do so in order not to alienate
themselves from the rest of the Muslim community [25].
Both religious leaders and healthcare professionals are
crucial in providing education and support for safer fasting
during Ramadan.
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Structured education
In a systematic review of randomized controlled trials of
the effectiveness of self-management training in people
with type 2 diabetes, educational interventions that
involved patient collaboration were more effective than
didactic interventions in improving glycaemic control
(<6 months), weight and lipid profiles [26].
Structured educational sessions specific to Ramadan
have been shown to be effective. In an observational study,
patients who fasted without attending a structured edu-
cation session had a fourfold increase in hypoglycaemic
events, whereas those who attended a Ramadan-focused
education programme had a significant decrease in hypo-
glycaemic events [27]. Patients, as well as their family,
are encouraged to attend so that awareness of hypo- and
hyperglycaemic symptoms, planning of meals, blood glu-
cose monitoring, administration of medications, physical
activity and management of acute complications such as
when to break the fast, are provided to the family as a
whole. It is also a good opportunity to encourage healthy
living advice, such as smoking cessation. It has been
shown that Ramadan fasting has a positive impact in that
it helps Muslim adults to quit smoking [28].
Management of type 1 diabetes
during Ramadan
Patients with poorly controlled type 1 diabetes should not
fast during Ramadan. If patients choose to fast against
medical advice, it is advantageous if they are on a basal
bolus regime and are familiar with carbohydrate counting
[24]. A small study (n = 9) of patients with type 1 diabetes
using insulin glargine and insulin lispro or aspart, divided
in a 6 : 4 ratio of the total 24-h insulin dose, reported no
episodes of severe hypoglycaemia or diabetic ketoacidosis
requiring hospitalization, and the haemoglobin A1c
remained stable at the end of Ramadan. As the insulin
requirement decreased by 28% from baseline (p = 0.002),
it has been suggested that insulin should be reduced by
70% of the pre-Ramadan doses during the fast [29].
Insulin lispro, as a short-acting component of the
basal bolus regimen, has been found to have a lower
2-h post-prandial glucose level after the sunset meal
(p = 0.026), with less hypoglycaemia (p < 0.01), as com-
pared to regular human insulin when given with neutral
protamine hagedorn insulin in an open-label crossover
study (n = 64) [30].
Insulin pump therapy (using a Medtronic MiniMed 722
model) was observed in 49 type 1 patients who fasted
during Ramadan. Seventeen patients had hypoglycaemia
requiring breaking the fast but no severe hypoglycaemia
was reported. Usual hyperglycaemia was reported in nine
patients, with one patient needing hospital admission due
to a disconnected pump. The authors concluded that fast-
ing during Ramadan is feasible in patients with type 1
diabetes using an insulin pump, provided that adequate
counselling and support are available [31].
Management of type 2 diabetes
during Ramadan
Oral hypoglycaemic drugs
For patients taking once-daily oral hypoglycaemic drugs
(OHDs), particularly sulphonylureas in the morning dur-
ing non-fasting times, it has been recommended that the
usual morning dose be moved to the evening [32]. How-
ever, a large prospective observational study (n = 332)
demonstrated that the hypoglycaemic rates and over-
all glycaemic control did not change when once-daily
glimepiride taken with breakfast before Ramadan was
switched to an evening dose taken at Iftar during
Ramadan [32].
Once-daily pioglitazone 30 mg has been considered
safe with no increase in hypoglycaemia during Ramadan
in patients already taking other OHDs or pioglitazone
alone [33].
For patients taking twice- or thrice-daily doses of OHDs,
most Ramadan studies have suggested adjusting to two
doses during Ramadan, one dose at Sohur and one at
Iftar [24,34,35]. As Iftar is usually the larger meal during
Ramadan, expert consensus suggested that the OHD dose
should be split such that two thirds of the dose is taken
at Iftar and one third at Sohur (as the lunchtime dose
during the daytime fast is not allowed). For instance, for
a regimen of metformin 500 mg three times a day, the
adjusted regimen during Ramadan would be 500 mg at
Sohur and 1000 mg at Iftar.
For patients who are not well controlled on metformin
alone and are planning to fast during Ramadan, there is
evidence showing that combining a dipeptidyl peptidase-4
inhibitor, rather than a sulphonylurea, with metformin led
to less incidence of hypoglycaemia and better glycaemic
control [36].
Thiazolidenediones and incretin-based therapies, such
as dipeptidyl peptidase-4 inhibitors (e.g. sitagliptin and
saxagliptin) and glucagon-like peptide-1 analogues (e.g.
exenatide), may not need dose adjustment during
Ramadan. However, other agents, such as sulphonylureas,
may need dose reductions when used as a combination
treatment.
Insulin treatment
Long-acting insulin, such as glargine, should be given at
Iftar to avoid potential hypoglycaemia during daytime
fasting [19]. A dose reduction of 20% has been
suggested in type 2 diabetic patients with a pre-Ramadan
haemoglobin A1c < 8% [18].
A randomized, open-labelled, crossover study compar-
ing Humalog Mix 25 and Humulin M3 showed that the
former offered better postprandial blood glucose control
after Iftar and a lower incidence of hypoglycaemia [37].
It has also been suggested that patients taking twice-daily
insulin should reduce the Sohur dose by 30% if they
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are well controlled, and consider switching to a Mix 50
preparation if their postprandial glucose remains raised
[38].
Special circumstances
Pregnancy
Even though fasting during Ramadan in women without
diabetes and with uncomplicated pregnancies has been
shown to result in no significant change in maternal ket-
onaemia or adverse effect on intrauterine development
[39], pregnant women with diabetes have been strongly
advised against fasting due to the potential maternal
and foetal risks associated with poor glycaemic control
in pregnancy [23,24]. Therefore, pregnant women with
diabetes should be made aware that they are exempted
from fasting and that fasting during pregnancy may be
associated with risks to the mother and foetus.
Bariatric surgery
Bariatric surgery is increasingly being performed for the
correction of morbid obesity in patients with diabetes. As
bariatric surgery limits the amount of food and fluid that
can be consumed in one sitting, patients who underwent
bariatric procedures who fast may encounter problems
with dehydration, vomiting and poor nutritional intake
as prolonged fasting can lead to the desire to consume
larger amounts quickly upon breaking the fast. It has been
advised that patients should avoid total fasts in the first
12–18 months after bariatric surgery when new dietary
habits are being established [40].
Conclusion
We have summarized (Figure 1) the recommendations
for people with diabetes who fast during the month of
Ramadan. There is an overwhelming need for better-
designed clinical trials, which could provide us with
evidence-based information and guidance in the man-
agement of patients with diabetes who wish to fast during
Ramadan. Currently, we advocate a thorough assessment
of a patient’s individual risk and modifying the treatment
accordingly, so as to reduce the risk of hypoglycaemia or
hyperglycaemia. One effective way of managing patients
would be by offering group education classes to enable
patients to be empowered to manage their condition
themselves during Ramadan.
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Recommended
2 – 4 months
before
Ramadan
Medical assessment
Tailored to individual needs
Review of overall glycaemic control, BP & lipids, renal function, weight and BMI.
Review of diabetes medications, i.e. therapy options, timing and dosage adjustment
Ramadan focused structured education
To educate patients, family and carers on the effects of fasting on diabetes,
including:
Meal planning and dietary advice with dietician
Appropriate exercise
Blood glucose monitoring
Recognition and management of acute complications e.g. hypo-, hyperglycaemia,
dehydration, and when to break fast
Oral hypoglycaemic agents
Metformin
suggested modification: 2/3 daily dose at Iftar; 1/3 daily dose at Suhur
Sulphonylureas (SU)
suggested dose adjustment: Reduce Suhur dose if taking twice daily SU,
e.g. gliclazide 80mg bid pre-Ramadan to gliclazide 80mg at Iftar (pm) and
40mg at Suhur (am) during Ramadan
DPP4 inhibitors, rapid acting insulin secretagogues and thiazolenediones may be
used at meal times without dose adjustments
During
Ramadan
Insulin
In general, use an overnight intermediate acting insulin, plus a rapid acting insulin
before meals
Dose and type of insulin may need adjustments, e.g. 1) reduce insulin glargine dose
by 20% 2) use Mix 50 in the evening instead of Mix 30 to avoid postprandial
hyperglycaemia
GLP-1 analogues
No treatment adjustment required, but concomitant use of SU may need dose
reduction
Follow-up
post-
Ramadan
HbA1c, weight, BP, lipids
Readjustment of medications where appropriate
Other opportunities for discussion of Ramadan issues with patients, include:
Pre-pregnancy counseling, at diagnosis, at annual diabetic review
Figure 1. The recommendations for people with diabetes who fast during the month of Ramadan
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Management of people with diabetes 
wanting to fast during Ramadan
E Hui,1 V Bravis,1 M Hassanein,2 W Hanif,3 R Malik,4 T A Chowdhury,5 M Suliman,6 D Devendra1 7
The holy month of Ramadan is one of five main pillars of 
being a Muslim. Most Muslims are passionate about fasting 
during this month. Although the Koran exempts sick  people 
from the duty of fasting,1 2 many Muslims with diabetes may 
not perceive themselves as sick and are keen to fast. A large 
epidemiological study of Muslims with diabetes in 13 Mus-
lim countries (n=12 914)—the EPIDIAR study—showed that 
43% of patients with type 1 and 79% of those with type 2 
diabetes fasted during Ramadan.3
As the month of Ramadan follows the lunar calendar, the 
fasting month is brought forward by about 10 days each year, 
which means that over time the season in which Ramadan 
falls changes. For the next decade Ramadan will fall in the 
summer in the northern hemisphere. As daylight hours vary 
considerably between summer and winter months in non-
equatorial countries, the length of the fast (which lasts from 
dawn to sunset) increases in the summer (to about 16-20 
hours). People with diabetes who fast are at risk of adverse 
events, and the risks may increase with longer fasting peri-
ods. We review the evidence for optimum management of 
diabetic patients who wish to fast during Ramadan, draw-
ing on a small evidence base comprising randomised trials, 
non-randomised comparison studies, and observational 
studies. We combine this with recommendations based on 
expert consensus. To reduce complications experienced by 
diabetic patients who fast during Ramadan, health profes-
sionals should aim to educate Muslim patients about safe 
fasting, not only before Ramadan but also at their annual 
diabetic review and at diagnosis. 
what does fasting during Ramadan involve?
Fasting during Ramadan involves abstaining from food and 
drink from dawn to sunset for about 30 days. Most people 
take two meals a day during Ramadan—suhur (the meal 
before dawn and iftar (the meal after sunset).
what are the risks of fasting for people with diabetes?
Most Muslim religious authorities accept that if a person is 
advised by a trusted health professional (such as a doctor 
or nurse) that fasting is harmful to his or her health, then 
that person is exempted from fasting.4 The risks of fasting 
include hypoglycaemia, hyperglycaemia, and dehydration. 
The EPIDIAR study found that the change in eating patterns 
during Ramadan increased the risk of severe hypoglycaemia 
4.7-fold (from 3 to 14 events per 100 people per month) in 
type 1 diabetes and 7.5-fold (from 0.4 to 3 events per 100 
people per month) in type 2 diabetes. It also found a five-
fold increase in the incidence of severe hyperglycaemia 
in patients with type 2 diabetes during Ramadan. A small 
observational study (n=41) conducted in 1998 found an 
increase in symptomatic hypoglycaemia,5 but other studies 
have not found a significant increase in the risk of hypogly-
caemia during Ramadan in patients treated with oral 
hypoglycaemic medications or insulin.6 7 One explanation 
for different findings among studies is that because Ram-
adan occurs in a different season every nine years, and the 
duration and temperature of fasting days change, rates of 
hypoglycaemia may vary according to the year in which the 
study was performed. The differences in methods and the 
small number of patients included in these studies would 
also explain the disparity of the results.
Over the coming decade, the number of fasting hours will 
progressively increase in the northern hemisphere as Ram-
adan falls in the summer months. This will have important 
implications for Muslims with diabetes who wish to fast.
How should patients with diabetes who fast for 
Ramadan be managed?
Assessment before Ramadan
Expert opinion recommends that if a patient has made it 
SummaRy pointS
Ramadan is one of the five main pillars of Islam
Muslims are obliged to abstain from food and drink from dawn to sunset during the month of 
Ramadan
Muslims with diabetes may be exempted from fasting during Ramadan, although a high 
proportion fast
Patients with diabetes who fast risk hypoglycaemia, hyperglycaemia, and dehydration
Guidelines from the National Institute for Health and Clinical Excellence emphasise the 
importance of individualising care on the basis of patients’ social, cultural, and religious needs
Diabetic patients who want to fast need an assessment before Ramadan and education to 
increase their awareness of the risks of fasting
SourCeS and SeleCtion Criteria
We searched Embase, Medline, and the Cochrane Library 
from January 1970 to May 2010 for systematic reviews, 
randomised trials, large population based studies, case-
control studies, observational studies, and published 
consensus statements. We used the search terms 
“Ramadan”, “fasting”, and “diabetes mellitus”.
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clear that they wish to fast during Ramadan their primary 
physicians and/or diabetes care specialists should assess 
whether they increase their health risk by doing so.8 Box 
1 outlines how patients planning to fast during Ramadan 
may be categorised as either high, moderate, or low risk of 
adverse events. Patients classed as high risk are advised not 
to fast as it can lead to worsening diabetes control, result-
ing in, for example, severe hypoglycaemia and diabetes 
ketoacidosis. Patients at moderate risk can reduce their 
level of risk if they see a healthcare professional several 
months before Ramadan and make necessary changes to 
their diabetes treatment. Those at low risk can fast with-
out healthcare advice. Patients who choose to fast despite 
advice not to do so need support to help them fast as safely 
as possible.
In case patients miss the opportunity for assessment 
before Ramadan, discussion with patients and provision 
of information packs (see the “Additional educational 
resources” box) that include advice on Ramadan fasting 
can be made available at diagnosis and also at annual dia-
betic review. 
Ramadan focused education 
Structured education interventions have been endorsed by 
the National Institute for Health and Clinical Excellence as 
important in empowering patients to improve their jour-
ney with diabetes. In a large observational study, patients 
who fasted during Ramadan without attending a structured 
education session had a fourfold increase in hypoglycae-
mic events, whereas those who attended an education pro-
gramme focusing on Ramadan had a significant decrease 
in hypoglycaemic events.9 We therefore recommend that 
Muslim patients with diabetes attend some form of struc-
tured education intervention to increase their chance of 
being well when fasting during Ramadan. Patients at high 
risk who plan to fast despite medical advice not to are also 
invited to attend structured education to support their self 
management and decision to fast. Box 2 outlines suggested 
content of Ramadan focused education.
How should fasting patients with type 2 diabetes be 
managed?
Patients taking oral hypoglycaemic agents
Metformin
Hypoglycaemia occurs in patients with type 2 diabetes 
taking metformin who are not fasting.14 A systematic 
review reported that levels of risk for hypoglycaemia 
among  people taking metformin who are not fasting 
range from 0% to 21%.15 No data exist for the incidence of 
 hypoglycaemia in people who fast for prolonged p eriods 
and take only metformin.
As iftar is usually the largest meal during Ramadan, 
expert consensus suggests that the metformin dose should 
be split such that two thirds of the dose is taken at iftar 
and one third at suhur (as the lunchtime dose during the 
 daytime fast is not allowed). So for a regimen of, for exam-
ple, metformin 500 mg three times a day, we recommend 
500 mg at suhur and 1000 mg at iftar. 
Acarbose
Acarbose inhibits the action of intestinal brush border 
alpha-glucosidases, which retards glucose absorption and 
modifies the secretion of insulin.16 A randomised double 
blind study showed that the risk of hypoglycaemia is low 
with this class of drugs,17 although we could not find any 
evidence that this is so during Ramadan. We suggest that 
it is acceptable to continue with the prescribed dose(s) of 
acarbose taken only with meals during fasting.
Box 1 | expert recommendations for risk stratification in patients with type 1 or type 2 
diabetes who fast during ramadan8
Patients at high risk
Those with severe and recurrent episodes of hypoglycaemia and unawareness•	
Those with poor glycaemic control•	
Those with ketoacidosis in the three months before Ramadan•	
Those who experience hyperosmolar hyperglycaemic coma within the three months •	
before Ramadan 
Those with acute illness•	
Those who perform intense physical labour•	
Pregnant women•	
Those with comorbidities such as advanced macrovascular complications, renal disease •	
on dialysis, cognitive dysfunction, uncontrolled epilepsy (particularly precipitated by 
hypoglycaemia)
Moderate risk
Well controlled patients treated with short acting insulin secretogogue, sulphonylurea, •	
insulin, or taking combination oral or oral plus insulin treatment
low risk
Well controlled patients treated with diet alone, monotherapy with metformin, dipeptidyl •	
peptidase-4 inhibitors, or thiazolidinediones who are otherwise healthy
Box 2 | Four key areas in ramadan focused education9  
Meal planning and dietary advice
The diet during Ramadan should be a healthy balanced diet•	
Slow energy release foods (such as wheat, semolina, beans, rice) should be taken before •	
and after fasting, whereas foods high in saturated fat (such as ghee, samosas, and 
pakoras) should be minimised10
Advise patients to use only a small amount of monounsaturated oils (such as rapeseed or •	
olive oil) in cooking 
Before and after fasting include high fibre foods such as wholegrain cereals, granary •	
bread, brown rice; beans and pulses; fruit, vegetables, and salads 
exercise
Regular light and moderate exercise is safe in type 2 diabetes patients•	 11
Rigorous exercise is not recommended as the risk of hypoglycaemia may be increased, •	
particularly in patients taking sulphonylureas or insulin
Encourage patients to continue their usual physical activity, especially during non-fasting •	
periods
Tarawaih prayers (a series of prayers after the sunset meal) should be considered as part •	
of the daily exercise regimen as they involve standing, bowing, prostrating, and sitting
Blood glucose monitoring
Blood glucose monitoring does not constitute the break of fast•	 12
All patients who fast should be provided with the means to monitor their blood glucose•	 13
Capillary blood glucose testing should be done when:•	
 -The patient suspects they have symptoms of hypoglycaemia (subjective to the 
individual). Patients should be advised to break their fast if hypoglycaemia is confirmed on 
blood glucose testing
 -The patient is unwell (eg, has a fever)
Testing at other times may be useful only if patients are able and willing to adjust their •	
diabetes treatment regimens, such as insulin dosage titration
recognising and managing complications
Patients should be aware of the warning symptoms of dehydration, hypoglycaemia, and •	
hyperglycaemia and should stop the fast as soon as any complications or acute illness 
occur
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Rapid acting insulin secretogogues
An open label, multicentre, randomised study showed that 
repaglinide, a rapid acting insulin secretogogue, contrib-
uted to improved glycaemic control, with a lower number 
of hypoglycaemic events among fasting patients during 
Ramadan when compared with glibenclamide. Patients 
taking repaglinide lowered their fructosamine levels from 
baseline, and there were 0.03 hypoglycaemic events per 
patient per month in this group versus 0.05 events per 
patient per month in the glibenclamide group.18
A small study compared repaglinide (n=27) with a group 
of patients taking a sulphonylurea (glimepiride (n=23) or 
gliclazide (n=17)). Fructosamine, HbA1c, and body weight 
did not change significantly in either group from before to 
after Ramadan. Hypoglycaemia was documented in only 
one patient who took glimepiride during Ramadan.19 The 
evidence cited suggests that rapid acting insulin secre-
togogues taken at suhur and iftar are a safer alternative 
than glibenclamide for patients who fast.
Sulphonylureas
Early studies examined the use of glibenclamide or 
glimepiride during Ramadan.20 A more recent, large 
prospective observational study (n=332) showed that 
changing once daily glimepiride from a morning dose 
taken with breakfast before Ramadan to an evening 
dose taken at iftar during Ramadan did not alter rates 
of hypoglycaemia or glycaemic control.21 However, the 
rate of hypoglycaemia in patients taking glimepiride 
in the mornings during Ramadan was not studied, so 
whether that rate is higher than the rate in those taking 
glimepiride in the evenings is unknown. The incidence 
of hypoglycaemic events did not differ between a group 
of patients taking once daily glimepiride (n=21) and 
a group taking twice daily repaglinide (n=20) (taken 
at suhur and iftar).22 More recently, gliclazide has 
been compared with newer agents, such as dipeptidyl 
 peptidase-4 inhibitors.23 
On the basis of the prospective study by the GLIRA study 
group21 we recommend that during Ramadan clinicians 
change the timing of the once daily dose of sulphonylurea 
(such as glimepiride) from the usual morning dose to the 
evening (at iftar). With regard to gliclazide, we recommend 
that patients take a larger dose at iftar than at suhur and 
that clinicians consider reducing the prescribed dose for 
suhur if the patient’s glycaemic control before Ramadan is 
stable (for example, change gliclazide 160 mg twice daily 
to 80 mg in the morning and 160 mg in the evening).
Thiazolidenediones
A randomised controlled trial that compared pioglitazone 
30 mg once daily with placebo in patients already tak-
ing other oral hypoglycaemic agents or alone, found no 
increase in hypoglycaemia during Ramadan fasting.24 No 
studies have been reported on the use of rosiglitazone use 
during Ramadan. Continuing with thiazolidenediones dur-
ing fasting is considered safe.
Dipeptidyl peptidase-4 inhibitors
A retrospective audit of Muslim patients with type 2 diabe-
tes showed that adding vildagliptin to metformin treatment 
was associated with a reduced incidence of hypoglycae-
mic events and improved glucose control compared with 
patients treated with gliclazide and metformin during 
 Ramadan.23 This low grade evidence suggests that it may be 
safer to combine dipeptidyl peptidase-4 inhibitors, rather 
than sulphonylureas, with metformin in patients who are 
not well controlled when taking metformin alone and are 
planning to fast during Ramadan.
Glucagon-like peptide-1 mimetics
Glucagon-like peptide-1 mimetics are currently used in 
combination with other oral hypoglycaemic agents. In 
non-Ramadan studies, hypoglycaemic events associated 
with glucagon-like peptide-1 mimetics occurred prima-
rily in patients taking a sulphonylurea.25 The findings of 
an audit suggested that its dosage does not need to be 
adjusted during Ramadan but that other agents, such as 
sulphonylureas, may need dose reductions when used as 
a combination treatment.26
Patients taking insulin 
Single basal insulin and oral combined treatment
A multicentre, prospective, observational study com-
pared fasting patients taking metformin combined with 
glimepiride (n=21), repaglinide (n=18), or glargine 
(n=10).7 Although the rate of hypoglycaemia was higher 
in the glimepiride group (14.3%) than in the repaglinide 
(11%) and glargine (10%) groups, the increased rate 
was not significant. Glimepiride was given before iftar; 
repaglinide was given with both meals; and glargine at 
10.00 pm. No studies have compared the incidence of 
hypoglycaemic events in patients taking insulin detemir 
or  isophane insulin (NPH) (such as Insulatard, Novo 
 Nordisk; or Humulin I, Lilly).
In a small prospective non-randomised study of 19 
patients who had type 2 diabetes, were at low risk of dia-
betic complications, and had a pre-Ramadan HbA1c con-
centration of <8%, neither fasting (n=11) nor non-fasting 
(n=8) patients who were taking repaglinide three times 
a day and glargine experienced hypoglycaemic events, 
additional eduCational reSourCeS
For healthcare professionals
Al-Arouj M, Bouguerra R, Buse J, Hafez S, Hassanein M, Ibrahim MA, et al. American •	
Diabetes Association recommendations for management of diabetes during Ramadan. 
Diabetes Care 2005;28:2305-11
Karamat MA, Syed A, Hanif W. Review of diabetes management and guidelines during •	
Ramadan. J R Soc Med 2010;103:139-47.
Benaji B, Mounib N, Roky R, Aadil N, Houti IE, Moussamih S, et al. Diabetes and Ramadan: •	
review of the literature. Diabetes Res Clin Pract 2006;73:117-25.
Ramadan health factsheet 2009 (from Muslim Spiritual Care Provision in the NHS, PO •	
box 57330, London E1 2WJ; nhsspiritualcare@mcb.org.uk)—Provides a brief summary of 
issues for doctors, healthcare staff, and patients
For patients 
LeicestershireDiabetes (www.leicestershirediabetes.org.uk)—Website with information •	
on fasting and insulin treatment during Ramadan
United Kingdom Ramadan Diabetes Network (www.ukRamadandiabetes.net) —Has a •	
useful publication on diabetes and fasting 
Ramadan health guide: a guide to healthy fasting. 2007. www.ramadan.co.uk/•	
RamadhanHealth_Guide.pdf. (Useful Department of Health document on healthy fasting, 
but not specifically about diabetes)
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and both groups maintained stable glycaemic control.6 
Those who fasted took repaglinide at iftar, at midnight, 
and at suhur, and the doses of repaglinide and glargine 
remained unchanged throughout Ramadan. We advise 
patients who take long acting basal insulin, such as 
glargine, to reduce the dose by 20% to avoid hypoglycae-
mia. Patients taking repaglinide and single dose glargine 
may continue taking the same doses of repaglinide but to 
be safer should  consider reducing glargine by 20%. The 
timing of repaglinide can be rearranged to coincide with 
suhur and iftar.
Premixed insulins
A randomised, open labelled, crossover study comparing 
Humalog Mix25 (Lilly) (25% short acting insulin lispro 
and 75% intermediate acting neutral lispro protamine) 
and Humulin M3 (Lilly) (human insulin 30% soluble, 
70% isophane) given in identical doses showed that 
the former offered better control of postprandial blood 
glucose after iftar and a lower occurrence of hypogly-
caemic events.27 However, the findings of an observa-
tional study suggested that using Humalog Mix50 (Lilly) 
at ifta instead of Mix30 reduced postprandial glucose 
excursions and reduced hypoglycaemia.28  We suggest 
that patients taking twice daily insulin should reduce 
the suhur dose by 30% if they are well controlled, and 
consider switching to a Mix 50 preparation if their post-
prandial glucose remains raised.
Is fasting safe for pregnant women with diabetes?
Pregnant women with diabetes, including gestational 
diabetes, are exempted from fasting and are strongly 
cautioned against fasting because clear maternal and 
fetal risks are associated with poor glycaemic control in 
pregnancy.29 However, no outcome study of women with 
diabetes specifically related to Ramadan fasting has been 
conducted. Preconception counselling for diabetic Muslim 
women must include education about the substantial risks 
associated with poor glycaemic control to help to dissuade 
them from trying to fast.
How should fasting patients with type 1 diabetes be 
managed?
A small study examined the use of glargine and insulin 
lispro or aspart, divided in a 6:4 ratio of the total 24 hour 
insulin dose in nine patients with type 1 diabetes.30 Of 
seven patients who started to fast, five continued for the 
whole month, and two broke the fast owing to hypogly-
caemia. None of the patients had any episodes of severe 
hypoglycaemia or diabetic ketoacidosis requiring admis-
sion to hospital, and the patients’ HbA1c concentrations 
remained stable at the end of Ramadan. As the insulin 
requirement in this study group decreased by 28% from 
baseline (P=0.002), the authors suggested a reduced dose 
(70% of a patient’s usual dose) during the fast. 
An open label, comparative, crossover study of 64 
patients with type 1 diabetes found significantly lower 
(P=0.026) two hour, postprandial glucose concentra-
tions after iftar and fewer hypoglycaemic events with 
insulin lispro than with regular human insulin.31 In 
both arms is ophane insulin (Humulin I) was given as 
the basal  insulin.
Medical assessment
• Individualised approach
• Review of overall glycaemic control, blood pressure, and lipids, renal function 
• Body weight and body mass index
• Change to diabetes medication regimens:  treatment choice, timing, and dosage
     adjustment
Two to four months before Ramadan
Thiazolidinediones
No treatment adjustment
  required
Oral insulin secretagogues
eg repaglinide 
• Short acting
• Take twice daily at suhur and
     iftar
Dipeptidyl peptidase-4
  inhibitors
Consider dipeptidyl peptidase-4
  inhibitors as an alternative to
  sulphonylureas if the risk of
  hypoglycaemia is high
Follow-up is essential after Ramadan
• HbA1c, weight, blood pressure, lipids
• Readjustment of medications where appropriate 
Sulphonylureas
Consider dose adjustment, eg
• Reduction in suhur dose if
     taking twice daily dose 
     (eg change a twice daiy dose
     of 80mg gliclazide to 80mg
     at iftar and 40mg at suhur)  
Consider timing adjustment, eg
• If taking once daily dose,
     switch it to iftar (eg take a
     once daily 4mg glimepiride
     dose at iftar)
Metformin
Modify timing of doses:
• Two thirds of daily dose at iftar
• One third of daily dose at
     suhur
• If taking modified release
     metformin once daily, take
     dose at iftar rather than at
     suhur
Diet controlled patients
• Split daily calories over two to three smaller meals
     during the non-fasting interval
• Eat complex carbohydrates (eg oatmeal, bran, brown
     rice) at suhur (predawn meal) and simple
     carbohydrates at iftar (sunset meal)
• Avoid food high in fat and sugar
• Ensure adequate fluid intake during non-fasting
     interval
Oral hypoglycaemic agents
• Choice of treatment should be individualised
• Dipeptidyl peptidase-4 inhibitors, rapid acting insulin
     secretagogues, and thiazolidinedione may be used
     at meal times without dose adjustments
• Ensure adequate fluid intake
Treatment with injectables
Insulin
• In general, use an overnight intermediate acting
  insulin, plus a rapid acting insulin before meals
• Adjustment to treatment necessary - eg reduce insulin
  glargine dose by 20% and use Mix 50 in the evening
  instead of Mix 30 to avoid postprandial hyperglycaemia 
Glucagon-like peptide-1 mimetics
No treatment adjustment required
Ramadan focused education
Education of  patients and carers on the effects of fasting on diabetes, including:
• Meal planning and dietary advice with dietitian
• Appropriate levels of exercise
• Blood glucose monitoring
• How to recognise and manage acute complications, eg hypoglycaemia,
     hyperglycaemia, dehydration, and when to break fast
an approach to oral treatment of type 2 diabetes during ramadan for patients planning to fast 
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Most studies of patients with type 1 diabetes have 
comprised small numbers of patients and some have 
excluded adolescents, elderly patients, or patients with 
comorbidities such as renal impairment. Suggested treat-
ments, therefore, may not be generalised to all fasting 
patients with type 1 diabetes, and no good evidence exists 
to allow us to give clear guidance for those who are not on 
a basal bolus regimen (basal insulins are intermediate or 
long acting insulins; bolus is rapid acting insulin taken 
with meals). 
We suggest that patients with type 1 diabetes who are 
on a basal bolus regimen four times daily should be dis-
couraged from fasting owing to the risks of poor glycaemic 
control.  If patients choose to fast despite medical advice, 
it will help if they are familiar with carbohydrate counting. 
We suggest they reduce their background insulin by 20% 
and omit the midday rapid acting insulin if their capillary 
blood glucose concentration is ≤7 mmol/l. If their blood 
glucose concentration is >7 mmol/l, patients will need to 
calculate their insulin correction dose as determined by 
their specialists. 
Conclusion
The figure summarises the recommendations given in 
this article, based on the best available and most current 
evidence and on our collective experience in managing 
patients who fast during Ramadan. Overall, the evidence 
available for guiding management of patients with dia-
betes who wish to fast during Ra madan is poor, and well 
designed studies are lacking. An assessment of a patient’s 
individual risk and a tailored approach to treatment seems 
to be the best management  strategy.  Offering structured 
education to enable patients to  manage their condition 
 better themselves during  Ramadan is  essential.
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The following case highlights the potential risks of both hypoglycaemia and 
renal impairment in Muslim patients with type 2 diabetes who fast during 
the lunar month of Ramadan from sunrise to sunset. A 66-year-old Muslim 
man with type 2 diabetes treated with metformin and gliclazide, was fasting 
during the daylight hours of Ramadan. He was admitted with symptomatic 
hypoglycaemia and acute renal impairment following a short history of 
diarrhoea. A diagnosis of viral gastroenteritis and dehydration secondary 
to prolonged fasting was made. The hypoglycaemia was precipitated by a 
combination of fasting, gliclazide use and acute renal impairment.  Although 
the choice of fasting rests with an individual, the risks could be minimised 
through patient education and medical assessment before Ramadan. It is 
also important for all healthcare professionals to be aware of and respect 
this religious obligation in order to provide appropriate care for patients with 
diabetes who choose to fast during Ramadan. 
Case History
A 66-year-old Muslim gentleman presented unresponsive on the sofa, 
following two days of loose watery diarrhoea. His capillary blood glucose 
measured 2.9mmol/L and he was given an intramuscular injection of 1mg 
glucagon followed by an intravenous bolus of 25ml of 50% dextrose solution 
to treat the hypoglycaemia. He had a 5-year history of type 2 diabetes 
treated with metformin 850mg and Gliclazide 80mg twice daily. Apart from 
retinopathy, there was no history of nephropathy or neuropathy; Background 
essential hypertension was controlled on Losartan 50mg daily. Following 
initial treatment, he was alert with a GCS 15/15; abdominal and neurological 
examinations were normal. Laboratory investigations identified a serum 
glucose of 12.0mmol/l and creatinine of 235µmol/L with a previously normal 
eGFR and creatinine level. Further history revealed that he had been fasting 
for Ramadan, 10 days prior to hospital admission. Stool culture was negative 
for infection and renal ultrasound demonstrated normal size kidneys. 
There was no recent antibiotic use, foreign travel or known contacts, and 
the acute episode of diarrhoea was likely secondary to viral gastroenteritis. 
He was rehydrated with intravenous fluids and was commenced on an 
insulin sliding scale. His oral medications were stopped for 2 days while the 
diarrhoea settled and was discharged from hospital when his renal function 
normalised after 3 days. He was recommended to consult medical advice if 
he decided to fast during the next Ramadan to assess his risks of fasting and 
whether his diabetes medications require adjustment prior to fasting. 
Discussion
This case highlights the potential risks of fasting during Ramadan in a type 
2 diabetes patient treated with metformin and gliclazide. Ramadan is the 
ninth month of the Islamic lunar calendar and healthy Muslims are obliged 
to abstain from eating and drinking from sunrise to sunset during this month. 
Most people take two meals a day during the month, one before sunrise 
and one after sunset. The Koran exempts the sick from fasting1, but some 
diabetes patients may not perceive themselves as ”sick” and instead choose 
to fast during Ramadan. Studies have shown that the pattern of daytime 
fasting and night-time meals during Ramadan can increase the rate of severe 
hypoglycaemia in type 2 diabetes 7.5-fold (from 0.4 to 3 events per 100 
people per month)2. Other risks include dehydration and hyperglycaemia3, 
due to the change in the dietary pattern during Ramadan, when the main 
meal is consumed in the evening.   
The duration of the Ramadan month varies between 29 and 30 days and 
the hours spent fasting can range from only a few hours to more than 20 
hours per day, depending on season and geographical location. The month 
of Ramadan will occur during summer in the Northern hemisphere in the 
next few years as the lunar year rotates from season to season, and the 
number of fasting hours will be progressively longer. Hence, it is important for 
healthcare professionals in the United Kingdom to be aware of this issue for 
Muslim patients with diabetes who intend to fast during Ramadan. 
The combination of diarrhoea and fasting may have contributed to the 
acute renal impairment secondary to pre-renal causes, which was corrected 
with supportive measures of fluid resuscitation, careful monitoring and 
replacement of any electrolyte disturbance, and adequate glycaemic control. 
Patients on sulphonylurea drugs, such as gliclazide, may be more prone to 
hypoglycaemia during the Ramadan fast. Changes to the timing and dosages 
of sulphonylureas may be needed during Ramadan. As patients tend to 
eat their main meal after sunset, it has been suggested that switching the 
usual evening dose of sulphonylurea to before dawn and the usual morning 
dose (together with any midday dose) to the evening may result in better 
glycaemic control4. In the case of this patient, an alternative solution would 
be to half the morning dose of sulphonylurea (taken with their sunrise meal) 
and combine the other half of the morning dose with his regular evening 
dose (taken with the sunset meal)5. He would thus be taking 40mg gliclazide 
in the morning and 120mg in the evening during Ramadan. 
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It is generally considered safe to continue with metformin during Ramadan 
as the risk of hypoglycaemia is low. However, metformin was stopped 
temporarily in our case due to the risk of lactic acidosis in the setting of acute 
renal failure. 
Table 1 summarises the recommended actions for various diabetic drug 
regimens during Ramadan. 
before Ramadan During Ramadan
On diet control Continue on diet control
On oral hypoglycaemic agents:
Metformin e.g. metformin 
500mg tds
Sulphonylurea
e.g. gliclazide 80mg bd
Dipeptidyl peptidase (DPP-IV) 
inhibitor e.g. vildagliptin 50mg 
bd Thiazolidinedione  
e.g. pioglitazone 30mg od
Metformin 500mg at Suhur; 
1g at Iftar
Gliclazide 40mg at Suhur; 
120mg at Iftar
No change in dose
No change in dose
On insulin
30/70 premixed insulin bd 
s/c e.g. 40 units morning, 
20 units evening 
Switch morning insulin dose 
to Iftar, half evening insulin dose 
and take it at Suhur
e.g. to 10 units morning, 
40 units evening
Or consider changing evening 
insulin to 50/50 premixed insulin
On GLP-1 agonist
e.g. exenatide 10mcg bd s/c
No change in dose
If in use in conjunction with 
sulphonylurea, dose adjustment 
may be needed for sulphonylurea.
table 1: summary of recommended actions during Ramadan.
od – once daily; bd – twice daily; tds – three times daily
s/c – subcutaneous; suhur – sunrise meal; Iftar – sunset meal
If a patient with diabetes chooses to fast during Ramadan, this decision 
should be respected and an appropriate care plan should be devised, taking 
into account the change in eating and sleeping patterns during the month, 
and any necessary treatment adjustments.  However, patients who are likely 
to encounter complications during prolonged daytime fast (such as patients 
with type 1 diabetes, those with poor pre-existing glycaemic control and 
pregnant women) should be strongly advised not to fast during Ramadan. 
The changes in diabetes treatment summarised above (Table 1) serve as 
a recommendation only. Patient variations should be taken into account 
when adjusting their diabetes treatment to tailor their individual needs. It is 
essential that these patients are encouraged to have a medical assessment 
and discussion with the appropriate healthcare professionals, such as their 
general practitioners or diabetes specialists, prior to the Ramadan fast.  
It is also beneficial for patients to attend focused structured education on 
meal planning, glucose monitoring and the recognition and management 
of complications. It has been shown that a Ramadan-focused structured 
education programme can reduce the risk of hypoglycaemia without 
compromising their glycaemic control or weight6. This would allow patients 
to make an informed decision on whether to fast during Ramadan and to 
minimise any risks involved. 
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Questions
Question 1: to minimize the risk of hypoglycaemia, advise patients 
taking short-acting sulphonylureas as follows: 
a) If two or three doses are taken each day, take half the normal evening dose 
before dawn and the normal morning (and any midday) dose after sunset.
b) Half the dose of the drug with each meal.
c) If a single daily dose is used, take this with the dawn meal.
d) If two or three doses are taken each day, take half the normal evening dose 
after sunset and the normal morning (and any midday) dose before dawn.
e) Continue with the same doses as outside the Ramadan period.
Question 2: For people with diabetes who choose to fast during 
Ramadan, in terms of diet, we advise:
a) Eat foods that are high in dietary fibre and have a low glycaemic index. 
b) Eat foods that are high in dietary fibre and have a high glycaemic index.
c) Eat foods that are low in dietary fibre and have a low glycaemic index.
d) Eat foods with a high glycaemic index until about half an hour after taking 
medications.
e) Eat foods with a low glycaemic index until one hour after taking 
medications.
Answers
answer: 1. b)
Explanation: During Ramadan the predawn meal is followed by a prolonged 
period of fasting and patients tend to consume the main meal at sunset. 
Regardless of the type of sulphonylureas used, the timing and dosages may 
need adjustment and possibly reducing, particularly the dose before the 
predawn meal. Patients should take a larger dose of sulphonylurea at the 
main meal at sunset (e.g. by switching the usual morning dose plus any 
lunchtime dose to the evening, and the usual evening dose to the morning). 
When used in combination with metformin, sulphonylurea dosages may 
need to be reduced. For instance, long-acting sulphonylureas should be taken 
in the evening at a reduced dose of two-thirds that normally taken during 
the non-Ramadan period. With short-acting sulphonylureas, both the morning 
dose, taken with Suhur, and the evening dose,  taken with Iftar, should be 
reduced by half.
to minimise the risk of hypoglycaemia, advise patients taking oral 
hypoglycaemic agents as follows: 
i. If taking a long acting sulphonylurea, switch to a short acting preparation 
or metformin, or both.
ii. If a single daily dose is used, take this with the sunset meal.
iii. If two or three doses are taken each day, take half the normal evening dose 
before dawn and the normal morning (and any midday) dose after sunset. 
answer: 2 a)
Explanation: For patients with type 2 diabetes who choose to fast during 
Ramadan, careful dietary advice should be provided. Encourage patients (ideally 
with input from a dietician trained to deal with cultural issues) to eat foods that 
are high in dietary fibre (such as whole grains, fruits, and vegetables) and have 
a low glycaemic index (such as beans and pulses) at the pre-dawn (Suhur) 
and sunset (Iftar) meals to promote glycaemic control. Discourage them from 
eating foods with a high glycaemic index (such as more than three dates, 
which are traditionally used to break the fast) until about half an hour after 
taking drugs to minimise sharp rises in blood sugar at sunset. 
The diet during Ramadan should not differ from a healthy balanced diet. 
Protein should comprise 10-20% of the daily calories, the remaining 80-90% 
being divided between fat and carbohydrates. 
Some authors suggested that slow energy-release foods (such as wheat, 
semolina, beans, rice) should be taken before and after fasting, whereas foods 
high in saturated fat (such as ghee, samosas and pakoras) should be minimised. 
If blood glucose is well controlled by diet alone, advise them that fasting is safe. 
Self monitoring of blood glucose is essential for safe fasting in patients taking 
antidiabetic drugs, particularly before and after the pre-dawn and sunset 
meals. It should guide the individual tailoring of treatment regimens. 
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